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 GENERAL INTRODUCTION 
 
 
 
 Dopamine was discovered as a brain neurotransmitter by Nobel prize winner 
Arvid Carlsson almost 60 years ago (Iversen & Iversen, 2007). Since the 
discovery of the role of dopamine in Parkinson’s Disease, several other 
neuropsychiatric diseases have been associated with dopamine dysfunction, 
including schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD), 
Alzheimer’s Disease and Huntington’s Disease (Nieoullon, 2002). Levodopa was 
discovered as a treatment for Parkinson’s Disease more than 40 years ago and 
is still considered the most efficacious one. Early developments in 
pharmacotherapy of schizophrenia, demonstrating effectiveness of dopamine 
antagonists against psychosis meant a major improvement in treatment of this 
disease (Marsden & Parkes, 1977). However, later advances have been 
disappointing. In spite of progress in knowledge and techniques in basic 
neuroscience, relatively few novel medications have been introduced on the 
market (Markou, Chiamulera, Geyer, Tricklebank, & Steckler, 2009; Sams-
Dodd, 2005). Hence, psychopharmacological research aiming at improvement 
of treatment of diseases that are associated with dysfunction of the dopamine 
neurotransmitter system continues to be highly relevant. A first step in the 
development of new dopaminergic agents is to increase our knowledge about 
the dopamine system. 
  
Dopamine in the brain 
Dopamine is a so-called catecholamine, meaning it has a catechol nucleus to 
which an amine group is attached (Julien, 2011). Noradrenaline is also 
classified as a catecholamine. The first step in dopamine synthesis 
encompasses the derivation of tyrosine from the amino acid phenylalanine. 
Tyrosine is transformed into L-Dopa, which is converted to dopamine (Mehta 
& Riedel, 2006). Dopamine can in turn be converted into noradrenaline and 
finally adrenaline. Dopamine synthesis and release are controlled by enzymes, 
genetic influences and autoreceptors (Julien, 2011).  
Released dopamine binds to postsynaptic receptors which are 
categorized based on their mechanism of action. The two main categories are 
D1 and D2. The D1 receptors are further subdivided in D1 and D5 subtypes, 
and the D2 family is subdivided in D2S, D2L, D3 and D4 receptor subtypes 
(Missale, Nash, Robinson, Jaber, & Caron, 1998). Removal of dopamine from 
the synaptic cleft occurs through enzymatic breakdown by monoamine oxidase 
(MAO) and catechol-o-methyltransferase (COMT) and binding to the dopamine 
transporter (Julien, 2011; Mehta & Riedel, 2006). Virtually each of these steps 
in neurotransmission, from synthesis, via release to enzymatic breakdown and 
reuptake can be targeted by pharmacological manipulations that regulate 
dopamine activity, constituting possible treatment options and/or models of 
neurotransmitter (dys)function. 
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 Dopamine pathways in the brain originate in the brainstem. These 
pathways are each associated with different processes. The 
tuberoinfundibular pathway from the hypothalamus to the pituitary gland is 
involved in hormonal regulation. In Parkinson’s Disease, neuronal loss is 
observed in the nigrostriatal pathway, which plays a major role in motor 
control. The meso-cortico-limbic pathways are implicated in cognitive 
control, including motivation, reward, punishment and (working) memory 
(Cools, 2008). Hence, the widespread innervation of the brain by the various 
dopamine pathways is reflected by the diversity of functions in which 
dopamine is thought to play a role.  
 In Parkinson’s disease, progressive loss of dopamine neurons 
eventually leads to severe motor symptoms including bradykinesia, muscle 
rigidity, resting tremor, and impairment of postural balance. However, more 
subtle effects of dopamine on psychomotor control can also be observed both 
in early stage Parkinson’s Disease patients as well as healthy volunteers and 
be detected by with a response preparation paradigm. Preparation of a motor 
response has been associated with dopamine release in the basal ganglia. Its 
electrophysiological correlate, the Contingent Negative Variation (CNV) 
amplitude is reduced in Parkinson’s Disease and varies with dopamine activity 
in healthy individuals (Amabile, et al., 1986; Oishi, Mochizuki, Du, & Takasu, 
1995; Tecce, 1991).  
A first indication of dopamine involvement in cognitive function was 
also provided by the deficits observed in Parkinson’s Disease patients. These 
patients display deficits in visuospatial abilities and executive function, 
including working memory and planning (Azuma, Cruz, Bayles, Tomoeda, & 
Montgomery, 2003). Dopamine level enhancement by levodopa treatment 
improves cognitive functions that depend on brain areas that are dopamine 
depleted in Parkinson’s Disease while functions depending on non-depleted 
areas deteriorate (Cools, 2006). These results can be explained in terms of 
the inverted-U relationship between dopamine and performance described in 
the literature, in which performance is mapped as a function of degree of 
neurotransmitter activity (Cools, 2006; Cools, Barker, Sahakian, & Robbins, 
2001). In an inverted-U relation, intermediate levels of neurotransmitter 
activity lead to optimal cognitive performance, but lower and higher levels 
may lead to suboptimal performance (Husain & Mehta, 2011).  
 It is unclear if normal dopamine levels in the healthy brain are 
optimal for cognitive performance and the question arises to what extent 
cognitive performance may be improved by dopaminergic manipulations. This 
issue is currently relevant in the context of the vast increase in the illicit use 
of prescription drugs in attempts to enhance normal cognitive performance. 
Methylphenidate, a catecholamine reuptake inhibitor prescribed for ADHD and 
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 Narcolepsy is more and more used by for example students and academic staff 
with the intention to enhance their cognitive performance (Maher, 2008). If 
this is acceptable and if so, in what context, is an interesting discussion in 
itself. However first of all, it is important to find out if cognitive performance 
can indeed be enhanced by dopaminergic drugs. 
  
Aims 
1. After more than 50 years of dopamine research, there is still a lot to 
be learned about the dopamine system. Studies in clinical conditions, 
including Parkinson’s Disease, have suggested a role for dopamine in 
cognition. The role of dopamine in cognitive processes in healthy 
volunteers is less clear. Moreover, recent increases in illicit use of 
prescription drugs such as methylphenidate by healthy individuals 
have raised interest in the question whether dopaminergic substances 
can enhance cognitive function. The first aim of this thesis is to 
determine the role of dopamine in cognitive function in the healthy 
population, primarily focusing on (working) memory.   
2. Dopamine is involved in several debilitating neuropsychiatric 
conditions including Parkinson’s Disease, schizophrenia and ADHD. To 
advance pharmacological treatment of these diseases, further 
research is needed. This research would be highly aided by a 
biomarker for dopamine activity. This thesis proposes the use of CNV 
amplitude, which is under the influence of changes in dopamine 
availability, as a marker of dopamine activity in the brain. The second 
aim of this thesis is, therefore, to validate the CNV paradigm and 
fine-tune its’ application as a dopaminergic biomarker. 
 
Methods 
In this thesis, the relationship between dopamine and cognitive function in 
healthy individuals is investigated by measuring performance on cognitive 
tests while dopamine activity is modulated, using a placebo controlled 
crossover design. Effects of both increased dopamine turnover as well as 
reduced dopamine activity on performance are studied.  
In the studies described in this thesis, dopamine availability is 
enhanced by administration of methylphenidate and levodopa. 
Methylphenidate binds to the dopamine transporter and thereby inhibits 
reuptake of the neurotransmitter from the synaptic cleft. Levodopa is the 
precursor of dopamine. It can cross the blood-brain barrier, and is 
transformed into dopamine.  
A reduction of dopamine activity is achieved by depleting the brain of 
tyrosine and phenylalanine, the amino acids that form the building blocks for 
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dopamine synthesis (Barrett & Leyton, 2004). Because these amino acids are 
transported into the brain by neutral amino acid transporters, amino acids 
have to compete with each other for binding to transporters. Lowering the 
relative amount of one or two specific amino acids worsens their position in 
this competition, which leads to decreased availability of these precursors in 
the brain (McTavish, et al., 2001).  
 To validate CNV as a dopaminergic biomarker, its dynamic range is 
studied under normal conditions compared with pharmacologically increased 
dopamine availability. The relationship between dopamine and psychomotor 
function is assessed with a response preparation paradigm, in which 
electrophysiological measurements are taken. From the 
electroencephalography (EEG), event-related potentials are extracted and the 
CNV amplitude can be determined. In addition, EEG measurements are taken 
during some of the cognitive tasks, to get a more comprehensive view of the 
brain functions (i.e. declarative and working memory) of interest.  
 
Outline of this thesis 
Part 1 discusses the role of dopamine in cognition. Both dopamine 
enhancement and reduction in dopamine activity are employed to study the 
relationship between dopamine and brain functions such as (working) 
memory, attention and executive function. Part 1a, consisting of Chapter 1, 2 
and 3, answers questions regarding the relationship between dopamine 
enhancement and cognitive function. Part 1b, Chapter 4, examines the effect 
a reduction in dopamine activity has on cognitive processes.  
Chapter 1 
The first chapter gives an overview of the literature on the cognitive effects 
of methylphenidate in healthy volunteers. Methylphenidate’s  effects on six 
cognitive subdomains are quantified in relation to the quality of the studies 
reviewed. In using this approach we aimed to find out if methylphenidate 
selectively affects specific subdomains of cognitive function. 
Chapter 2  
This chapter describes an experimental study in which dose related effects of 
methylphenidate on declarative memory, working memory, attention and 
executive functions are examined. 
Chapter 3 
To elucidate whether the effects of methylphenidate on cognitive function 
reported in chapter 2 are mediated by the dopaminergic or noradrenergic 
neurotransmitter system, the experimental study described in chapter 3 
compared the effects of methylphenidate to the purely dopaminergic effects 
of levodopa on cognitive function in healthy volunteers. 
11 
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Chapter 4 
In contrast with the preceding three chapters, chapter 4 describes an 
experiment with a manipulation leading to a decrease in the level of 
dopamine. This is achieved by tyrosine/phenylalanine depletion; the 
administration of an amino acid mixture excluding the building blocks for 
dopamine synthesis. Effects of reduced dopamine activity on declarative 
memory and working memory and their electrophysiological correlates are 
studied. 
 
Part 2 focuses on psychomotor control and how it is mediated by dopamine. 
Psychomotor function is assessed by response preparation tasks which induce 
the Contingent Negative Variation. The studies in this part aim to validate the 
use of the CNV as a dopaminergic biomarker. 
Chapter 5 
The first chapter of Part 2 studies differences between several paradigms that 
elicit a CNV. In an effort to optimize the CNV paradigm, a new task using 
dynamic stimuli was introduced. The aim of the first experiment was to see if 
dynamic stimuli would lead to increased attention and motivation and induce 
a larger amplitude of the CNV wave, compared to a task with static stimuli. 
The second experiment investigates how variation in response requirement 
affects the CNV wave and task performance. 
Chapter 6 
Chapter 6 aimed to determine the sensitivity of CNV amplitude to dopamine 
activity and hence, if it could serve as a pharmacodynamic marker of 
dopamine activity. To this end the dose related effects of methylphenidate on 
the static and dynamic response preparation paradigms described in chapter 5 
are investigated in chapter 6.  
Chapter 7 As methylphenidate does not only affect dopamine but also 
noradrenaline activity, the final chapter investigates the specific 
dopaminergic influence on the CNV amplitude by comparing the effects of 
methylphenidate on CNV to those of levodopa.  
 
General discussion 
In the general discussion, the findings from the individual chapters are 
reviewed to form a comprehensive view with respect to the two central aims 
of this thesis. The role of dopamine in cognitive function in the healthy 
population is discussed. Furthermore, the relationship between dopamine and 
the CNV is described. It is evaluated whether CNV amplitude could serve as a 
dopaminergic biomarker. 
 PART 1: THE ROLE OF DOPAMINE IN COGNITION 
 
 
  
  
PART 1A: THE EFFECT OF DOPAMINE ENHANCEMENT ON COGNITION 
 
  
 Chapter 1. Cognitive effects of methylphenidate in healthy volunteers: A 
review  
 
Submitted for publication 
 
Abstract 
 
Methylphenidate (MPH), a stimulant drug with dopamine and noradrenaline 
reuptake inhibition properties is mainly prescribed in attention deficit 
hyperactivity disorder, is increasingly used by the general population, 
intending to enhance their cognitive function. We aim to answer whether this 
is effective and present a novel way to determine the extent to which MPH 
enhances cognitive performance in a certain domain. Namely, we quantify 
this by a percentage that reflects the number of studies showing positive 
effects of MPH. To evaluate whether the dose-response relationship follows an 
inverted-U-shaped curve, MPH effects on cognition are also quantified for 
low, medium and high doses respectively. The studies reviewed here show 
that MPH improves cognitive performance in the healthy population in the 
domains of working memory (68% of included studies) and speed of processing 
(61%), and to a lesser extent may also improve verbal learning and memory 
(34%), reasoning and problem solving (18%) and attention and vigilance (16%), 
but does not have an effect on visual learning and memory. MPH effects are 
dose dependent and the dose response relationship differs between cognitive 
domains. In conclusion, healthy individuals should be very careful when 
considering using MPH for cognition enhancing purposes; effects may be 
disappointing to abusers. 
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Introduction 
 
Methylphenidate (MPH, also see Table 1 for an overview of abbreviations used 
in this article) is a stimulant drug that is mainly prescribed in attention deficit 
hyperactivity disorder (ADHD, (Leonard, McCartan, White, & King, 2004)). In 
the past decades there has been a vast increase in the use of MPH (Diller, 
1996). Not only by patients to whom MPH is prescribed, but also by the 
general population, who believe MPH enhances their cognitive functions 
(Maher, 2008). Especially the latter has raised ethical concern (Larriviere, 
Williams, Rizzo, & Bonnie, 2009; Sahakian & Morein-Zamir, 2007; Stix, 2009). 
Discussions in popular scientific literature consider safety, potential abuse 
and side effects (Stix, 2009; Swanson & Volkow, 2008) of cognition enhancing 
drugs. However, even if these issues were no reason for concern, a critical 
question would still be: ‘How effective are supposed cognition enhancing 
drugs actually?’. Although there are some indications that MPH may improve 
certain aspects of cognitive function (e.g. working memory (Mehta, et al., 
2000)), there are also reports of impaired performance on cognitive tasks 
after MPH (e.g. planning (Elliott, et al., 1997)). While a reasonable amount of 
studies have examined cognitive effects of MPH in healthy volunteers, the 
evidence is undeniably mixed.  
Cognitive effects of MPH in children with ADHD have been reviewed 
by Pietrzak et al. (2006). Their extensive review includes evidence on a broad 
range of cognitive functions and presents it classified into several cognitive 
domains. An equivalent review on cognitive effects of MPH in healthy 
volunteers is not available yet. Previous reviews on the cognition enhancing 
effects of drugs have focused on attention, learning, memory and executive 
function (Repantis, Schlattmann, Laisney, & Heuser, 2010; M. E. Smith & 
Farah, 2011). In the current review the full spectrum of cognitive function is 
considered. As Pietrzak et al. (2006) also argue, the differences between 
studies on cognitive effects of MPH, such as differences in methodology, MPH 
dose, neuropsychological instruments employed do not encourage conducting 
a meta-analysis. As we did not want to limit our review to one particular 
measure or cognitive domain, we used a similar approach as Pietrzak et al. 
(2006). However,because the review by Pietrzak et al. (2006) focused on 
studies involving children with ADHD, the reported tasks differ slightly from 
those in studies with healthy volunteers, since both clinical status (i.e. ADHD 
diagnosis) and age (children vs. adults) may call for a different selection of 
tasks. Inspection of the range of tasks used in studies with MPH in healthy 
volunteers, and the fact that the classification applied by Pietrzak et al. 
(2006) does not seem to be based on factor analysis or any other established 
way of classifying cognitive tasks (or is at least not reported to be) led us to 
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look for a classification that was more appropriate for the available data 
(Pietrzak, Mollica, Maruff, & Snyder, 2006).  
 
Table 1 
Abbreviations 
ADHD attention deficit hyperactivity disorder 
A/V   attention/vigilance 
CNV contingent negative variation 
CPT continuous performance test 
DSST digit symbol substitution 
ID/ED  intra-/extradimensional shift task 
MPH Methylphenidate 
PAL  paired associates learning 
PASAT  paced auditory serial addition test 
RPS  reasoning and problem solving 
RT  response time 
RVIP rapid visual information processing 
SERS stimulus evaluation/response selection task
SMS Sternberg memory scanning task 
SoP speed of processing 
TMT trail making test 
TOVA test of variables of attention 
VEM Verbal learning and memory 
VSM Visual learning and memory 
WLT  Word learning test 
WM Working memory 
 
The categorization based on the Identification of separable cognitive factors 
in schizophrenia by a committee of the National Institute of Mental Health 
(NIMH) (Nuechterlein, et al., 2004) is based on a number of factor analytic 
studies and fine-tuned by a committee of field experts. Although the 
identification considered cognitive function in schizophrenia patients, it is 
generally accepted that cognitive domains are broadly the same in healthy 
controls (Dickinson, Ragland, Calkins, Gold, & Gur, 2006; Genderson, et al., 
2007). Since the cognitive domains (i.e. speed of processing, 
attention/vigilance, working memory, verbal learning and memory, visual 
learning and memory and reasoning and problem solving) fit well with the 
literature on healthy volunteers, we decided to employ this in the current 
review (Riedel, Mehta, & Unema, 2006).  
Considering the mixed nature of the literature, a descriptive statistic 
quantifying the evidence would facilitate its interpretation. Pietrzak et al. 
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(2006) summarize the results within each domain as a percentage of studies 
reporting cognition enhancing effects of MPH. This does, however, not take 
into account study characteristics such as the number of subjects tested or 
correction for multiple comparisons. The result of a study testing a high 
number of subjects has more statistical power than a study with a low number 
of subjects. Therefore, it is important to weigh studies according to the 
number of subjects (Kleijnen, Knipschild, & Riet ter, 1991). Furthermore, a 
study including many tests is more likely to find a result than a study assessing 
performance on just one test. In order to take these factors into account, we 
established a weighed percentage reflecting the contribution of each 
task/measure in each study to the effect of MPH on cognitive function. Details 
on the calculation of this percentage can be found in the method section. 
Effects of dopamine on cognition are often described to follow an 
inverted-U-shaped curve in which intermediate levels of neurotransmitter 
activity lead to optimal cognitive performance, but lower and higher levels 
may lead to suboptimal performance (Husain & Mehta, 2011). Since MPH 
blocks the dopamine and noradrenaline transporters, thereby blocking 
reuptake of these neurotransmitters, MPH leads to increased levels of 
dopamine and noradrenaline availability (Hannestad, et al., 2010; Volkow, 
Wang, Fowler, Gatley, et al., 1998) and may demonstrate inverted-U 
properties. Moreover, dose-response relationships may vary between cognitive 
domains. To evaluate the dose-response relationship between MPH and its 
effects on the different cognitive domains we report a weighed percentage 
reflecting MPH effects, equivalent to the one described above for low, 
medium and high doses respectively (see method section for more details).  
The aim of this review is to answer the question whether MPH can enhance 
cognitive function in healthy individuals. Unlike previous reviews on MPH 
effects of cognitive function in healthy individuals, this review specifically 
looks at the acute effects of MPH on healthy adults (i.e. excluding effects of 
other medications, effects on children or the elderly, effects after sleep 
deprivation and long term effects). Further improvements compared to earlier 
reviews include: (1) the results from the studies included in this review are 
carefully categorized in cognitive domains; and: (2) the extent to which MPH 
affects each domain is quantified in relation to the studies’ quality. Although 
we are aware of the ethical issues involved, these are not further considered 
here. In this review we give an overview of the relevant literature and report 
the extent to which MPH enhances cognitive performance within each 
cognitive domain.  
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Method 
 
Literature search 
A literature search was performed in PubMed and Psychinfo using the search 
term Methylphenidate combined with the terms cognition, neuropsychology, 
executive, working memory, vigilance and inhibition in separate searches. 
Reference lists of extracted articles were screened for omissions in our 
search. Studies that were included fulfilled the following criteria: used 
immediate release formulation of MPH; assessed healthy human adults aged 
between 18 and 60 years of age (of studies including older participants, only 
data of participants aged between 18-60 were included in this review); 
assessed the effects using cognitive tasks; were written in English; and were 
published in a peer-reviewed journal. The earliest study included was 
published March 1978 and the last included study was published June 2012. 
 
Categorization 
The neuropsychological tests were categorized into 6 different cognitive 
domains: speed of processing, attention/vigilance, working memory, verbal 
learning and memory, visual learning and memory and reasoning and problem 
solving (Nuechterlein, et al., 2004). Tasks employed in the included articles 
were categorized following the classification by Nuechterlein et al. (2004). If 
more than one cognitive domain was applicable, tasks were still classified as 
measuring one domain only (i.e. the most salient domain). Tasks that could 
not be categorized in any of these 6 cognitive domains were not included in 
the analysis (for instance ‘spatial bias’ in (Dodds, Muller, & Manly, 2008). 
 
Outcome measure  
For each domain a weighed percentage was calculated reflecting to what 
extent MPH affects task performance in that specific domain. It was 
calculated as follows:  
Outcome measure = (∑ (number of participants * outcome significance testing 
* relative contribution)) / (∑ (number of participants * relative contribution)) 
*100% 
 in which outcome significance testing was defined as: 1 = significantly 
improved task performance; -1 = significantly impaired task performance; 0 = 
no significant effect; 0.5 = trend towards improved task performance; -0.5 = 
trend towards impaired task performance and the factor to correct for 
multiple comparisons (relative contribution) was the defined as: 1/number of 
tasks or measures within the study that are reported in Table 2 (i.e. if 3 
measures were reported in the article, but only 2 were listed in Table 2, the 
factor was 1 / 2 = 0.5).  
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Dose effects 
The outcome measure as detailed above was also calculated for low, medium 
and high doses separately. A low, medium or high dose was defined as 
follows: low: <= 10 mg or <=0.15 mg/kg; medium: >10 mg, <=20 mg or >0.15 
mg/kg, <=0.3 mg/kg; high: >20 mg or >0.3 mg/kg. If it was not clearly stated 
which dose(s) led to significant effects, it was assumed that the reported 
effect was applicable to every administered dose.  
 
Results and discussion 
 
In total 45 studies met the inclusion criteria. These studies are listed in Table 
2. The extent to which MPH enhances cognitive performance (quantified by a 
weighed percentage) is reported in Table 3. The results show that MPH most 
effectively enhances performance in the domain of working memory. Second 
most affected were tasks measuring speed of processing, followed by verbal 
learning and memory, reasoning and problem solving, attention/vigilance and 
visual learning and memory. In the next few paragraphs, the results per 
domain are discussed in more detail. 
 
Working memory 
Working memory involves the temporary storage and manipulation of 
information (Baddeley, 1992). For the purpose of this review, no distinction 
will be made between short term memory and working memory tasks. A 
common working memory task is the digit span, requiring subjects to repeat a 
sequence of digits either in the exact same or reversed order. More complex 
tasks include memory scanning tasks and N-back tasks. Memory scanning tasks 
present participants with probes that they have to compare to a memory set 
that may vary in size, and hence, memory load (Sternberg, 1966). N-back 
tasks require a response to stimuli that are the same as the stimulus that was 
presented N-trials before. Other tasks specifically assess spatial working 
memory, which is often associated with dopaminergic activity (Mehta & 
Riedel, 2006).  
 Although the number of MPH studies including a test of working 
memory is not very high, the proportion that shows enhancing effects in this 
cognitive domain is the highest of all reported domains, namely 68%. This can 
not be attributed to MPH effects on a specific type of test, but reflects the 
general pattern across a variety of tests. For example, there are four reports 
of scanning tests, three of which observe improved performance after MPH 
(Brumaghim, Klorman, Strauss, Lewine, & Goldstein, 1987; Fitzpatrick, 
Klorman, Brumaghim, & Keefover, 1988; Halliday, Callaway, Naylor, 
Gratzinger, & Prael, 1986). Similarly, three of the five spatial working 
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memory assessments showed enhancing effects. Better performance was 
observed after 10, 20 and 40 mg of MPH on the spatial span test (requiring 
subjects to reproduce a spatial sequence that is presented) and on a self-
ordered search task in which participants search for tokens in an array of 
boxes displayed on a computer screen (Elliott, et al., 1997; Mehta, et al., 
2000). The latter task was also employed by Clathworthy et al. (2009) but 
performance was not improved in this study, in which 60 mg of MPH was 
administered. An object relocation task, which assesses spatial working 
memory, was also not affected by 10, 20 and 40 mg of MPH (Linssen, 
Vuurman, Sambeth, & Riedel, 2012). 
 Two studies, both using medium doses of MPH, assessed digit span 
performance, one reporting improved performance and one reporting no drug 
effects (Agay, Yechiam, Carmel, & Levkovitz, 2010; Oken, Kishiyama, & 
Salinsky, 1995). A medium dose also lead to faster response times on an N-
back task, but did not improve accuracy on this task (Tomasi, et al., 2011).  
 Two other studies did not observe any effect of MPH on working 
memory task performance, using a medium dose (Kuypers & Ramaekers, 2005; 
Studer, et al., 2010). The task used by Kuypers and Ramaekers (2005) involved 
deciding whether the presented sentences describing the order of two letters, 
A and B, corresponded to the presented letterpairs. Studer et al. (2010) used 
a task in which pictures were presented and participants were probed with 
the same pictures in the retention phase and had to indicate what position in 
the sequence the probe was in.  
 
Speed of Processing 
Tasks that are classified as a measure of speed of processing are relatively 
simple, involving fundamental processes such as perception and motor action. 
This category includes for example Digit symbol substitution (DSST) and Trail 
making tests (TMT; version A and B). In the former, participants are asked to 
complete as many digit/symbol pairings as they can within 90 seconds. The 
TMT test involves connecting letters and/or numbers in ascending order. A 
task employed by some older studies, the stimulus evaluation/response 
selection (SERS) task, requires fast responses to a target stimulus that is 
either presented alone or surrounded by distracter stimuli. Different trials 
may either require a simple key press or the selection of the correct key, 
depending on the location of the target stimulus.  
 The speed of processing domain was with 61 % the second most 
affected domain in terms of performance enhancing effects of MPH. This is 
consistent with the notion that MPH speeds response time in healthy 
volunteers (Elliott, et al., 1997), reflecting response readiness enhancing 
effects (Linssen, et al., 2011). Tasks requiring participants to press (a series  
  
Table 2 
Summary of studies on cognitive effects of MPH in healthy volunteers 
Study Nr. of pp M, F (age) Dose Task/measure Domain Effect 
  design         
Agay et al. (2010) 18M, 14F (32.7) 15 mg (1) CPT (omission errors) A/V ns 
[1] placebo controlled  CPT (commission errors) A/V ns 
 between groups  Digit span WM sig 
Aman et al. (1984) 5M, 7F(28.3) 0.3 mg/kg CPT (omission errors) A/V ns 
[2] placebo controlled  CPT (commission errors) A/V sig 
 crossover  CPT (RT) A/V ns 
Anderer et al. (2002) 10M, 10F (23-34) 20 mg Oddball (error rate) A/V ns 
[3] placebo controlled      
 crossover      
Bishop et al. (1997) 6M, 3F (21-35) 10 mg (2x/day) divided attention A/V ns 
[4] placebo controlled  auditory vigilance A/V ns 
 crossover     
Brignell et al. (2006) 30HV (23.5) 40 mg fear conditioning VSM ns 
[5] placebo controlled     
 between groups     
Brignell et al. (2007) 32HV (22.8) 40 mg story task VEM trend (2) 
[6] placebo controlled     
 between groups     
Brumaghim et al. (1998) 12M, 20F (20.9) 0.3 mg/kg PAL (CVC pairs) VEM ns 
[7] placebo controlled     
 crossover     
Brumaghim et al. (1987) 19M (19.4) 0.3 mg/kg SMS WM sig 
  
study 1 placebo controlled     
[8] crossover     
Brumaghim et al. (1987) 6M, 8F (20.0) 0.3 mg/kg SMS WM sig 
study 2 placebo controlled     
[8] crossover     
Callaway (1984) 8F (30-40)  5/10/20 mg SERS SoP sig 
[9] placebo controlled     
 crossover     
Camp-Bruno et al(1994) 22M, 26F(23.0) 20 mg CPT (RT) A/V sig 
[10] placebo controlled  CPT (sensitivity) A/V ns 
 between groups  CPT (ln beta) A/V ns 
   Word learning VEM ns 
   Buschke selective reminding VEM sig 
Clark et al. (1986a) 12M (18-30) 0.65 mg/kg Dichotic monitoring task A/V ns  
[11] placebo controlled   (target detection)   
 crossover  
Dichotic monitoring task (error 
rate) A/V ns  
   Dichotic monitoring task (RT) A/V ns  
   Dichotic monitoring task A/V ns  
    (signal detection)   
Clark et al. (1986b) 10M (18-30) 0.65 mg/kg Dichotic monitoring task A/V ns 
[12] placebo controlled   (target detection)   
 crossover  
Dichotic monitoring task (error 
rate) A/V sig 
   Dichotic monitoring task (RT) A/V ns 
   Dichotic monitoring task A/V ns 
    (signal detection)   
  
Study Nr. of pp M, F (age) Dose Task/measure Domain Effect 
  design         
Clatworthy (2009) 10M (22-32) 60 mg Reversal learning VSM ns 
[13] placebo controlled  Spatial WM WM ns 
 crossover     
Coons  et al. (1981) 13M (23.84) 20 mg CPT X (omission errors) A/V ns 
study 1 placebo controlled  CPT X (commission errors) A/V ns 
[14] crossover  CPT BX (omission errors) A/V ns 
   CPT BX (commission errors) A/V ns 
Coons  et al. (1981) 23M (19.7) 20 mg CPT X (omission errors) A/V ns 
study 2 placebo controlled  CPT X (commission errors) A/V ns 
[14] crossover  CPT BX (omission errors) A/V sig 
   CPT BX (commission errors) A/V ns 
   CPT Double (omission errors) A/V sig 
   CPT Double (commission errors) A/V ns 
   Oddball (omission errors) A/V ns 
   Oddball (commission errors) A/V ns 
   Choice RT (omission errors) SoP sig 
   Choice RT (commission errors) SoP ns 
   Choice RT (response time) SoP ns 
Cooper et al. (2005) 32M (22.3) 5/15/45 mg CPT (omission errors) A/V sig 
[15] placebo controlled  CPT (commission errors) A/V ns 
 crossover  CPT (RT)/N back A/V sig 
Dodds et al. (2008) 14M, 6F (22.2) 60 mg Probabilistic reversal learning VSM ns 
[16] placebo controlled     
 crossover     
Elliott et al. (1997) 28M (21.3) 20/40 mg Spatial WM WM sig (3) 
  
[17] placebo controlled  Tower of London (old) RPS sig (4) 
 crossover  Tower of London (new) RPS sig (5) 
   Verbal fluency test SoP ns 
   Spatial span WM sig (3) 
   ID/ED shift task A/V ns 
   Sequence generation RPS sig 
   RVIP (response latency) A/V sig 
   RVIP (performance) A/V ns 
Finke et al. (2010) 9M, 9F (20-35) 40 mg Visual perceptual processing speed SoP sig 
[18] placebo controlled  Visual short-term memory storage  VSM ns 
 crossover   capacity   
Fitzpatrick et al. (1988) 20M (19.7) 0.3 mg/kg Memory scanning task WM sig 
[19] placebo controlled     
 crossover     
Halliday et al. (1986)  8F (30-40) 5/10/20 mg SERS SoP sig  
exp 1 placebo controlled  SMS WM ns 
[20] crossover     
Halliday et al. (1986) 12M (26) 10 mg SERS SoP sig  
exp 2 placebo controlled  CPT (commission errors)  A/V sig  
[20] crossover  motor task SoP sig 
Hermens et al. (2007) 32M (22.3) 5/15/45 mg Oddball A/V sig  
[21] placebo controlled  CPT (RT) A/V sig 
 crossover  CPT (omission errors)  A/V sig 
   CPT (commission errors) A/V ns 
   CPT (total errors) A/V sig 
   Maze RPS ns 
  
Study Nr. of pp M, F (age) Dose Task/measure Domain Effect 
  design         
   Mackworth clock (RT variability) A/V sig 
   Mackworth clock (false negatives) A/V sig 
   Mackworth clock (false positives) A/V ns 
   Mackworth clock (total errors) A/V sig 
   Verbal memory recall VEM ns 
   Choice reaction time SoP ns 
   Switching of attention (TMT A) SoP ns 
   Switching of attention (TMT B) SoP ns 
   PASAT (RT) A/V sig  
   PAL (word pairs) VEM ns 
Hink et al. (1978) 12M (19-28) 10 mg Target detection task A/V ns 
[22] placebo controlled     
 crossover     
Izquierdo et al. (2008) 7M, 5F (40-74) 10 mg Incidental memory task VEM sig 
[23] placebo controlled     
 crossover     
Izquierdo et al. (2008) 11M, 9F (35-74) 10 mg Formal memory task VEM sig 
[23] placebo controlled     
 crossover     
Kollins et al. (1998) 5M, 5F (30.7) 20/40 mg DSST SoP ns 
[24] placebo controlled  circular lights task SoP sig 
 crossover     
Kratz et al. (2009) 8M, 6F (20-40) 20 mg Go/No-go task (hit rate) A/V ns 
[25] placebo controlled  Go/No-go task (RT) A/V sig 
  
 crossover  Impulsivity errors A/V ns 
Kupietz et al. (1980) 5M, 4F (28.7) 5/10 mg Learning beginning reading     
[26] placebo controlled  vocabulary (simultaneous method) VEM sig 
 crossover  (progressive method) VEM ns 
Kuypers et al. (2005) 9M, 9F (26.2) 20 mg WLT VEM ns 
[27] placebo controlled  Syntactic resasoning task WM ns 
 crossover  DSST SoP ns 
Kuypers et al.(2007) 9M, 9F (26.2) 20 mg spatial memory task VSM ns 
[28] placebo controlled  change blindness task VSM ns 
 crossover     
Linssen et al. (2011) 19M (23.4) 10/20/40 mg CNV Lines SoP sig 
[29] placebo controlled   CNV Stoplight SoP sig 
 crossover     
Linssen et al. (2012) 19M (23.4) 10/20/40 mg WLT VEM sig 
[30] placebo controlled   Spatial WM WM ns 
 crossover  Set shifting A/V sig 
   Stop signal task A/V sig 
   Tower of London RPS ns 
Mehta et al. (2000) 10M (34.8) 40 mg Spatial WM WM sig 
[31] placebo controlled     
 crossover     
Naylor et al.(1985) 8F (30-39) 5/10/20 mg SERS SoP sig 
[32] placebo controlled     
 crossover      
Oken et al. (1995) 11M, 12F (25) 0.2 mg/kg Covert orienting spatial attention   
[33] placebo controlled   (RT) A/V sig 
  
Study Nr. of pp M, F (age) Dose Task/measure Domain Effect 
  design         
 Crossover   (Errors) A/V ns 
   Parallel visual search task (RT) A/V ns 
   Parallel visual search task (Errors) A/V ns 
   Serial visual search task (RT) A/V ns 
   Serial visual search task (Errors) A/V ns 
   Digit span WM ns 
Roehrs  et al. (1999) 2M, 4F (21-30) 10 mg Divided-attention task   
[34] placebo controlled   (central RT) A/V sig 
 crossover   (peripheral RT) A/V ns 
    (tracking deviations) A/V ns 
   auditory vigilance task    
    (mean RT) A/V ns 
    (Errors) A/V ns 
Rogers et al. (1999) 32M (20.5) 40 mg ID/ED shift task A/V sig (decreased 
[35] placebo controlled     performance) 
 between groups     
Rush et al. (2001) 4M, 4F (28) 20/40 mg DSST SoP ns 
[36] placebo controlled     
 crossover     
Rush et al. (1998) 2M, 3F (36) 5/10/20/40 mg DSST SoP ns 
[37] placebo controlled     
 crossover     
Schroeder et al. (1987) 10M (18-40) 0.15/0.30 mg/kg Concurrent probability matching   
[38] No placebo   (hit rate) RPS ns 
  
 between groups   (changeover) RPS sig (decreased 
      performance) 
    (strategy) RPS sig (decreased 
      performance) 
Stoops et al. (2005) 2M, 5F (24) 10/20/40 mg Arithmetic problems RPS sig 
[39] placebo controlled     
 crossover     
Strauss et al. (1984) 22M (19.2) 20 mg CPT Double (omission errors) A/V sig 
[40] placebo controlled  CPT Double (commission errors) A/V trend 
 crossover  CPT Double (sensitivity) A/V sig 
 crossover  CPT Double (RT) A/V sig 
   PAL (CVC pairs) VEM ns 
Studer et al. (2010) 5M, 6F (29.7) 20 mg Serial visual WM task WM ns 
[41] placebo controlled     
 crossover     
Tomasi et al. (2011) 32M (34.5) 20 mg N-back task (RT) WM sig  
[42] placebo controlled  N-back task (accuracy) WM ns  
 between groups  visual attention task A/V ns 
Unrug et al. (1997) 6M, 6F 20 mg WLT VEM ns 
[43] placebo controlled     
 crossover     
Volkow et al. (2008) 12M, 11F (32) 20 mg numerical problems RPS ns 
[44] placebo controlled     
 crossover     
Wetzel et al. (1981) 6M, 6F (27.5) 0.5 mg/kg PAL (word pairs) VEM sig (decreased 
      performance) 
  
Study Nr. of pp M, F (age) Dose Task/measure Domain Effect 
  design         
exp 1 placebo controlled  picture recognition VSM ns 
[45] crossover  Story recall VEM sig (decreased 
      perforance) 
Wetzel et al. (1981) 6M, 6F (26.6) 0.1/0.25 mg/kg PAL (word pairs) VEM ns 
exp 2 placebo controlled  Picture recognition VSM ns 
[45] crossover  Story recall VEM ns 
(1) Participants received 15 mg MPH unless high or low in body weight in which case they received 20 or 10 mg respectively 
(2) MPH lessens effect of emotionally arousing material on memory, higher performance on neutral material compared to placebo 
(3) Enhanced performance when MPH was taken on the first session 
(4) MPH causing impairment when taken on second session 
(5) Enhanced performance when MPH was taken on the first session, but impaired when taken on second session 
 
Table  3 
Percentages of studies showing cognition enhancing effects of methylphenidate in each of six cognitive domains (Total) and per dose level (Low, Medium, High). 
Study reference numbers refer to studies described in Table 2 
  Total Low Medium High nr. of measures Study references 
           (nr. of studies)   
Working memory 68 0 65 65 15 (12) 1,7,13,17,19,20,27,30,31,33,41,42 
Speed of processing 61 79 57 47 20 (12) 9,14,17,18,20,21,24,27,29,32,36,37 
Verbal learning and memory 34 64 64 25 18 (11) 6,7,10,21,23,26,27,30,40,43,45 
Reasoning and Problem solving 18 1 18 74 10 (6) 17,2130,38,39,44 
Attention and vigilance 16 41 32 -3 71 (20) 1,2,3,4,10,11,12,14,15,17,20,21,22, 
      25,30,33,34,35,40,42 
Visual learning and memory 0 0 0 0 8 (6) 5,13,16,18,28,45 
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of) keys in response to certain stimuli showed improved performance after 
MPH, including the SERS task, the circular lights task, two Contingent 
Negative Variation (CNV) tasks and a motor task (Callaway, 1984; Halliday, et 
al., 1986; Kollins, Rush, Pazzaglia, & Ali, 1998; Linssen, et al., 2011; Naylor, 
Halliday, & Callaway, 1985). DSST was employed in four studies, none of 
which found effects of MPH (Kollins, et al., 1998; Kuypers & Ramaekers, 2005; 
Rush, Essman, Simpson, & Baker, 2001; Rush, Kollins, & Pazzaglia, 1998). One 
study employed a verbal fluency test, requiring participants to generate as 
many words as possible within one minute starting with a certain letter or 
from a certain semantic category, and found no MPH effect (Elliott, et al., 
1997), while another study observed that participants could process more 
letters (that were presented on a computer screen and which the participants 
were asked to report after the trial) per second after 40 mg of MPH (Finke, et 
al., 2010). The TMT was left unaffected by MPH (Hermens, et al., 2007). 
 
Reasoning and problem solving 
The next cognitive domain involves planning and decision making, aspects of 
cognition that are usually referred to as executive functioning. However, in 
order to allow a separate category on working memory, which is often 
included in executive functioning, this domain is named reasoning and 
problem solving. A typical task in this domain is the Tower of London, in 
which balls have to be arranged on pegs according to a predefined pattern in 
as little steps as possible. Performance on this task was observed to decrease 
with MPH when the drug was administered on the second session in a 
crossover study (Elliott, et al., 1997). However, in a non-motor version of this 
task, in which participants are required to work out how many steps are 
needed without actually performing them, improved performance was 
observed when MPH was administered on the first session but performance 
was impaired by MPH when administered on the second session (Elliott, et al., 
1997). It is important to note though that there were no statistically 
significant main effects across the sessions. In a similar (non-motor) task, 
some minor performance enhancing effects of MPH were observed, but these 
were more likely spurious findings (Linssen, et al., 2012).  
 The study previously referred to also administered a task in which 
participants are asked to touch four red squares on a computer screen in as 
many different  sequences as possible (Elliott, et al., 1997). Performance on 
this task was improved by MPH. A variety of other tasks is classified as 
assessing reasoning and problem solving skills, for example arithmetic 
problem solving and maze learning. Two studies tested MPH effects on the 
ability to solve arithmetic problems (Stoops, Lile, Fillmore, Glaser, & Rush, 
2005; Volkow, et al., 2008). Improved performance was observed in one of 
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the studies, but not in the other. Maze learning was not affected by MPH 
(Hermens, et al., 2007). A more complex task is the arcade like game called 
Telekinesis Star Wars, described by Schroeder et al. (1987). It assesses 
problem solving, using three variables that reflect performance and the 
extent to which high level strategies are developed. MPH did not affect hit 
rate and decreased the rate at which adaptive strategies are developed 
(Schroeder, Mann-Koepke, Gualtieri, Eckerman, & Breese, 1987). 
 Overall, 18% of the results reflected improved performance within this 
domain after MPH. Based on the limited number of studies that assessed 
effects on reasoning and problem solving tasks, conclusions on the dose-
response relationship within this category will not be drawn. 
 
Attention/vigilance 
As William James already stated in 1890, ‘everyone knows what attention is’ 
(James, 1890). It is, however, difficult to give a clear and inclusive definition. 
It involves filtering information, focusing on certain aspects of what is 
perceived, while disregarding others. Many different forms of attention are 
distinguished (e.g. sustained attention, focused attention, divided attention). 
In this review, however, a collective domain attention and vigilance is 
employed.  
The continuous performance test (CPT) is one of the most applied and 
most sensitive tests to assess sustained attention and vigilance (Riccio, 
Waldrop, Reynolds, & Lowe, 2001). CPT  requires participants to respond to 
relatively infrequent target stimuli that are embedded in a continuous 
presentation of stimuli. Different variables reflecting task performance may 
be reported, including omission errors (failing to respond to target stimuli), 
commission errors (responding to non-target stimuli), response time and 
sensitivity (measuring the ability to discriminate target stimuli from non-
target stimuli). CPT was employed in 8 MPH studies, six of which showed 
improved performance on at least one of the reported measures (Agay, et al., 
2010; Aman, Vamos, & Werry, 1984; Camp-Bruno & Herting, 1994; Coons, et 
al., 1981; Cooper, et al., 2005; Halliday, et al., 1986; Hermens, et al., 2007; 
Strauss, et al., 1984). Hence, CPT results have quite a significant share in the 
16% of measures that are improved by MPH. A task similar to the CPT is the 
rapid visual information processing task applied by Elliott et al. (1997) in 
which participants have to respond to three different pre-specified sequences 
of digits within a stream of rapid presentations of digits. In this study no 
effect of MPH on response accuracy was observed, but MPH did speed the 
responses. Besides the CPT and the Rapid visual information processing 
(RVIP), a wide variety of similar tasks exists, that all entail detection of a 
target stimulus or event, and are used to assess sustained attention or 
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vigilance. These include for example oddball tasks and the Mackworth clock 
task. The majority of these tasks were not affected by MPH (Anderer, Saletu, 
Semlitsch, & Pascual-Marqui, 2002; Bishop, Roehrs, Rosenthal, & Roth, 1997; 
Coons, et al., 1981; Hink, Fenton, Tinklenberg, Pfefferbaum, & Kopell, 1978; 
Oken, et al., 1995; Roehrs, Papineau, Rosenthal, & Roth, 1999; Tomasi, et al., 
2011), but some showed improved performance after MPH (Hermens, et al., 
2007). MPH speeded responses on the Paced auditory serial addition test, 
which is also considered a measure of sustained attention (Hermens, et al., 
2007).  
In another well known type of tasks, the Go/No-go tasks, stimulus 
response contingencies are exactly opposite to those in target detection 
tasks. That is, instead of only responding in target trials, Go/No-go tasks 
require participants to respond in the majority of trials (Go) but withhold 
their response to certain stimuli (No-go). One study reported to use this task, 
observing speeded response times but no effect on hit rate or impulsivity 
errors (Kratz, et al., 2009). Performance of the stop signal task, in which 
participants have to inhibit an initiated Go response was observed to improve 
on MPH (Linssen, et al., 2012). 
Set shifting tasks require flexibility and are sometimes classified as 
divided attention tasks. In one example of such a test participants have to 
switch between attending to visual and auditory stimuli, responding only to 
target stimuli. MPH significantly enhanced performance on this task (Linssen, 
et al., 2012). A slightly more complex task is the intra-/extradimensional 
(ID/ED) shift task which requires participants to make visual discriminations 
while stimulus characteristics vary along different dimensions and the 
relevant dimension reverses between different task stages. Of the two studies 
employing this task, one found no effect of MPH whereas another study 
observed decreased performance on this task after MPH (Elliott, et al., 1997; 
Rogers, et al., 1999).  
Other divided attention tasks have been used in several studies. A 
typical task requires participants to track a moving target with a joystick 
while simultaneously responding to the appearance of white circle. Using this 
task, one study found no effect of MPH (Bishop, et al., 1997), whereas 
another observed speeded response times to the white circle when it was 
presented in the center of the screen (Roehrs, et al., 1999). A task requiring 
both divided as well as focused attention is the dichotic monitoring task. Most 
variables measured in this task were not affected by MPH, but the drug did 
reduce the error rate in one of the two studies (Clark, Geffen, & Geffen, 
1986a, 1986b). MPH also improved performance on the covert orienting of 
spatial attention task (Oken, et al., 1995).  
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Visual learning and memory 
The last cognitive domain to discuss is visual learning and memory. Tasks 
classified as assessing performance in this cognitive domain are for example 
picture recognition tests and other learning and memory tasks involving visual 
stimuli. None of the studies found an effect of MPH on visual learning and 
memory (Brignell & Curran, 2006; Bullmore, et al., 2003; Clatworthy, et al., 
2009; C. M. Dodds, et al., 2008; Finke, et al., 2010; Kuypers & Ramaekers, 
2007; Wetzel, et al., 1981).  
 
Conclusions 
 
In this review we present how effectively MPH affects performance in several 
cognitive domains. The extent to which MPH enhances cognitive performance 
was quantified by giving a percentage (weighed on the basis of specified 
criteria such as number of subjects) that reflects the number of studies 
showing positive effects of MPH. This is a major improvement compared to 
earlier reviews on the effect of MPH on cognition in which: only some domains 
of cognition were considered; the categorization in domains was less well 
specified (Repantis, et al., 2010; M. E. Smith & Farah, 2011); and/or the 
quality was either not taken into account or based on criteria that hardly 
differentiate between studies (e.g. double blind design, randomization 
(Jadad, et al., 1996)). Furthermore, it must be noted that this review 
compares 45 studies, which is considerably more than was done in previous 
reviews. The studies reviewed here show that MPH improves cognitive 
performance in the healthy population in the domains of working memory and 
speed of processing, and to a lesser extent may also improve verbal learning 
and memory, reasoning and problem solving and attention and vigilance but 
does not have an effect on visual learning and memory (see Table 3).  
There were quite large differences between the domains with respect 
to the cognition enhancing effect of MPH, the lowest percentage being 0 and 
the highest almost 70%. These differences confirm that in studying cognitive 
performance it is important to distinguish between different domains of 
cognitive function. MPH may not globally improve cognitive performance, but 
it has potential to enhance certain aspects of cognitive performance at 
certain doses.  
 Considering the known involvement of dopamine in working memory, 
MPH may be expected to improve working memory. Indeed, working memory 
was the most affected cognitive domain. The proportion of the effect of MPH 
was similar across different types of tasks and medium and high doses. 
However, in the spatial working memory tests, it is possible that the MPH-
effect follows an inverted U shaped curve as a function of dose, since a high 
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dose (60 mg) exerted no effect on a spatial working memory task that was 
affected by lower doses in other studies ((Clatworthy, et al., 2009; Elliott, et 
al., 1997; Mehta, et al., 2000), but note that Elliott et al. (1997) found no 
main effects).  
The second most affected domain was speed of processing. Most of 
the affected tasks involve simple motor responses, whereas the tasks that are 
not affected are generally slightly more difficult. Another striking observation 
is that the low dose exerts the highest proportion of effects on cognitive 
performance in this domain, followed by the medium dose and the highest 
dose showing the lowest proportion of effects. This suggests that within this 
domain the optimal dose is rather low and the higher the dose, the less 
healthy volunteers benefit from it.  
 Declarative memory is not typically associated with dopaminergic 
activity. It is therefore not surprising that the domain of verbal learning and 
memory is less affected by MPH compared to the first two domains. Positive 
effects of MPH on declarative memory fit well with accounts of related 
stimulant drugs affecting word list learning (Soetens, Casaer, D'Hooge, & 
Hueting, 1995; Soetens, D'Hooge, & Hueting, 1993; Zeeuws & Soetens, 2007). 
The relationship between MPH dose and its effect on word list learning seems 
to be a positive and linear one. This contrasts with the striking finding that a 
high MPH dose can decrease performance on a PAL task and story recall. 
Across the domain of verbal learning and memory the low and medium doses 
exert more cognition enhancing effects than the high dose. Hence, even 
within one domain, different dose-response relationship may be observed for 
different tasks. 
 The domains of reasoning and problem solving and attention and 
vigilance were virtually equally affected by MPH. Within the domain of 
reasoning and problem solving, MPH seems to mainly affect the Tower of 
London task. However the small amount of measures reported within in this 
domain restrict the conclusions regarding the effects of MPH on specific tasks 
or dose related effects. 
 Based on previous literature, associating attention with dopaminergic 
activity (Cools & Robbins, 2004; Nieoullon, 2002; Nieoullon & Coquerel, 2003) 
it was expected that attention enhancing effects of MPH would be revealed in 
this review. However, only a relatively small proportion of studies showed 
that attention was affected by MPH. With 71 measures reported in this 
domain, the conclusion that MPH has little effect on attention and vigilance in 
the healthy population should be a reliable one.  
Visual learning and memory remained unaffected by MPH in all studies 
listed here. It is, however, important to note that the data reported within 
this domain only comprises 8 measures. This gives the conclusion regarding 
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the absence of an MPH effect on visual learning and memory somewhat less 
weight.  
The dose response relationship of the cognition modulating effect of 
MPH differs across different cognitive domains. Performance on working 
memory tasks is most effectively enhanced by medium and high doses. On the 
other hand, in the domains of speed of processing, verbal learning and 
memory and attention and vigilance, lower doses are more effective. An 
explanation for this may be that in healthy volunteers, the dopamine 
availability is already close to the optimal level. Enhancing dopamine activity 
may push the level of dopamine beyond the optimum without improving 
performance or even leading to suboptimal performance.  
Factors limiting the conclusions in this review relate to the decisions 
that were made on how to categorize, list and present the data. As there 
were quite some tasks that were not described in the papers on which the 
categorization in dimensions was based, the authors had to assign those to the 
different domains. Although this was done very carefully, the choices may 
sometimes be arbitrary. Other decisions that were well thought through, but 
might still be somewhat arbitrary include: (1) some tasks were split into 
several measures whereas others were not; (2) a statistical trend was given a 
weight of 0.5; (3) if it was not clear which of the reported doses led to 
significant effects, it was assumed that the reported effect was applicable to 
every dose; (4) sometimes two low doses are reported, but they are only 
weighed once; (5) there was no correction for multiple comparisons for 
multiple dosing. Finally a major limitation of any review is that studies that 
did not show significant effects are generally underreported (i.e. publication 
bias). Therefore, any review is likely to present an overestimation of the 
reported effects.  
In sum, the studies reviewed here showed improvement of working 
memory and speed of processing and, to a lesser extent of verbal learning and 
memory, reasoning and problem solving and attention and vigilance. As 
detailed above, the effects are not such that taking MPH guarantees better 
cognitive function. In fact, performance could even decrease after MPH 
intake. MPH effects are dose dependent and the dose-response relationship 
differs between the different cognitive domains. For speed of processing, 
verbal learning and memory and attention and vigilance there is a negative 
dose-response relationship whereas the results within the working memory 
domain are consistent with the inverted-U curve. It is important to note that 
this review only included studies on acute dose effects and we cannot 
comment on effects of long-term MPH use. In conclusion, healthy individuals 
should be cautious when considering using MPH. The actual effects may be 
smaller than expected by abusers 
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Abstract 
 
Rationale: Methylphenidate inhibits the reuptake of dopamine and 
noradrenaline and is used to treat children with attention deficit 
hyperactivity disorder (ADHD). Besides reducing behavioral symptoms, it 
improves their cognitive function. There are also observations of 
methylphenidate-induced cognition enhancement in healthy adults, although 
studies in this area are relatively sparse. We assessed the possible memory-
enhancing properties of methylphenidate.  
Objective: In the current study, the possible enhancing effects of three doses 
of methylphenidate on declarative and working memory, attention, response 
inhibition and planning were investigated in healthy volunteers.  
Methods: In a double blind placebo-controlled crossover study, 19 healthy 
young male volunteers were tested after a single dose of placebo or 10, 20 or 
40 mg of methylphenidate. Cognitive performance testing included a word 
learning test as a measure of declarative memory, a spatial working memory 
test, a set-shifting test, a stop signal test and a computerized version of the 
Tower of London planning test.  
Results: Declarative memory consolidation was significantly improved relative 
to placebo after 20 and 40 mg of methylphenidate. Methylphenidate also 
improved set shifting and stopped signal task performance but did not affect 
spatial working memory or planning.  
Conclusions: To the best of our knowledge, this is the first study reporting 
enhanced declarative memory consolidation after methylphenidate in a dose-
related fashion over a dose range that is presumed to reflect a wide range of  
dopamine reuptake inhibition. 
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Introduction 
 
Cognition enhancement has received much attention in recent scientific 
literature, due to our aging society and the increasing prevalence of 
Alzheimer’s Disease. However, the healthy young population also engages in 
drug use to enhance cognition as is illustrated by the abundant illicit use of 
drugs that are normally prescribed for the treatment of attention deficit 
hyperactivity disorder (ADHD) including methylphenidate (Ritalin) and other 
amphetaminelike stimulants, which are believed to improve cognitive 
performance (Greely, et al., 2008; Maher, 2008). This has raised concern 
regarding the ethical and safety aspects of potential cognition-enhancing 
drugs (Greely, et al., 2008; Larriviere, et al., 2009; Sahakian & Morein-Zamir, 
2007). These issues aside, it is important to know if these drugs do actually 
have cognition-enhancing effects in healthy subjects.  
Methylphenidate inhibits the reuptake of the catecholamines 
dopamine and noradrenaline by blocking the transporters and thus enhances 
catecholamine availability (Hannestad, et al., 2010; Volkow, Wang, Fowler, 
Gatley, et al., 1998). Methylphenidate treatment does not only reduce 
behavioural symptoms in children with ADHD but also improves their cognitive 
function (Pietrzak, et al., 2006). There are also observations of 
methylphenidate induced cognition enhancement in healthy adults (Elliott, et 
al., 1997; Mehta, et al., 2000), although studies in this area are relatively 
sparse.  
Previous studies on the effects of methylphenidate on cognitive 
function in healthy volunteers have mainly focused on cognitive domains 
which are known to be affected in ADHD or to involve dopaminergic action. 
These include attention, response inhibition, planning and (working) memory 
(Cools & Robbins, 2004; Luciana & Collins, 1997; Luciana, Depue, Arbisi, & 
Leon, 1992; Mehta, Sahakian, McKenna, & Robbins, 1999; Pietrzak, et al., 
2006). One aspect of attention studied in healthy volunteers is divided 
attention. Methylphenidate has been observed to improve performance on a 
divided attention task, in which participants have to track a moving target 
with a joystick and simultaneously press a button in response to the 
appearance of a visual stimulus (Bishop, et al., 1997; Roehrs, et al., 1999). 
These effects were most prominent when participants were sleep-deprived.  
Attentional control has been assessed in healthy volunteers using an 
intradimensional/extradimensional shift task, which requires participants to 
make visual discriminations while stimulus characteristics vary along different 
dimensions and the relevant dimension reverses between different task stages 
(Rogers, et al., 1999). Although Elliott et al. (1997) found no effect of 
methylphenidate on this task, Rogers et al. (1999) observed an enhanced 
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ability to reallocate attention towards newly relevant features of 
environmental stimuli after methylphenidate.  
 Response inhibition, as assessed in a Go-NoGo task has been shown to 
improve with methylphenidate in older adults (Ben-Itzhak, Giladi, 
Gruendlinger, & Hausdorff, 2008). Planning is also observed to be affected by 
methylphenidate in healthy adults. In two versions of the Tower of London 
task, enhanced performance was observed when methylphenidate was 
administered in the first of two sessions as opposed to impaired performance 
when the drug was taken in the second session (and placebo in the first, 
(Elliott, et al., 1997)). Elliott et al. explain this result hypothesizing that 
methylphenidate enhances performance on novel tasks but impairs 
performance on familiar tasks.  
There are several reports of improved performance on both nonspatial 
and spatial working memory tasks after methylphenidate administration in 
healthy adults. For example, methylphenidate enhances performance on the 
Sternberg memory scanning task, in which participants are asked to judge 
whether probe letters were in the memory set that was learned at the 
beginning of the task (Brumaghim & Klorman, 1998; Fitzpatrick, et al., 1988). 
Improvement of spatial working memory has been observed within a self-
ordered search task in which participants search for tokens in an array of 
boxes displayed on a computer screen  (Elliott, et al., 1997; Mehta, et al., 
2000). 
Besides the domains described above, few researchers have studied 
the influence of methylphenidate on immediate and delayed recall of word 
lists (Bray, et al., 2004; Camp-Bruno & Herting, 1994; Hermens, et al., 2007; 
Kuypers & Ramaekers, 2005), none of whom found a significant effect. This is 
surprising as methylphenidate is known to enhance delayed recall of word lists 
in ADHD (Evans, Gualtieri, & Amara, 1986). The pharmacologically similar 
compound amphetamine has shown to improve consolidation and retention of 
word lists while leaving acquisition unaffected (Advokat, 2010). Experiments 
from Soetens and Zeeuws (Soetens, et al., 1995; Soetens, et al., 1993; 
Zeeuws & Soetens, 2007) have shown that amphetamine facilitates verbal 
memory recall if it is active in the brain during the consolidation phase 
(Soetens, et al., 1995). Additional experiments showed that the effect 
increases with longer presentation time of the words, lasts at least three 
days, is independent of retrieval and generalizes to recognition (Soetens, et 
al., 1995; Zeeuws, Deroost, & Soetens, 2010; Zeeuws & Soetens, 2007). 
 Importantly, task procedures used by Soetens and Zeeuws were rather 
different from those used in the methylphenidate studies cited above. 
Hermens et al., Kuypers & Ramaekers and Bray et al. used word lists 
containing only 12 or 15 items. In combination with repeated presentations 
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(three or four times), this may have led to a ceiling effect in performance. In 
line with this notion, using lists of 24 easy nouns that were presented only 
once, Camp-Bruno & Herting (1994) did observe improved performance in 
both immediate and delayed recall, although this effect was not significant. 
The aim of the current study was to find out whether enhanced word 
recall could be observed after methylphenidate with a more optimal 
experimental design. In order to avoid possible ceiling effects suspected to 
have influenced the studies mentioned above, a 30-word learning test was 
used in the current study. Performance on the 30 word lists of the visual 
verbal learning task was tested in 19 healthy volunteers after 10, 20 or 40 mg 
of methylphenidate and placebo. To get a more complete view of 
methylphenidate’s cognitive effects, not only extending previous findings but 
also putting current effects of methylphenidate on word learning into 
perspective, additional cognitive tasks were administered. These additional 
tasks were carefully selected to represent the most relevant cognitive 
domains, both with respect to the most common clinical application of 
methylphenidate (i.e. treatment of ADHD) and dopaminergic involvement. 
Hence, we included tasks assessing attention, response inhibition, planning 
and working memory.  
The design of the current study, using three different doses of 
methylphenidate in a placebo-controlled within-subjects experiment allows 
examination of a dose-response relationship for this drug and its effect on 
cognition. It addresses some methodological issues observed in other studies 
using only a single dose or comparing different doses in parallel groups 
(Elliott, et al., 1997; Mehta, et al., 2000). Dose related effects of moderate to 
high doses of methylphenidate on memory consolidation were expected to be 
reflected by better delayed recall. Performance on the other tasks was also 
expected to improve after moderate to high doses of methylphenidate. Based 
on the effect of methylphenidate on psychomotor function it was expected 
that improved performance on these tasks may mainly be reflected by faster 
response times. 
 
Method 
 
Participants 
Nineteen healthy male volunteers (mean age = 23.4, SD = 5.4, range = 19-37) 
were selected and paid to participate. Participants were recruited by means 
of local advertisements. Prescreening occurred using a medical history 
questionnaire and was followed by medical examination. 
The main inclusion criteria were: between 18 and 40 years of age, 
body mass index between 18 and 30 kg/m2 and right-handedness. The main 
42 
Chapter 2 
exclusion criteria were history or presence of mental or physical disorders 
consumption of more than 21 alcohol units per week or more than five 
caffeine containing drinks per day. In addition, volunteers with polymorphisms 
of the CES1 gene indicative of being a poor metabolizer of methylphenidate 
were excluded. One participant was excluded based on this criterion. 
All subjects gave written informed consent. The study was carried out 
in accordance with the Declaration of Helsinki and approved by the medical 
ethical committee of Maastricht University. 
 
Design 
The study was conducted according to a double-blind, placebo-controlled, 
four-way crossover design. Between the testing days a period of at least 48 h 
elapsed, but generally testing days were scheduled approximately 1 week 
apart. Each participant received one of four single treatments including 
placebo (PLA) and 10, 20 and 40 mg methylphenidate (M10, M20 and M40) on 
each testing day. The order of the treatments was randomized following a 
Williams Latin Square design resulting in four different sequences.  
 
Visual verbal learning test 
This task is an adapted version of Rey’s Auditory Verbal Learning Test (Lezak, 
1995). The VVLT was used to measure declarative memory. It included 30 
words that were presented on a computer screen (stimulus presentation time 
and inter-stimulus interval were 1000 ms, (Klaassen, Riedel, Deutz, & Van 
Praag, 2002)). This presentation was repeated three times using the same 
sequence of words, each time followed by immediate free recall of all 
remembered words. Thirty minutes after immediate free recall of the final 
series participants were subjected to a delayed recall test and a recognition 
test. During the latter, 30 words were presented, 15 of which were previously 
presented and another 15 that were new. Outcome measures of the 
immediate and delayed recall tests were total number of correctly recalled 
words during immediate recall (summed over three trials) and number of 
correctly recalled words during delayed recall. The dependent measures of 
the recognition test were median reaction time, measured in milliseconds and 
sensitivity (A’). A’ is calculated as follows: A’=1 - 1/4[fr / cr+(1 – cr) / (1 - 
fr)], with fr = falsely recognized words and cr = correctly recognized words.  
 
Spatial working memory task 
The ‘Object relocation’ program was used as a spatial working memory task 
(Kessels, Postma, & de Haan, 1999; Kessels, Postma, Wester, & de Haan, 
2000). In this task participants were required to relocate ten visual stimuli 
(small drawings of objects such as a car or a flower) that were presented on a 
 43
Methylphenidate and declarative memory consolidation in healthy volunteers 
computer screen in a 15-cm2 sized square to their original location. The task 
consisted of two parts. In the first part, called ‘object to position’ or OTP, 
participants had 15 s time to memorize the locations of the objects and were 
asked to drag the objects to the correct positions, which were cued with 
black dots. In the second part, the combined (COM) part, participants had 30 s 
to memorize the locations and this time, there were no cues to indicate the 
previous positions. Participants were instructed to place the objects in their 
original position as accurately as possible. In both parts, there was no time 
limit for the relocation of the stimuli. The dependent variables were 
percentage correct for OTP and percentage correct, absolute error and 
positional fit for COM. In the COM part, percentage correct was calculated 
such that relocation would be correct when the object was placed within 20 
mm from the original location. Absolute error was the absolute distance in 
millimeters an object was relocated away from its original position. Positional 
fit measured the ability to remember the locations per se, independent from 
the ability to remember which object was in each location and computed as 
the best fit score yielding the smallest distance error for the stimulus as a 
whole.  
 
Set shifting task 
The set shifting task used in this study combined the methods of Müller and 
Townsend (J. Muller, et al., 2007; Townsend, Adamo, & Haist, 2006). The task 
measured cognitive flexibility and the influence of reward. Participants were 
presented with a stream of auditory and visual stimuli, including light and 
dark blue squares on a computer screen and high and low tones through 
headphones (stimulus presentation time was 150 ms and inter-stimulus 
interval was 850 ms). Assignments so as to respond to the tones (‘Hear trials’) 
or the squares (‘Look’ trials) were interspersed with the stimuli and presented 
for 1.000 ms. Participants were told to respond only to the dark blue square 
and the high tones, while ignoring the light blue squares and low tones. In half 
of the trials, a ‘€’ sign on the computer screen indicated that if they would 
perform very well (correct and fast responses), they would earn an additional 
monetary reward (awarded to the best performer in the study). The 
experiment contained six blocks, of which three were ‘reward blocks’ and 
three were ‘nonreward blocks’. Each block contained 56 stimuli and switching 
occurred after a variable number of trials, ranging between five and nine 
trials. The sequence of blocks was randomized between participants and 
sessions. After a block containing the reward stimuli, the participants 
received feedback on how well they performed. Participants were expected 
to respond faster in the reward than in the control conditions. Dependent 
measures were response times in correct trials and percentage of correct 
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responses. These were calculated separately for the four different trial types: 
Look in the reward blocks; Look in the non-reward blocks; Hear in the reward 
blocks; and Hear in the nonreward blocks. 
 
Stop signal task 
The stop signal task was used to measure motor impulsivity and adapted from 
that used by Fillmore et al. (Fillmore & Rush, 2002). In this task participants 
were required to respond to go signals and inhibit the response when a stop 
signal was presented. On a computer screen, the go signals were visually 
presented letters, A, B, C and D (stimuli were presented for 500 ms, or until 
the participant responded; interstimulus interval was 1500 ms). The stop 
signal was the visual presentation of a ‘*’at one of the corners of the screen. 
Participants were instructed to respond as fast as possible with left (to A and 
C) and right (to B and D) index fingers. Stop signals were presented at delays 
of 50, 150, 250, and 350 ms.  A single test consisted of 176 trials in which 
each of the four-letter stimuli was presented equally often. A stop signal 
occurred in 48 trials during a test. Dependent variables were the proportion of 
commission errors on stop trials and the reaction times on go and stop-signal 
trials (i.e. stop reaction time). Reaction time to stop-signal trials represented 
the estimated mean time required to inhibit a response. The method for 
calculating stop reaction time was taken from the race model of inhibitory 
control (Logan, 1994). Stop reaction time was calculated by subtracting the 
stop-signal delay from the reaction time on go-trials associated with the nth 
percentile of the reaction time distribution. The nth percentile corresponds to 
the percentage of commission errors (Logan, 1994; Ramaekers, et al., In 
press). 
 
Tower of London 
Planning ability was assessed by a computerized version of the Tower of 
London task (Sobczak, et al., 2002). On a computer screen, two arrays of 
differently colored balls (red, yellow and blue) on sticks were presented until 
the subject responded. The subject was requested to indicate the minimal 
number of steps necessary to rearrange the balls on the lower configuration to 
match the arrangement presented on the top half of the screen. The subjects 
had to count the number of moves and then respond by pressing the 
appropriate response button (two to six steps) as quickly as possible. The 
complexity of the task was dependent on the minimal number of steps in 
which the rearrangement could be achieved: two, three, four and five steps 
and sometimes six steps, to avoid guessing (only two to five are analyzed). 
Performance was indicated by the slope coefficient of the linear regression of 
the median response time as a function of the number of steps. In addition, 
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percentage correct and response time calculated per number of minimally 
required steps were taken into account. 
 
Procedure 
The current study was integrated in a larger study  on the effects of 
methylphenidate on the Contingent Negative Variation (Linssen, et al., 2011). 
A training session in which the tasks were practiced took place within 2 weeks 
before the first testing day. Participants abstained from alcohol during the 
last 24 h prior to each testing day. On testing days, they were collected at 
their home and arrived at the lab in fasted condition at either 8.00 am or 8:30 
am. Inclusion and exclusion criteria were checked. Next, participants were 
given a standardized meal for breakfast at 80 min pre dose (t = -80). At t = -
30, stop signal, set shifting and spatial working memory tests were 
administered to get a baseline measurement. At t = 0 participants ingested 
four capsules with water, which contained either PLA, M10, M20 or M40. The 
stop signal, set shifting and spatial working memory tests were administered 
again at t = 90 and t = 270. The verbal word learning test and the Tower of 
London were administered at t = 150, followed by delayed recall and 
recognition testing of the words approximately 30 min later. At the end of the 
testing day participants were returned to their home. 
 
Data analysis 
Data were analyzed using a repeated measures analysis of variance. Because 
one subject dropped out, there was a minimal deviation from complete 
balancing of treatment orders (order 1=PLA, M10, M20, M40 (five 
participants), order 2 = M10, M40, PLA, M20 (five participants), order 3 = M20, 
PLA, M40, M10 (four participants) and order 4 = M40, M20, M10, PLA (five 
participants)). For this reason, treatment order was entered as a between 
subjects factor. Since treatment consisted of different doses of the same 
drug, main effects of the drug were not evaluated. Instead, a priori planned 
comparisons between each dose relative to placebo were tested for 
significance, at p<.05, using LSD correction.  
 
Results 
 
Visual verbal learning test 
Mean values of dependent measures of the visual verbal learning task are 
presented in Figure 1. Methylphenidate had no effect on immediate recall. 
However, delayed recall improved after M20 (F1,14=4.937, p<.05) and M40 
(F1,14=6.084, p<.03) compared to placebo. 
46 
Chapter 2 
Median reaction time on the recognition test was slower after M40 
(F1,14=5.953, p<.05). Sensitivity was higher after 40 mg of methylphenidate 
(F1,14=4.878, p<.05). 
Figure 1. Means of dependent measures (a: Total number of correctly recalled words in 
immediate recall; b: Number of words recalled in delayed recall; c: Median response time in 
recognition test; d: Sensitivity of recognition test) of the word learning test after placebo and 
methylphenidate, 10, 20 and 40 mg (PLA, M10, M20 and M40 respectively). Significant differences 
relative to placebo are indicated by *. 
 
Spatial working memory task 
Methylphenidate did not significantly affect spatial working memory task 
performance (Table 1).   
 
Set shifting task 
Methylphenidate did not affect response time and percentage correct in the 
‘look’ trials in the reward blocks. In the nonreward blocks there was also no 
effect of the drug on percentage correct. However, methylphenidate led to 
faster responses on the ‘look’ trials of the nonreward blocks after M40 at T90 
(F1,15=9.589, p<.01) and after M10 and M40 at T270 (M10: F1,14=5.363, p<.04, 
M40: F1,14=14.145, p<.01) 
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 Responses to ‘hear’ trials were faster in the non-reward parts of the 
task at T270 (M401,14=6.885, p<.03). Methylphenidate improved performance 
in the hear trials in both reward (M40: F1,15=10.261, p<.01) and non-reward 
trials (M20: F1,15=4.713, p<.05, M40: F1,15=5.809, p<.03) at T90 and reward 
trials at T270 (M40: F1,14=6.764, p<.03).  
 
Stop signal task 
A dose of 20 mg of methylphenidate led to faster go and stop responses at 
T270 (go: F1,14=5.479, p<.04; stop:F1,14=9.341, p<.01). Performance on this 
task, as measured by percentage correct was improved after M40 in stop trials 
at T90 (F1,15=10.698, p<.01).  
 
Tower of London  
Methylphenidate only positively affected performance of trials that could be 
solved in three steps, when given at a dose of 20 mg (F1,15=5.065, p<.05). 
Participants responded faster after M10 and in the trials that could be solved  
in five steps (M10: F1,15=7.616, p<.02) (Table 2). 
 
Discussion 
 
In this dose-response study, different doses of methylphenidate were tested 
for their effect on memory and other cognitive functions in healthy 
volunteers. Methylphenidate improved delayed recall of word lists. In 
addition, set shifting and stop signal test performance improved after 
methylphenidate. Methylphenidate had little effect on the Tower of London 
task performance and no effect on performance of the spatial working 
memory task.  
Based on earlier findings of enhanced declarative memory 
consolidation after amphetamine, it was expected that methylphenidate 
would improve performance on the 30-word learning test. Results of the 
current study confirmed this expectation. Participants recalled more words in 
the delayed recall test after 20 and 40 mg of methylphenidate, compared to 
placebo. Since no improvement was observed at immediate recall, enhanced 
delayed recall is likely caused by better consolidation. To the best of our 
knowledge we are the first to report better consolidation of word lists after 
methylphenidate in healthy adults. Since previous studies used similar doses 
(20 or 45 mg), suboptimal dosing is an unlikely explanation for the lack of 
performance-enhancing effects in those studies. An important factor may be 
word list length. When testing memory in healthy volunteers, a ceiling effect 
is easily reached if relatively short lists are presented repeatedly. Since it was 
hypothesized that enhanced dopamine activity induced by methylphenidate  
  
Table 1  
Mean values (SEM) of dependent measures of the spatial working memory test (SWM), Set shifting (SSHT) and stop signal (SST) after placebo and methylphenidate 
10, 20 and 40 mg (PLA, M10, M20 and M40 respectively). (OTP=object to position; COM=combined; abs err=absolute error; pos fit=positional fit; Look €=Look 
reward trials; Look=Look non-reward trials; Hear €=Hear reward trials; Hear=Hear non-reward trials; RT=response time) 
    T60               T240               
  PLA  M10  M20  M40  PLA  M10  M20  M40  
SW  M
ST
                 
OTP % correct 5.6 (4.5) -9.6^ (5.5) -5.3 (-5.5) -6.9 (4.9) 2.4 (5.0) -5.3 (6.0) -4.9 (6.0) -1.0 (4.0) 
COM % correct -7.5 (6.0) 9.9^ (6.4) -10.0 (3.0) -5.0 (6.3) -8.5 (4.4) 3.4 (6.9) -11.9 (5.5) 2.6 (6.8) 
 abs err -17.6 (27.6) -58.6 (33.8) 21.7 (25.4) 8.6 (21.7) 25.2 (19.4) 16.9 (23.3) 25.6 (20.6) 6.0 (28.9)
 pos fit 3.9 (10.8) -15.7 (13.6) 9.0 (8.4) -0.0 (11.9) 22.4 (10.9) -15.5^ (12.5) 16.1 (11.8) 3.9 (13.0)
SSHT                  
Look € RT -1.3 (2.3) -1,6 (-2.4) -1,8 (-2.8) -2,9 (2.0) 1.6 (2.6) -2.6 (2.3) -5.4 (2.3) -4.8 (2.2) 
 % correct 0.2 (0.8) 0.6 (1.0) 1.0 (0.7) 2.1 (1.8) -0.4 (1.2) -0.7 (1.3) 0.6 (0.9) 0.4 (1.6) 
Look  RT 0.7 (1.9) -3.3 (1.8) -0.9 (1.8) -6.9* (1.8) 3.0 (2.8) -3.9* (1.6) -4.0^ (1.6) -9.6* (1.7) 
 % correct 2.1 (1.3) 0.2 (0.5) 0.5 (1.2) 0.4 (0.6) 1.0 (1.3) 1.3 (0.5) 0.6 (1.1) -0.1 (0.4) 
Hear € RT -8.5 (2.5) -5.8 (2.3) 2.5^ (4.1) -3.8 (2.2) -6.9 (2.5) -4.7 (1.5) -4.3 (3.0) -4.2 (3.4) 
 % correct -1.5 (0.9) 0.3 (0.4) 0.96^ (1.0) 2.3* (0.9) -1.0 (0.5) 0.3 (0.6) 1.0 (0.9) 2.1* (1.1) 
Hear  RT 0.3 (2.6) -5.1 (2.5) -1.5 (2.5) -6.9^ (2.0) -0.5 (1.7) -7.2^ (2.3) -5.9 (2.1) -8.7* (2.6) 
 % correct -1.3 (0.5) -1.3 (0.5) 1.3* (1.0) 0.4* (0.3) -1.1 (0.9) -0.7 (0.5) 0.9 (0.6) -0.1 (0.3) 
S                   
Go RT -9.3 (5.4) -20.1 (6.8) -20.0 (7.6) -33.6^ (11.8) 2.4 (7.4) -14.9^ (7.3) -20.7* (6.7) -24.6^ (9.8) 
 % correct 0.7 (0.7) 0.4 (0.6) -1.0 (1.2) 0.5 (0.8) 0.4 (0.7) -0.8 (0.5) -1.1 (1.0) -1.3 (1.0) 
Stop RT -9.4 (8.8) -11.9 (8.5) -32.2 (13.5) -3.1 (17.2) 4.6 (11.6) -3.2 (13.8) -44.2* (19.0) -21.0 (16.2)
  % correct -0.6 (1.9) 2.3 (2.1) 0.8 (2.3) 6.3* (1.6) -0.1 (2.1) 3.0 (2.8) 1.6 (2.4) 0.2 (1.9) 
*p<0.05, ^p<.1. 
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Table 2  
Mean values (SEM) of dependent measures of Tower of London (ToL) after placebo and 
methylphenidate 10, 20 and 40 mg (PLA, M10, M20 and M40 respectively). (RT=response time) 
    T160               
  PLA  M10  M20  M40  
Slope  0.4 (0.0) 0.4 (0.0) 0.4 (0.3) .4 (0.0) 
2 steps RT 4277 (300) 4356 (366) 4458 (418) 4760 (508) 
 % correct 95.8 (2.3) 95.9 (2.1) 95.1 (1.6) 94.9 (2.3) 
3 steps RT 6039 (502) 6461 (333) 5835 (446) 6128 (583) 
 % correct 95.5 (1.4) 95.1 (1.9) 98.9* (0.7) 94.5 (1.5) 
4 steps RT 9416 (895) 9197 (861) 8636 (715) 9892 (1153) 
 % correct 91.6 (2.3) 89.6 (2.1) 93.5 (2.2) 94.3 (2.7) 
5 steps RT 13458 (1007) 15770 (1231) 15076 (1321) 15441 (1291) 
  % correct 84.1 (3.3) 85.3* (3.0) 79.8 (2.7) 85.4^ (3.3) 
*p<0.05, ^p<.1. 
 
may lead to improved word learning test performance, the use of lists of 12 to 
15 words in previous studies (Bray, et al., 2004; Hermens, et al., 2007; 
Kuypers & Ramaekers, 2007) may have left no room for improvement. 
 There are ample indications of dopamine involvement in (spatial) 
working memory (Ellis, et al., 2007; Landau, Lal, O'Neil, Baker, & Jagust, 
2008; Robbins, 2005). Indeed, methylphenidate has been shown to improve 
spatial working memory performance (Elliott, et al., 1997; Mehta, et al., 
2000). This effect was, however, not replicated in the present study. A 
possibly important difference between the self-ordered search tasks used in 
previous studies and the spatial working memory task used here is that 
encoding of spatial locations occurs under time pressure in the current task. 
Previous research has suggested that methylphenidate may induce  activity 
and arousal in healthy volunteers (Clark, et al., 1986b; Elliott, et al., 1997). 
Hence, participants may have had difficulties to encode information due to 
over-arousal.  
 Methylphenidate generally improved performance of the set shifting 
task, as was indicated by both faster responses and a higher percentage of 
correct responses. Most effects were observed on the hear trials, suggesting 
that methylphenidate affected auditory attention more than visual attention. 
It is unclear why this should be the case. Our expectation that the effect of 
methylphenidate would be more pronounced in the reward parts of this task 
was not confirmed. Participants may not have paid attention to the ‘€’ sign, 
which indicated that they were in the reward condition. 
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Methylphenidate improved stop signal task performance as was 
indicated mainly by faster responses. Effects were most prominent in the go 
trials. Faster responses (both in the set shifting and the stop signal task) may 
partly reflect the response readiness-enhancing effect of methylphenidate 
(Linssen, et al., 2012)  increasing the speed of performance (Elliott, et al., 
1997). Furthermore, taking into account the relatively high number of 
statistical comparisons being made in this study, some of the effects reported 
here including those on the Tower of London task may not be genuine drug 
effects. Therefore, the overall pattern of results was considered when 
describing drug effects. Thus, generally, MPH improved measures of 
declarative memory, attention and response inhibition. 
The effects of methylphenidate were observed within a rather wide 
time window, between 90 and 270 min after drug intake. This likely reflects a 
relatively long lasting enhancement of dopamine levels in the blood after 
methylphenidate. Blood dopamine levels cannot be measured directly, but 
changes in prolactin level in blood are a good surrogate marker, since the 
prolactin level is known to rise as the dopamine level decreases and vice versa 
(Ben-Jonathan, 1985). Indeed, prolactin levels were decreased between 60 
and 240 min after methylphenidate administration in this group of 
participants (Linssen, et al., 2011).  
 Most studies into effects of dopaminergic drugs on aspects of cognitive 
performance describe results according to an inverted U curve when 
performance is mapped as a function of degree of neurotransmitter activity 
(Levy, 2009; Mehta, Goodyer, & Sahakian, 2004). The design of the present 
study, using three doses of methylphenidate, the highest of which corresponds 
to 75% blocking of dopamine reuptake sites (Volkow, Wang, Fowler, Gatley, et 
al., 1998), should allow to reveal the inverted-U curve, if present. This would 
be reflected by improved performance at low and intermediate dosing levels 
and a drop in performance enhancement at the higher dose. However, the 
current findings suggest that methylphenidate influences memory 
consolidation in a monotonic positive fashion. Although dose-response 
relationships may differ between cognitive domains, it has been shown that 
methylphenidate effects on response readiness can also not be described in 
terms of the inverted U function (Linssen, et al., 2011). Methylphenidate’s 
enhancing effects on response readiness were observed even after a dose as 
low as 10 mg and grew more consistent and prominent with increasing doses. 
Hence, our data challenge the existence of the inverted U relationship, at 
least with respect to declarative memory consolidation and response 
readiness.  
In conclusion, this was the first study to find dose-related effects of 
methylphenidate on declarative memory consolidation. This result is in line 
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with earlier described findings of amphetamine-induced enhancement of 
memory consolidation. Improved performance was also observed on stop 
signal and set shifting tasks.  
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Abstract 
 
Previous research has shown that methylphenidate (MPH) improves cognitive 
function in ADHD. The evidence for cognition enhancing effects of MPH in 
healthy individuals is inconsistent. The current study aimed to investigate 
effects of MPH on declarative and working memory, specifically focusing on 
robustness and specificity of previous results. To study the dopaminergic 
contribution to MPH effects, effects of 40 mg of MPH on memory performance 
were compared to 100 mg of levodopa (LEV) in a placebo-controlled crossover 
study with 30 healthy volunteers. Memory performance testing included a 
word learning test and several working memory tests. Simultaneously with the 
word learning test, event-related brain potentials (ERPs) were measured. 
Subjective and physiological recodings were included as control measures. 
MPH decreased memory decay over a period of 24 hours. MPH and LEV had 
opposite effects on memory task performance and electrophysiological 
correlates. It is suggested that MPH enhances cognitive function under 
challenging conditions and that the LEV manipulation in this study did not 
lead to enhanced dopaminergic activity. 
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Introduction 
 
Methylphenidate has been shown to not only reduce behavioral symptoms of 
children with ADHD, but also improve cognitive function in this group 
(Pietrzak, et al., 2006). Lately, interest in methylphenidate as a possible 
cognitive enhancer for the healthy population has increased (Repantis, et al., 
2010; Sahakian & Morein-Zamir, 2007; M. E. Smith & Farah, 2011). Evidence 
for a global cognition enhancing effect of methylphenidate is lacking, as the 
results are reported to be mixed or inconsistent (Advokat, 2010; Repantis, et 
al., 2010; M. E. Smith & Farah, 2011). However, enhanced performance 
following methylphenidate administration has been observed within specific 
domains of cognitive function such as speed of processing and working 
memory (Agay, et al., 2010; Elliott, et al., 1997; Halliday, et al., 1986; 
Kollins, et al., 1998; Linssen, et al., 2011; Mehta, et al., 2000). Recently, 
methylphenidate has been shown to have a dose-related performance 
enhancing effect on a word learning task in healthy volunteers (Linssen, et 
al., 2012). With this being the first study to find dose-related effects of 
methylphenidate on declarative memory consolidation, the robustness and 
specificity of these findings should be further studied. 
 Methylphenidate blocks the reuptake of the catecholamines dopamine 
and noradrenaline by binding to the transporters, thereby increasing 
catecholamine availability (Hannestad, et al., 2010; Kuczenski & Segal, 1997; 
Volkow, Wang, Fowler, Gatley, et al., 1998). Whether the effects of 
methylphenidate on cognition are mediated by dopamine or noradrenaline is 
unclear. It is suggested that methylphenidate’s potency may be higher for the 
noradrenaline- than the dopamine transporter (Kuczenski & Segal, 1997). But 
as dopamine is also transported by the noradrenaline transporter, it is not 
clear if noradrenaline or dopamine is more affected by methylphenidate 
(Hannestad, et al., 2010; Pacholczyk, Blakely, & Amara, 1991).  
Previous research suggests that dopamine mediates working memory 
function. Working memory is impaired in conditions in which dopamine levels 
are suboptimal such as in Parkinson’s disease (Dujardin & Laurent, 2003; 
Nieoullon, 2002; Owen, Iddon, Hodges, Summers, & Robbins, 1997) and can be 
restored by dopaminergic treatment (Costa, et al., 2003; Lewis, Slabosz, 
Robbins, Barker, & Owen, 2005; Moustafa, Sherman, & Frank, 2008). In 
healthy volunteers dopamine agonists enhance working memory performance 
whereas dopamine antagonists impair it (Elliott, et al., 1997; Luciana, et al., 
1992; Mehta, et al., 1999). Declarative learning and memory are also 
modulated by dopamine. Associative learning and retention of these 
associations is enhanced by levodopa, the precursor of dopamine 
(Breitenstein, Floel, et al., 2006; Knecht, et al., 2004). Recognition of 
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emotional material is impaired by sulpiride, a dopamine antagonist (Mehta, 
Hinton, Montgomery, Bantick, & Grasby, 2005). 
Noradrenaline is also thought to play a role in memory (Chamberlain, 
Muller, Blackwell, Robbins, & Sahakian, 2006; Kobayashi & Yasoshima, 2001). 
Noradrenaline antagonists, such as the beta-blocker propranolol impair 
working memory and emotional memory (Chamberlain, et al., 2006; U. Muller, 
et al., 2005; Oei, Tollenaar, Elzinga, & Spinhoven, 2010; van Stegeren, et al., 
2005). However the exact nature of the role of noradrenaline in memory is 
relatively poorly understood. 
Hence, both modulation of noradrenaline- and dopamine alters 
cognitive function and methylphenidate’s effect on memory consolidation 
may be mediated through either dopamine, noradrenaline or both. To study 
the contribution of each of these neurotransmitters to methylphenidate’s 
effects on cognitive function, methylphenidate should be contrasted with 
pure dopaminergic and/or noradrenergic drugs. As discussed above, 
catecholamine-transporter blockers, even if specifically blocking only either 
transporter type, will affect both neurotransmitters. In the current study the 
cognitive effects of methylphenidate were compared to those of levodopa. 
Levodopa is used to treat Parkinson’s disease (Nutt, 2008) and is a dopamine 
precursor which is converted to dopamine both in the peripheral as well as 
the central nervous system (Julien, 2005), increasing dopamine availability in 
body and brain. While the mechanism of increasing dopamine levels in the 
brain is different from that of methylphenidate, levodopa administration 
allows the study of purely dopaminergic effects on cognition without 
interfering with noradrenaline levels.  
In Parkinson’s disease, levodopa’s effects on cognitive function have 
been reported to differ between patients (Kulisevsky, 2000). Reported effects 
of levodopa on cognition range from impairment and no effect to better 
performance (Ghilardi, et al., 2007; Shohamy, Myers, Geghman, Sage, & 
Gluck, 2006; Shohamy, Myers, Grossman, Sage, & Gluck, 2005). In healthy 
volunteers levodopa has been shown to improve motor memory formation 
(Floel, et al., 2005; Floel, et al., 2008). Furthermore accelerated associative 
learning and better retention of pseudowords were observed in healthy 
volunteers who received levodopa over five training days (Breitenstein, Floel, 
et al., 2006; Knecht, et al., 2004). 
The current study aimed to replicate and extend the previous finding 
of enhanced declarative memory consolidation in healthy volunteers after 
methylphenidate. In order to study the dopaminergic contribution to the 
methylphenidate effect on the word learning test, the effect of a 40 mg dose 
of methylphenidate was compared to that of 100 mg of levodopa in a placebo 
controlled crossover designed study with 30 healthy volunteers. It was 
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hypothesised that the effect of levodopa would be similar to that of 
methylphenidate, as levodopa has been shown to have the potential to 
improve retention of verbal information (Breitenstein, Floel, et al., 2006; 
Knecht, et al., 2004). Such a result would suggest a major role for dopamine 
in the memory enhancing effect of methylphenidate. Besides a standard word 
learning test, additional memory tasks were administered including spatial 
and verbal (working) memory tasks to investigate the specificity of the 
memory enhancing effect. Heart rate, blood pressure and subjective measures 
were included as control measures. 
 
Method 
 
Participants  
Thirty healthy volunteers (20 male, 10 female, mean age=20.7, SD=2.3, 
range=18-28) were selected and paid to participate. Participants were 
recruited by means of local advertisements. Prescreening occurred using a 
medical history questionnaire and was followed by medical examination.  
The main inclusion criteria were: between 18 and 45 years of age, 
body mass index between 18 and 30 kg/m2 and right-handedness. The main 
exclusion criteria were history or presence of mental or physical disorders, 
consumption of more than 21 alcohol units per week or more than five 
caffeine-containing drinks per day, pregnancy or lactation, use of medication 
other than oral contraceptives, use of recreational drugs from 2 weeks before 
until the end of the experiment. 
All subjects gave written informed consent. The study was carried out 
in accordance with the Declaration of Helsinki and approved by the medical 
ethical committee of Maastricht University.  
 
Design  
The study was conducted according to a double-blind, placebo-controlled, 
three-way crossover design. Between the testing days, a period of at least 48 
hours elapsed, but generally, testing days were scheduled approximately one 
week apart. Each participant received one of three single treatments 
including placebo (PLA), 40 mg of methylphenidate (MPH) and 125 mg of 
levodopa/carbidopa (LEV) on each testing day. LEV was given in combination 
with 10 mg of domperidone (a peripheral dopamine antagonist) to prevent 
nausea. Six different treatment sequences were used, with each sequence 
occurring 3 or 4 times. 
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Dependent measures 
Visual verbal learning test 
This task is an adapted version of Rey’s Auditory Verbal Learning Test (Lezak, 
1995). The VVLT was used to measure declarative memory. It included 30 
words that were presented on a computer screen (stimulus presentation time 
and interstimulus interval were 1.000 ms, (Klaassen, et al., 2002)). This 
presentation was repeated three times using the same sequence of words, 
each time followed by immediate free recall of all remembered words. Thirty 
minutes after immediate free recall of the final series, participants were 
subjected to a delayed recall test and a recognition test. During the latter, 30 
words were presented, 15 of which were previously presented and another 15 
that were new. The delay was filled with other tasks. Twenty-four hours later 
participants were again subjected to a delayed recall and recognition test. 
Outcome measures were total number of correctly recalled words during 
immediate recall (summed over three trials) and number of correctly recalled 
words during delayed recall tests. The electrophysiological dependent 
measures were amplitude and latency of the P3a, P3b and P600 ERP 
components, measured during encoding (averaged across three trials). P3a 
and P3b are two subcomponents of the P300, which is interpreted to brain 
activity related to updating the mental representation of incoming stimuli 
(Polich, 2007; Polich & Criado, 2006). P3a is induced by novel or unexpected 
stimuli, while P3b is associated with context updating and subsequent 
memory storage (Coull, 1998; Polich, 2007). P600, sometimes referred to as 
late positive component or positive slow wave has been associated with 
several higher-level functions, including syntactic processing, item recognition 
and working memory capacity (Chan, Chan, Kwan, Ting, & Chui, 2012; 
Friedman & Johnson, 2000; Lefebvre, Marchand, Eskes, & Connolly, 2005; 
Mecklinger, 2010; Swaab, Ledoux, Camblin, & Boudewyn, 2012). 
The behavioral dependent measures of the recognition test were 
median reaction time, measured in milliseconds and sensitivity (A’). A’ is 
calculated as follows: A’=1-1/4[fr/cr+(1-cr/1-fr)] with fr = falsely recognized 
words and cr = correctly recognized words. The electrophysiological 
dependent measures of the recognition task were amplitude and latency of 
the P3a, P3b and P600 ERP components. 
 
Sternberg memory scanning task 
Sternberg’s memory scanning test assesses the speed of scanning items 
maintained in working memory (Sternberg, 1966). In the current test, 
somewhat modified compared to the original, participants were briefly shown 
a set of 1, 2 or 4 unrelated consonants and were told to memorize them. This 
set is labeled the memory set. Then a series of 48 letters was sequentially 
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displayed on a computer screen (stimulus presentation time was 1000 ms and 
interstimulus interval was 2000 ms). The participants were required to 
indicate if the presented items matched those of the memory set by pressing 
either of two buttons. Half of the presented stimuli were part of the memory 
set. In this task reaction time increases linearly with the workload; that is, 
the number of items in the memory set. The slope of this function is an 
indication of the speed of scanning of short-term memory, whereas intercept 
is a measure of psychomotor speed. The dependent variables were slope, 
intercept, reaction time (in ms), and accuracy (indicated by a number 
between 0 and 1 with 0 indicating 100% incorrect and 1 indicating 100% 
correct). 
 
Paired associates learning 
The visual paired associates learning test requires participants to learn the 
association between an object and it’s location. On the first trial, two boxes 
were displayed on the screen and opened one by one. Each box contained a 
different object. The objects were then displayed in the middle of the screen, 
one at a time, and the subject was asked to click the box that contained the 
object. On each consecutive trial the number of boxes increased by one if the 
subject made no error (locations and objects differed between the trials) and 
decreased by one if the subject made an error, until a total of three errors 
was made, at which point the task was ended. The outcome measures of this 
test were maximum number of paired associates that was correctly recalled 
and mean number of paired associates that was correctly recalled across 
trials. 
 
Spatial working memory task 
The ‘Object relocation’ program was used as a spatial working memory task 
(Kessels, et al., 1999; Kessels, et al., 2000). In this task, participants were 
required to relocate ten visual stimuli (small drawings of objects such as a car 
or a flower) that were presented on a computer screen in a 15-cm2 sized 
square to their original location. The task consisted of two parts. In the first 
part, called ‘object to position’ or OTP, participants had 15 seconds time to 
memorize the locations of the objects and were asked to drag the objects to 
the correct positions, which were cued with black dots. In the second part, 
the combined (COM) part, participants had 30 seconds to memorize the 
locations and this time, there were no cues to indicate the previous positions. 
Participants were instructed to place the objects in their original position as 
accurately as possible. In both parts, there was no time limit for the 
relocation of the stimuli. The dependent variables were percentage correct 
for OTP and percentage correct, absolute error and positional fit for COM. In 
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the COM part, percentage correct was calculated such that relocation would 
be correct when the object was placed within 20 mm from the original 
location. Absolute error was the absolute distance in millimeters an object 
was relocated away from its original position. Positional fit measured the 
ability to remember the locations per se, independent from the ability to 
remember which object was in each location and computed as the best fit 
score yielding the smallest distance error for the stimulus as a whole.  
 
Subjective measures 
Participants completed two rating scales of subjective effects, the Profile of 
Mood States (POMS; (McNair, Lorr, & Droppleman, 1992)) and the Bond and 
Lader (B&L) visual analogue scales (Bond & Lader, 1974). These rating scales 
consisted of 16 (B&L) or 32 (POMS) bipolar items. Each item consisted of two 
words describing mood states. Participants had to score their preference for 
either of the items in accordance with their mood by marking the line closer 
to one of the two words. Dependent measures were factor scores on the 
dimensions Alertness (B&L), Depression, Anger, Fatigue, Vigour and Tension 
(POMS). Both rating scales were administered at four time points (T0, T50, 
T130 and T180) on each testing day. 
 
Physiological measures 
Physiological measures included systolic and diastolic blood pressure and 
heart rate and were taken at four time points (T0, T50, T130 and T180) on 
each testing day. 
 
Electroencephalography 
During the visual verbal learning task, EEG was recorded using 11 electrodes 
attached to a cap according to the international 10-20 system (Jasper, 1958) 
at the Fz, F3, F4, Cz, C3, C4, C3’, C4’, Pz, P3 and P4 electrode positions. The 
ground electrode was placed on the AFz location, on the forehead. Two 
electrodes placed on the mastoids served as reference channels. An electro-
oculogram (EOG) was measured bipolarly vertically above and below the right 
eye and horizontally next to the right and the left eye. Data were sampled at 
250 Hz and filtered online between 0.05 and 100 Hz. Offline, data were 
screened for artefacts and filtered between 1 and 30 Hz. ERPs were extracted 
by stimulus-locked averaging of epochs from 100 ms before to 1000 ms after 
stimulus presentation. In the ERPs extracted from the electroencephalogram 
during encoding several peaks could be discerned. P3a and P3b were 
respectively determined as the highest amplitude within 200-350 and 280-420 
ms after stimulus onset, while checking that two distinct peaks were picked 
by the program. The P600 was determined as the highest amplitude between 
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450 and 650 ms after stimulus onset. In addition, the latencies of these peaks 
were included in the analysis. In the ERPs measured during the recognition 
task, the same components were determined, with P3a and P3b between 200-
300 ms and 380-420 ms after stimulus onset and P600 within 450-650 ms. The 
latencies of these peaks were included in the analysis. 
 
Procedure 
The current study was integrated in a larger study on the effects of 
methylphenidate and levodopa on cognition and psychomotor function. A 
training session in which the tasks were practiced took place within 2 weeks 
before the first testing day. Participants abstained from alcohol during the 
last 24 h prior to each testing day. On testing days, participants were either 
collected at their home or came by public transport. They arrived at the lab 
in fasted condition at either 8.30 am or 9:00 am. Due to the differences in 
Tmax of the medication, drug administration occurred at different time 
points, MPH at T=0 (in minutes) and LEV at T=60. Domperidon was 
administered at T=30. To ensure double blinding, participants received 
identically appearing capsules at all time points on each testing day. 
Participants were given a standardized meal for breakfast. Then, the 
electrode cap was placed and participants could relax until actual testing 
started at T=120. First, a baseline EEG measurement was taken, followed by 
cognitive testing in the following order: Visual verbal learning test, Sternberg 
memory scanning task, delayed recall and recognition test of the visual verbal 
learning test, paired associates learning and spatial working memory task. In 
addition, two blood samples were taken at T=120 and T=180. Subjective and 
physiological measures were taken at four time points (T0, T50, T130 and 
T180). At the end of the testing day, participants were returned to their home 
by car.  
 
Data analysis 
The part of the data-analysis aimed at testing whether previous results were 
replicated consisted of one-sided paired t-tests between MPH and PLA. 
Next, the LEV data were entered in the analysis. Data were analyzed 
using a repeated measures analysis of variance (ANOVA), with the within 
subjects factor treatment (3 levels: PLA, MPH and LEV). For the EEG data 
additional within subjects factors were electrode (3 levels: Fz, Cz, Pz) and 
trial (3 levels for the three presentations of the word list).  
Since treatment effects of MPH and LEV were expected to go into the 
same direction, the main effects of treatment, electrode and trial were not 
evaluated. Instead, a priori planned comparisons between each drug relative 
to PLA were tested for significance at alpha <.05 using LSD correction.  
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Because of the different nature of the subjective and physiological 
measures, effects on these measures were assessed by paired t-tests between 
either drug vs. PLA on difference scores (relative to morning baseline). 
 
Results 
 
Visual verbal learning test 
Task performance 
Mean values of dependent measures of the VVLT and p-values of the planned 
comparisons are presented in Table 1.  
First, replication of previous results was tested by means of a one 
sided paired t-test between MPH and PLA. MPH did not affect immediate or 30 
minute delayed recall. However, when participants learned the words when 
under the influence of MPH, they remembered significantly more words at 24 
hour delayed recall, compared to PLA (t29=-2.033, p<.05, one-sided). None of 
the variables of the recognition tests was affected by MPH. 
 Next, effects of PLA, MPH and LEV were tested in a repeated 
measures ANOVA with planned comparisons between the two drug conditions 
and PLA (see Table 1). This analysis revealed a near significant difference 
between PLA and MPH (p<.052) in line with the previously mentioned t-test 
showing better memory recall at the 24h delay after methylphenidate. 
Although comparisons between LEV and PLA did not reveal significant 
differences on any of the variables, inspection of the averages suggested that 
LEV and MPH effects may not go in the same direction. Post hoc analysis, 
comparing LEV to MPH revealed that performance on the 24h delayed recall 
was significantly better after MPH compared to LEV (p=.049). Again, the 
recognition test was not affected by either MPH or LEV. 
 
ERP measures 
Grand average ERPs, averaged over the three learning trials after PLA, MPH 
and LEV are shown in Figure 1. A repeated measures ANOVA with treatment, 
electrode and trial as within subjects factors was run on these data. This 
analysis showed that P3b latency was delayed after LEV relative to PLA (PLA: 
mean (SEM)=340.8 ms (3.4); LEV: mean (SEM)=351.3 ms (3.5); PLA vs. LEV: 
p<.002). P600 amplitude was larger after LEV compared to PLA (PLA: mean  
(SEM)=4.47 μV (.37); LEV: mean (SEM)=5.09 μV  (.31); PLA vs. LEV: p<.018).  
Figure 2 depicts grand average ERPs measured during recognition 
testing after PLA, MPH and LEV. The analysis did not reveal significant 
differences between any of the treatments. 
  
Table 1 
Mean scores (SEM) on the Visual Verbal Learning test 
  Mean (SEM) scores on the VVLT  Contrasts     
 PLA  MPH  LEV  PLA vs. MPH PLA vs. LEV MPH vs. LEV 
 Immediate recall 43.7 (2.0) 43.0 (2.0) 42.6 (2.3) .726 .567 .823 
 Delayed recall 30 min 17.0 (1.1) 17.2 (1.1) 16.6 (1.1) .855 .566 .504 
 Delayed recall 24 h 13.0 (1.2) 14.7 (1.2) 13.1 (1.1) .051 .927 .049* 
Recognitio  n          
 Reaction time (ms) 30 min 660 (1.5) 664 (16) 677 (18) .803 .320 .413 
 Sensitivity (A') 30 min 2.7 (0.1) 2.7 (0.1) 2.6 (0.1) .863 .305 .431 
 Reaction time (ms) 24 h 693 (23) 669 (19) 685 (22) .194 .736 .447 
 Sensitivity (A') 24 h 2.5 (0.1) 2.5 (0.1) 2.4 (0.1) .777 .064 .095 
*p<.05 
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Figurure 1. Grand average ERPs showing the P3a, P3b and P600 during the encoding phase 
(averaged across three learning trials) of the visual verbal learning test. The ERPs depicted were 
recorded at Cz. 
 
Behavioral data revealed improved 24h delayed recall performance after MPH 
relative to PLA and LEV, but this result was not reflected by the ERP results. 
It was therefore decided to do a further analysis only including the EEG of  
words that were recalled at the 24h delayed recall to see if the differences in 
performance would be reflected by the ERPs at encoding (Grand averages are 
shown in Figure 3). This analysis again revealed delayed P3b latency after LEV 
compared to PLA (PLA: mean (SEM)=343.0 ms (5.4); LEV: mean (SEM)=356.1 
ms (4.7); PLA vs. LEV: p<.049). P600 amplitude was larger after LEV relative 
to MPH (MPH: mean (SEM)=5.45 μV (.51); LEV: mean (SEM)=7.44 μV (.54); MPH 
vs. LEV: p<.006). P600 latency was delayed after LEV relative to MPH (MPH: 
mean (SEM)=558.9 ms (8.5); LEV: mean (SEM)=577.0 ms (6.3); MPH vs. LEV: 
p<.037). 
 
Other cognitive tasks 
Mean values of dependent measures of the Sternberg memory scanning task, 
Paired Associates learning and the spatial working memory task are presented 
in Table 2.  
MPH and LEV influences on the Sternberg Memory Scanning task 
variables did not differ significantly from PLA. However, inspection of the 
averages again suggested a difference between the two drug conditions. The 
contrast MPH vs. LEV revealed that responses were significantly faster after 
MPH relative to LEV (see Table 2).  
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On the Paired Associates Learning task there was again no difference 
between either drug condition and PLA, while the two drug conditions did 
differ significantly from each other. Both max and mean values were higher 
for MPH compared to LEV. 
  Performance on the spatial working memory task was similar in all 
conditions.  
a 
a 
b 
Figure 2. Grand average ERPs showing the P3a, P3b and P600 during the recognition phase of the 
visual verbal learning test for old (a) and new (b) items. The ERPs depicted were recorded at Cz. 
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Figure 3. Grand average ERPs showing the P3a, P3b and P600 during encoding of words that were 
remembered at 24h delayed recall. of the visual verbal learning test. The ERPs depicted were 
recorded at Cz. 
 
Subjective measures 
Analysis of POMS factor scores indicated that after methylphenidate, 
participants experienced less fatigue at 1 and 3 hours after drug intake 
(p<.015 and p<.020 respectively). Methylphenidate also caused an increase in 
reported tension at 1 hour and 2 hours after administration (p<.041 and 
p<.016 respectively). Factor scores indicated less vigour at 1 and 3 hours after 
methylphenidate intake (p<.004 and p<.006 respectively). The Bond & Lader 
factor scores indicated that participants felt more alert 3 hours after MPH 
intake (p<.038). LEV did not affect subjective feelings as reported by 
participants. 
 
Physiological measures 
MPH significantly increased heart rate compared to PLA at all time points 
(T50: p<.001; T130: p<.001; T180: p<.001). Furthermore, compared to PLA, 
MPH also significantly increased systolic at all time points (T50: p<.001; T130: 
p<.001; T180: p<.001) and diastolic blood pressure (T50: p<.001; T130: 
p<.003; T180: p<.003). LEV did not affect heart rate and systolic blood 
pressure at T130, but significantly decreased diastolic blood pressure relative 
to PLA (p<.048). In both PLA and LEV, heart rate decreased from T0 to T180, 
but this decrease was significantly smaller after LEV (p<.036). At T180, there 
were no effects of LEV on blood pressure. Please note that changes in  
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Table 2 
Mean scores (SEM) on the Sternberg Memory Scanning, Paired Associates Learning and Spatial working memory tests 
  Mean (SEM) scores  Contrasts     
 PLA  MPH  LEV  PLA vs. MPH PLA vs. LEV MPH vs. LEV 
Sternberg Memory Scanning          
slope 40 (3) 37 (3) 40 (3) .163 .923 .224 
intercept 359 (8) 352 (10) 361 (8) .450 .758 .296 
accuracy 0.97 (0.00) 0.97 (0.00) 0.97 (0.00) .252 .488 .191 
reaction time (ms) 471 (11) 456 (11) 476 (10) .097 .380 .029* 
Paired Associates Learning          
maximum 5.7 (0.1) 6.0 (0.2) 5.6 (0.2) .222 .344 .037* 
mean 4.0 (0.1) 4.2 (0.1) 3.9 (0.1) .165 .379 .024* 
Spatial working memory          
OTP % correct 80.5 (2.5) 83.5 (2.6) 80.8 (2.7) .359 .912 .462 
COM % correct 80.7 (2.2) 78.5 (2.6) 80.8 (2.4) .473 .949 .469 
COM abs err 154.9 (8.4) 166.7 (13.1) 156.4 (10.6) .372 .865 .487 
COM pos fit  124.6 (4.9) 125.0 (5.2) 117.2 (4.3) .946 .117 .156 
*p<.05 
 
 
Chapter 3 
physiological measure reported here are relatively small and all values are 
still within a normal clinical range for healthy individuals.  
 
Discussion 
 
This study aimed to replicate and extend the previous finding of MPH induced 
enhancement of declarative memory consolidation, by testing memory 
performance of healthy volunteers under influence of PLA, MPH or LEV. MPH 
failed to improve 30 minute delayed recall of word lists. However, 
performance on the 24 hour delayed recall was better when words had been 
learned under the influence of MPH compared to PLA and LEV. The P3b and 
P600 latencies were delayed and P600 amplitude was larger after LEV 
compared to PLA and MPH. MPH speeded response times on the Sternberg 
Memory Scanning task and improved performance on the Paired Associates 
Learning task, relative to LEV. The Spatial working memory task was not 
affected by the treatments.  
A recent study showed that MPH improved 30 minute delayed word 
recall. That finding was not replicated by the present study. The discrepancy 
between the current and previous findings may be explained by differences in 
the study procedures. Although timing of task performance relative to dosing 
was the same in both studies, the hours before administration of the word 
learning task were spent rather differently. While participants in the previous 
study had already been subjected to 3.5 hours of cognitive testing, the 
participants in the present study were well rested before word learning task 
performance. As MPH is known to reverse the performance disruptive effects 
of sleep deprivation (Bishop, et al., 1997), MPH may have similarly reduced 
the impact of fatigue, induced by 3.5 hours of computerized (cognitive) 
testing, on cognitive performance in the previous study.  
 The finding that when participants learned the word lists under the 
influence of MPH remembered more words during the second delayed recall 
after 24 hours, compared to the PLA condition, suggests that MPH led to less 
memory decay between 30 minutes and 24 hours after word learning. To 
remember the word lists over a 24 hour period could be considered rather 
challenging. Combined with the observations on the first delayed recall test in 
the present and previous study discussed above, this finding may suggest that 
MPH has potential to improve cognitive performance in challenging 
conditions. If this is true, it has implications for the use of MPH by healthy 
individuals who wish to enhance their cognitive performance. This may be 
effective, but only when one needs to perform under demanding 
circumstances, including fatigue or a particularly difficult task.  
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It was hypothesized that LEV and MPH would both enhance memory 
consolidation compared to PLA, which would suggest that MPH effects would 
be primarily mediated by dopamine activity. However, like MPH, LEV failed to 
improve 30 minute delayed recall. In addition, LEV also failed to enhance 24 
hour delayed recall. In fact the averages even suggest that MPH and LEV have 
opposite effects on memory, although statistical testing only confirmed that 
MPH improved performance at 24 h delayed recall relative to PLA and LEV.  
Latencies of two ERP components, P3b and P600 were delayed after 
LEV relative to PLA and MPH. As P300 latency is associated with mental speed 
(Polich, 2012), and P300 and P600 are closely related (Swaab, et al., 2012), 
these effects suggest that LEV slows down memory processing. P600 
amplitude was larger after LEV compared to PLA and MPH. Although P600 is 
usually related to syntactic processing (Swaab, et al., 2012), its similarity to 
the P300 with respect to sensitivity to stimulus salience, probability and task 
relevance suggest that an increase in amplitude may reflect increased effort 
to memorize items.  
Based on previous findings of dopamine involvement in working 
memory (Ellis, et al., 2007; Landau, et al., 2008; Robbins, 2005) and better 
working memory performance after MPH (Elliott, et al., 1997; Mehta, et al., 
2000), MPH and LEV were both hypothesized to improve performance on the 
Sternberg memory scanning, Paired associates learning and spatial working 
memory tasks relative to PLA. The present findings were not in agreement 
with these hypotheses as performance in the MPH condition nor the LEV 
condition differed from performance under PLA. Contrary to our expectations, 
MPH and LEV conditions differed from each other on several working memory 
related variables, suggesting that MPH slightly improved working memory 
while LEV may have minor deleterious effects on working memory 
performance.  
The results from the current study thus suggest that MPH has minor 
though positive effects on cognitive function, which is in line with our 
expectations. The LEV effects, on the other hand, were not. In contrast with 
previous findings, LEV did not enhance performance. Rather, relative to MPH, 
LEV appeared to have disadvantageous effects on cognitive performance, 
partly reflected by general slowing after LEV. Hence, these findings do not 
support the hypothesis that dopamine plays a major role in cognition 
enhancing effects of MPH. However, based on this study, the role of dopamine 
in MPH effects can neither be declined. There are several other explanations 
for these results that need to be taken into account, and will be discussed 
below.  
LEV has the potential to enhance presynaptic dopamine availability 
and thus may affect both tonic and phasic dopaminergic processes. This is a 
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crucial difference between LEV vs. MPH and other dopamine agonists, which 
only affect tonic dopaminergic neurotransmission (Breitenstein, Korsukewitz, 
et al., 2006; Seeman & Madras, 2002). Tonic and phasic activity differentially 
affect extracellular dopamine availability. Increased tonic dopamine activity 
on postsynaptic receptors and autoreceptors reduces phasic dopamine signals 
(Breitenstein, Korsukewitz, et al., 2006; Seeman & Madras, 2002). 
Dopaminergic agents have biphasic effects, where low doses reduce phasic 
dopamine release while high doses induce widespread stimulation of 
postsynaptic receptors, prevailing over presynaptic inhibition (Seeman & 
Madras, 2002). The LEV dose may thus have been too low, and have  failed to 
enhance dopamine availability. The observed lack of subjective effects of LEV 
suggests there was a net null effect of LEV on dopaminergic activity. 
Unfortunately there are no prolactin data (prolactin levels decrease under the 
influence of increased dopamine availability) to support this suggestion as the 
concomitant treatment with domperidon, a peripheral dopamine antagonist, 
would compromise the blood test results.  
If, in contrast with the previous suggestion, it would be assumed that 
LEV did enhance dopamine availability, another explanation of the current 
results could be that the crucial factor determining the cognition enhancing 
effects of MPH is the inhibition of both dopamine and noradrenaline reuptake. 
Due to the lack of availability of a pure noradrenergic drug, the MPH effects 
can only be compared to those of the purely dopaminergic treatment with 
LEV. The current design therefore leaves open two options: either the 
noradrenergic effects of MPH may be essential in performance enhancement 
or the combination of dopaminergic and noradrenergic effects are the key to 
enhanced performance on cognitive tasks. However, either explanation 
cannot account for the apparent detrimental effects of LEV relative to MPH. 
As discussed above, low doses of dopaminergic drugs may reduce phasic 
activitiy by stimulation of autoreceptors. It is therefore more likely that LEV 
dose was indeed too low and not only failed to enhanced dopamine activity 
but perhaps even decreased dopamine availability relative to MPH, paralleling 
electrophysiological and behavioral results showing differential effects of MPH 
vs. LEV.  
In sum, the current study showed that MPH led to decreased memory 
decay over a period of 24h hours. Furthermore, MPH and LEV had opposite 
effects on memory task performance and electrophysiological correlates. It is 
suggested that MPH enhances cognitive function under challenging conditions 
and that the LEV manipulation in this study did not lead to enhanced 
dopaminergic activity. 
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Abstract 
 
Dopamine is well known for involvement in reinforcement, motor control and 
frontal lobe functions, such as attention and memory. Tyrosine/phenylalanine 
depletion (TPD) lowers dopamine synthesis and can therefore be used as a 
model to study the effects of low dopamine levels. This is the first study to 
assess the effect of TPD on memory performance and its electrophysiological 
correlates. In a double blind placebo (PLA)-controlled crossover design, 17 
healthy volunteers (six males, 11 females) aged between 18 and 25 were 
tested after TPD and PLA. Working memory was assessed using a Sternberg 
memory scanning task (SMS) and episodic memory using the Visual Verbal 
Learning Test (VVLT). Simultaneously, event-related potentials (ERPs) were 
measured. The tyrosine and phenylalanine ratio was significantly reduced 
after TPD and increased after PLA. Working memory performance was not 
affected by TPD. However, ERP measures were affected by the treatment, 
indicating that TPD impaired stimulus processing during working memory 
performance. Episodic memory was not impaired after TPD. Again, alterations 
in ERP measures suggested adverse effects of TPD on memory-related 
processing. These results suggest that dopamine is involved in both working 
memory and episodic memory-related processing, although the effects are too 
small to be detected by performance measures.  
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Introduction 
 
Dopamine is one of the most thoroughly studied neurotransmitters. It is known 
to be involved in reinforcement and motor control (Nieoullon, 2002). In 
addition, evidence is accumulating that dopamine is likewise involved in 
cognitive function, including frontal lobe functions such as attention, planning 
and working memory (Cools & Robbins, 2004). Previous research has shown 
that in diseases in which dopamine transmission is altered, such as Parkinson’s 
Disease, working memory is disturbed (Nieoullon, 2002; Owen, et al., 1997). 
Dopaminergic treatment alleviates this problem (Costa, et al., 2003; Lewis, et 
al., 2005; Moustafa, et al., 2008). Similarly, dopamine elevating compounds 
improve working memory performance in healthy volunteers (Elliott, et al., 
1997; Luciana & Collins, 1997; Luciana, et al., 1992). Administration of 
dopamine lowering compounds, on the other hand, results in impairment of 
working memory (Luciana & Collins, 1997; Mehta, et al., 1999). 
 A way to study dopamine function is to acutely lower dopamine levels 
in the brain by depleting its precursors, tyrosine and phenylalanine (Barrett & 
Leyton, 2004). Because these amino acids are transported into the brain by 
neutral amino acid transporters, amino acids have to compete with each 
other. Lowering the relative amount of one or two specific amino acids 
worsens their position in this competition, which thereby leads to decreased 
availability of these precursors in the brain (Barrett & Leyton, 2004; 
McTavish, et al., 2001). Indeed, there is evidence that TPD reduces dopamine 
release, dopamine synthesis and attenuates induced elevation of dopamine 
levels (Bongiovanni, Newbould, & Jaskiw, 2008; M.  Le Masurier, Houston, 
Cowen, Grasby, & Hume, 2004; Leyton, et al., 2004; McTavish, Cowen, & 
Sharp, 1999; Montgomery, McTavish, Cowen, & Grasby, 2003). The effect of 
TPD is anatomically selective and preferentially affects dopamine rich areas 
such as caudate and putamen while not affecting other regions such as frontal 
and cingulate cortex (M. Le Masurier, Cowen, & Sharp, 2004).  
 The findings with respect to various cognitive functions have been 
very inconsistent; some studies found effects of TPD lowering scores on 
spatial recognition and spatial working memory tasks (Gijsman, et al., 2002; 
Harmer, McTavish, Clark, Goodwin, & Cowen, 2001; Harrison, et al., 2004; 
Nathan, et al., 2002), whereas others did not (Ellis, et al., 2007; Lythe, 
Anderson, Deakin, Elliott, & Strickland, 2005; Mehta, Gumaste, Montgomery, 
McTavish, & Grasby, 2005), even though lower spatial working memory and 
planning accuracy scores were associated with decreased striatal dopamine 
levels (Mehta, Hinton, et al., 2005). Furthermore, TPD impairs vigilance and 
sustained attention when combined with serotonin depletion (Matrenza, et 
al., 2004), but TPD alone does not (Harrison, et al., 2004). Grevet et al. 
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(2002) found impaired performance on delayed recall in Rey’s auditory verbal 
learning test (RAVLT) after TPD (Grevet, et al., 2002), while Harrison et al. 
(2004) found no effect on a visual word learning task.  
More recently, TPD has been used to study the relationship between 
dopamine function and mood. It has been suggested that TPD induces 
decreases in mood in healthy volunteers (Leyton, et al., 2000; McLean, 
Rubinsztein, Robbins, & Sahakian, 2004; Ruhe, Mason, & Schene, 2007).  
Furthermore, after TPD both healthy volunteers and recovered depressed 
patients display higher sensitivity to negative words and lower sensitivity to 
positive words in an affective Go/No-Go task (McLean, et al., 2004; Roiser, et 
al., 2005; Vrshek-Schallhorn, Wahlstrom, Benolkin, White, & Luciana, 2006).  
 Research on the relationship between dopamine and ERP components 
is scarce. The available evidence, chiefly regarding P300, a component that is 
related to novelty processing and stimulus evaluation, is inconsistent (Coull, 
1998; Farber, Beteleva, & Ignat'eva, 2004; Prasher & Findley, 1991; Stanzione, 
et al., 1991). For instance, P300 latency has been reported to be increased 
both in cases of enhanced as well as reduced dopamine transmission; delayed 
latency has been observed in PD and after administration of both dopamine 
antagonists as well as dopamine agonists (Prasher & Findley, 1991; Stanzione, 
et al., 1991). 
 Because previous studies produced conflicting results with respect to 
the memory modulating effects of altered dopamine transmission, this study 
aimed to further explore the effects of TPD on memory function, including 
working memory and episodic memory. This was done by measuring 
performance using the Sternberg memory scanning task and a verbal learning 
task, and event-related potentials (ERPs) extracted from 
electroencephalography (EEG) recordings. As to our knowledge, no study 
currently exists that has combined TPD and EEG during cognitive processing. 
Because working memory deficits have been observed after depletion of 
dopamine in PD, the intake of dopamine antagonists and TPD (Gijsman, et al., 
2002; Harmer, et al., 2001; Harrison, et al., 2004; Mehta, et al., 1999; 
Nathan, et al., 2002; Nieoullon, 2002), it was expected that depletion of 
tyrosine and phenylalanine would interfere with working memory function. 
Furthermore, it was hypothesized that TPD may disturb verbal learning 
(Grevet, et al., 2002) and possibly enhance sensitivity to negative words.    
 
Method 
 
Participants 
Twenty-two healthy volunteers aged between 18 and 25 years were recruited 
by means of advertisement posters at Maastricht University. Preselection 
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occurred on basis of pre-screening by telephone. Participants without any 
presence of psychiatric and neurologic diseases were subjected to a medical 
screening by means of a medical questionnaire. Inclusion criteria were normal 
binocular activity (corrected or uncorrected), a body mass index between 
18.5 and 30 and signed informed consent.  
 Exclusion criteria were a history or presence of mental or physical 
disorders such as cardiac, hepatic, renal, pulmonary, neurological 
gastrointestinal, haematological or psychiatric illnesses, and sensory or motor 
deficits that could affect test performance. Furthermore, participants were 
excluded if pregnant or lactating, in case of drug abuse, when drinking more 
than 20 alcoholic beverages a week or more than five caffeine containing 
beverages a day.  
Five participants did not complete the study because they had to vomit after 
intake of the amino-acid drink. The 17 participants (11 females, 6 males) who 
completed this study had a mean age of 21.1 years (SD=2.0 years).  
 The study was approved by the ethical committee of Maastricht 
University and conducted in accordance with the ethical principles that have 
their origin in the Declaration of Helsinki 1975, revised Hong Kong 1989.  
 
Design  
The study was conducted according to a double-blind, placebo-controlled, 
three-way crossover design. The three testing sessions were spaced apart by a 
period of at least one week. On one occasion participants received a balanced 
amino acid drink (PLA). On the other two occasions they received an amino 
acid drink either lacking tyrosine and phenylalanine (TPD) or histidine (HID, as 
part of a larger research study (van Ruitenbeek, Sambeth, Vermeeren, Young, 
& Riedel, 2009). 
 
Procedure 
The study was integrated in a larger study on the influence of TPD and HID on 
brain and behaviour. This section describes the procedure of the complete 
study.  
 Participants were not allowed to use drugs or medication, except oral 
contraceptives within two weeks before the first test-day until the end of the 
study. The participants were instructed to arrive at the lab in fasted 
condition. Furthermore they were requested to abstain from alcohol and 
caffeine from 9 p.m. the night before. Testing days started at either 8.30 am 
or 10.30 am. A catheter was placed in order to collect blood samples, which 
were used to verify if depletion was successful. Blood samples were obtained 
at 0, 2, 4, 6 and 7 hours. After the first blood sample was collected, 
participants completed two questionnaires: Bond & Lader and the complaint 
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list. Subsequently participants received the amino acid drink, which had to be 
consumed within 15 minutes. This was followed by a break in which 
participants could consume water or caffeine free tea. After three hours 
participants had lunch. The lunch consisted of three slices of gluten free 
bread with honey, apple treacle or jam, an apple and a caffeine free soda 
drink.  
 Four and half hours after consumption of the drink, the EEG cap was 
placed. EEG recording started five hours after consumption of the drink with 
four minutes baseline measurement, two minutes with eyes open and two 
minutes with eyes closed. Thereafter participants were subjected to a test 
battery of approximately 90 minutes (with a 10 minute break in between), 
consisting of the following tests: Visual Verbal Learning Test, Critical Tracking 
Task, Sternberg Memory Scanning task, Visual Verbal Learning Test: delayed 
recall and delayed recognition, Choice Reaction Time task, Simple Reaction 
Time task, and an Oddball paradigm. In this study only the Sternberg Memory 
Scanning task and the Visual Verbal Learning Test are of interest. After 
completion of the test battery baseline EEG measurement was repeated. After 
the last blood sample was taken, the catheter was removed and participants 
completed the mood questionnaire and the complaint list a second time. 
 
Material 
Drink composition 
The quantities of amino acids in the mixture, as given to male participants, 
were based on those used by Young et al. (Young, Smith, Pihl, & Ervin, 1985). 
Female participants received 85% of this amount based on their average lower 
body weight (Ellenbogen, Young, Dean, Palmour, & Benkelfat, 1996). The 
content of the TPD mixture was the same as the balanced drink except that it 
lacked tyrosine and phenylalanine. The amino acids were solved in 200 ml (for 
males) or 170 ml (for females) water. 
 
Blood samples 
Blood samples were collected via a catheter placed in the participants’ 
dominant arm. After collection of the blood, the catheter was cleaned with 
heparin and blood samples were centrifuged for 5 minutes at 4°C (at 4000 
rpm). Subsequently, 1 ml of plasma was stored at -20°C until performance of 
amino acid analysis (van Eijk, Rooyakkers, & Deutz, 1993). Dependent 
measures were the percentage of change from T0 to T7 in both tyrosine and 
phenylalanine plasma levels and tyrosine and phenylalanine/ΣLNAA ratio. 
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Questionnaires 
Two questionnaires were used to asses mood; the Bond & Lader Visual 
Analogue Scale (VAS) and the Complaint List. The VAS required participants to 
score bipolar items by marking a 100 mm line, with a normal state being 
indicated by marking the middle of the line. The dependent measures were 
total scores, measured in millimetres, on three dimensions: alertness, 
contentment and calmness. On the complaint list participants have to 
indicate, on a scale from 0 to 3, to what extent they experienced the 
presented complaints, including for example nausea, headache and feeling 
cold. Dependent measure was the total score summed over the 31 items.  
 
Tasks  
Sternberg Memory Scanning task (SMS) 
The memory scanning task (Sternberg, 1966) was used as a measure of 
working memory. In this task participants were required to memorize 1, 2 or 4 
consonants. After memorization, 48 consonants were presented and 
participants were required to indicate if the presented items appeared in the 
memorized sequence. The stimuli were presented in six blocks of 48 items 
each. In the first three blocks workload increased, so participants had to 
memorize 1 letter in the first block, 2 letters in the second and 4 letters in 
the third block. In the fourth, fifth and sixth block this order was reversed. In 
this task reaction time increases linearly with the workload, that is, the 
number of items that has to be held in memory. The slope of this function is 
an indication of speed of scanning of short term memory, whereas the 
intercept is a measure of psychomotor speed. The behavioural dependent 
measures were slope, intercept, reaction time, measured in milliseconds, and 
accuracy indicated by a number between 0 and 1, with 0 indicating that the 
answer was false and 1 indicating that the answer was right. The 
electrophysiological dependent measures were the amplitude and latency of 
the P150, N200, P3a and P3b ERP components. 
 
Visual verbal learning test (VVLT) 
This task is an adapted version of Rey’s Auditory Verbal Learning Test (Lezak, 
1995). The VVLT was used to measure episodic memory. It included 30 words, 
12 of which are positive, 12 are negative and 6 are neutral, as was 
determined by valence ratings of word lists by a pool of healthy volunteers 
(Klaassen, et al., 2002). These words were presented on a computer screen 
three times in a row, each time followed by immediate free recall of all 
remembered words. After 30 minutes, participants were subjected to a 
delayed recall test and a recognition test. During the latter, 30 words were 
presented, 15 of which were previously presented and another 15 that were 
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new. Outcome measures of the immediate and delayed recall tests were hits 
(correctly recalled words), false alarms (words named that were not on the 
list) and doubles (words named twice). In addition, performance was assessed 
taking into account the valence of the words, by taking the same measures for 
each of the valence categories separately. 
 The behavioural dependent measures of the recognition test were 
reaction time, measured in milliseconds, accuracy, indicated by a number 
between 0 and 1, with 0 indicating that the answer was false and 1 indicating 
that the answer was right and sensitivity (A’). A’ is calculated as follows: A’ = 
1 - ¼ [fr/cr + (1 – cr) / ( 1 -fr)], with fr = falsely recognized words and cr = 
correctly recognized words. The electrophysiological dependent measures 
were the amplitude and latency of the P150, N200, P3a and P3b ERP 
components. 
 
Electroencephalography 
The electroencephalogram (EEG) was recorded using 32 electrodes attached 
to a cap according to the international 10-20 system (Jasper, 1958). The 
ground electrode was placed on the AFz location, on the forehead. An 
electrode placed at the left mastoid served as reference. An electro-
oculogram (EOG) was measured bipolarly vertically above and below the right 
eye and horizontally next to the right and the left eye.  
 Data were sampled at 1000 Hz and filtered online between 0.05 and 
100 Hz. Offline, data were screened for artefacts and filtered between 1 and 
30 Hz. Event-related potentials were extracted by stimulus locked averaging 
of epochs from 100 milliseconds before to 1000 milliseconds after stimulus 
presentation.  
 For both tasks, ERPs were analysed at Fz, FCz, Cz, CPz, Pz, P3 and P4. 
In the ERPs extracted from the EEG during the SMS task, five peaks could be 
discerned. P150 was determined as the highest amplitude within 110-210 ms 
after stimulus onset and N200 as the lowest amplitude within 180-300 ms 
after stimulus onset. P3a and P3b were determined as the highest amplitude 
within  windows individually specified for each participant. The windows for 
P3a and P3b were not overlapping and had to be between 260 and 430 ms 
after stimulus onset. In addition, the latencies of these four peaks were 
included in the analysis. 
In the VVLT, the same components were observed. P150 was 
determined as the highest amplitude within a window of 130-210 ms after 
stimulus onset, N200 as the lowest amplitude within 180-260 ms after stimulus 
onset and P3a and P3b were again determined as the highest amplitude within 
windows individually specified for each participant. The windows for P3a and 
P3b were chosen such that they would not overlap and fell between 230 and 
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420 ms after stimulus onset. Latencies of these four peaks were included in 
the analysis.  
 
Statistical analysis 
All behavioural and ERP data were analyzed by means of repeated measures 
analysis of variance (ANOVA) with the within subjects factor treatment, which 
had two levels: PLA and TPD. Additional within subject factors were electrode 
position (five levels), workload (three levels: 1, 2 and 4 letters memorized) 
and stimulus type (2 levels: old and new) for the SMS task. For the VVLT 
additional variables were electrode position (five levels), trial (three levels: 
trial 1, 2 and 3) and valence (three levels: positive, negative and neutral) for 
the immediate recall part and stimulus type (two levels: old and new) for the 
recognition part. Behavioural data, including reaction time and accuracy, and 
ERP data, including amplitudes and latencies, were tested for main effects 
and all possible interaction effects. The effects were evaluated using the 
Greenhouse-Geisser correction and were considered significant at p<.05. 
Where necessary the Bonferroni correction was applied. In case of a 
significant main effect, posthoc pairwise comparisons were conducted. 
Interaction effects were analyzed post hoc by conducting additional repeated 
measures ANOVAs, including only those factors that were involved in the 
interaction.  
 
Results 
 
Blood samples 
After TPD, plasma tyrosine and phenylalanine level was significantly reduced 
by 57% at T7, compared to T0 (F1,13=131.161, p<.001) and the tyrosine and 
phenylalanine/ΣLNAA ratio was reduced by 62% at T7 (F1,13=108.134, p<.001). 
Tyrosine and phenylalanine level was increased by 61% at T7 compared to 
baseline (F1,15=24.150, p<.001) in the placebo condition and the tyrosine and 
phenylalanine/ΣLNAA ratio was increased by 40% at T7 (F1,15=21.992, p<.001).  
 
Questionnaires 
Neither the Bond & Lader Visual Analogue Scale nor the complaint list showed 
significant differences between the PLA and TPD conditions (Fs<1.391).  
 
Sternberg Memory scanning task 
Task performance 
The behavioural measures slope, intercept, reaction time and accuracy, were 
not affected by the treatments (see Table 1). However, TPD appeared to 
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speed up reaction time (F1,16=3.995, p=.063), although this effect did not 
reach significance.  
 
Table 1 
 Mean scores for dependent variables of the SMS task after PLA and TPD 
  Mean (SEM) scores   
 PLA TPD 
Reaction time (ms) 472 (12) 460 (11) 
Accuracy 0.96 (.01) 0.96 (.01) 
Slope (ms/letter) 41 (3) 37 (3) 
Intercept (ms) 417 (11) 410 (9) 
 
To evaluate whether the task worked appropriately, the effects of workload 
and stimulus type on reaction time and accuracy were analyzed. Reaction 
time increased as workload increased (F1.35,21.64=202.805, p<.001) and reaction 
time was longer for new as compared to old items (F1,16=71.148, p<.001).  
 
ERP measures 
Figure 1 depicts the grand average ERPs per treatment condition and task 
manipulation at Cz. The ERP latencies and amplitudes were analyzed using 
repeated measures ANOVA with treatment, electrode position, workload and 
stimulus type as within subjects factors. Inspection of the main effects of 
workload and stimulus type learned that the task produced the expected 
effects on the ERPs. For instance, P3a amplitude decreased with increasing 
workload (F1.56,24.94=20.790, p<.001).  
Figure 1. Grand average ERPs during the SMS task, corresponding to the six combinations of 
workload and stimulus types (workload 1, 2 and 4 and old versus new stimuli), for Cz. Treatment 
conditions are depicted in separate plots (left: PLA, right: TPD). 
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The relationship between treatment and amplitude and latency of the ERP 
components is plotted in Figure 2. Treatment affected amplitude and latency 
of several components. There was no significant main effect of the treatment 
on P150 amplitude or latency. N200 was delayed after TPD (F1,16=4.911, 
p<.05), as compared to PLA. TPD decreased P3a amplitude, as compared to 
PLA (F1,16=5.715, p<.05). Furthermore analysis of the P3a latency revealed an 
interaction between treatment, workload and stimulus type (F1.97,31.56=6.473, 
p<.01). Post hoc analysis did not reveal any significant effects of treatment. 
For P3b latency, an interaction between treatment and electrode position was 
found (F2.41,38.53=3.398, p<.05). Post hoc analysis revealed that at the Fz 
electrode, P3b latency was increased by TPD (F1,16=5.229, p<.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Grand average ERPs during the SMS task after PLA and TPD at Fz. 
 
Visual Verbal Learning Test 
Task performance 
Immediate recall scores and delayed recall scores are listed in Table 2. 
The hit rate in the immediate recall phase of the VVLT was not 
affected by the treatment. However, TPD reduced false alarms and doubles 
(false alarm: F1,16=6.272, p<.05; doubles: F1,16=7.385, p<.05). Hit rate 
significantly increased over trials (F1.67,26.75=170.913, p<.01), as should be 
expected. Neither delayed recall (see Table 2, Fs< 1.595 for hits, false alarms 
and doubles) nor recognition (see Table 3, Fs<1.358 for accuracy, RT and A’) 
were affected by the treatment. However, accuracy was lower when an old 
item was presented compared to when a new item was presented in the 
recognition test (F1,16=7.264, p<.05). Valence of the words did not affect 
memory performance.  
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Table 2  
Means of percentages of hits, false alarms and doubles of the VVLT after PLA and TPD 
  Mean (SEM) of percentages of words recalled     
 PLA   TPD   
 Hits False alarms Doubles Hits False alarms Doubles 
immediate recall 55.6 (2.4) 1.7 (.5) 4.6 (.8) 52.9 (2.9) 0.7 (.2) 2.5 (.4) 
delayed recall 61.6 (3.7) 2.4 (.8) 2.9 (.7) 57.3 (4.3) 1.8 (.6) 1.8 (.6) 
Immediate recall-postive words 56.9 (3.2)  3.8 (1.1) 53.6 (2.8)  1.8 (.5) 
immediate recall-negative words 53.8 (3.1)  4.1 (.8) 52.6 (3.7)  3.1 (.7) 
immediate recall-neutral words 57.2 (3.6)  5.6 (1.3) 52.0 (4.2)  2.6 (1.4) 
delayed recall-postive words 20.3 (1.6)  .7 (.4) 19.6 (1.3)  1.1 (.3) 
delayed recall-negative words 19.8 (1.3)  1.1 (.4) 18.3 (1.8)  .3 (.2) 
delayed recall-neutral words 22.5 (1.7)   1.0 (.7) 19.6 (2.0)   .0 (.0) 
 
Table 3  
 Mean reaction time, accuracy and sensitivity of the VVLT, recognition test after PLA and TPD 
  Mean (SEM) scores  
 PLA TPD 
Reaction time (ms) 749 (23) 738 (21) 
Accuracy 0.91 (.02) 0.89 (.02) 
Sensitivity (A') 0.95 (.01) 0.94 (.01) 
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ERP measures 
Grand average ERPs, averaged over trials, after PLA and TPD are shown in 
Figure 3. A repeated measures ANOVA with treatment and electrode position 
as within subjects factors was run on these data. P150 latency was increased 
after TPD compared to PLA (F1,16=6.610, p<.05).  For N200 amplitude an 
interaction between treatment and electrode position was found 
(F1.92,30.66=5.448, p<.05). Post hoc analysis revealed that the amplitude was 
different over different electrode positions for the placebo condition, but 
there was no clear pattern. P3b latency was delayed after TPD as compared 
to PLA (F1,16=6.398, p<.05). Furthermore, there was an interaction between 
treatment and electrode position (F2.32,40.37=2.788, p<.05). Post hoc analysis 
showed that the latency increasing effect of TPD was significant on FCz and 
Cz electrode positions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Grand averages during the encoding phase of the VVLT after PLA and TPD at Fz. 
 
Figure 4 depicts grand average ERPs measured during recognition testing after 
PLA and TPD. ERP amplitudes and latencies were again analyzed using a 
repeated measures ANOVA with treatment (PLA and TPD) and stimulus type 
(old and new) as within subjects factor. This analysis revealed that P150 was 
not altered by TPD. Nor were any main effects of treatment observed for the 
N200 component. As for the latency data, however, an interaction between 
treatment and stimulus type was found (F1,16=8.278, p<.05), which indicated 
that N200 latency decreased after TPD when an old item was presented 
P3a latency was decreased after TPD as compared to PLA (F1,16 =6.868, p<.05).  
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Figure 4. Grand average ERPs during the recognition test of the VVLT after PLA and TPD at 
presentation of old and new items at Fz,. 
 
Discussion  
 
This is the first study that investigated the effects of dopamine depletion on 
working memory and episodic memory, as well as their electrophysiological 
correlates. After TPD, the tyrosine and phenylalanine/ΣLNAA ratio was 
decreased by 62%. This is a significant level of depletion and similar to 
previous studies using the same method (Grevet, et al., 2002; Harrison, et al., 
2004).  
TPD did not significantly affect working memory performance but did 
have some effects on episodic memory, as was indicated by a decreased false 
alarm rate and a decrease in the double mentioning of words. During the 
performance of a working memory task, TPD delayed N200 latency, decreased 
P3a amplitude and increased P3b latency. 
After TPD, both P150 and P3b latency were increased during episodic 
memory encoding. During the recognition phase, TPD decreased P3a latency. 
Accordingly, the hypothesis that TPD would interfere with working memory 
was not confirmed by the behavioural data. The hypothesis that TPD would 
negatively affect episodic memory was even disconfirmed by the behavioural 
data, since fewer false alarms and doubles were observed after TPD. On the 
other hand effects observed on ERPs suggest that there was a memory 
modulating effect of TPD. It is suggested that these effects were too small to 
be detected in the behavioural data. 
 Previous studies showed conflicting results with respect to the effect 
of TPD on working memory (Ellis, et al., 2007; Gijsman, et al., 2002; Harmer, 
et al., 2001; Harrison, et al., 2004; Lythe, et al., 2005; Mehta, Gumaste, et 
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al., 2005; Nathan, et al., 2002). A satisfying explanation for this inconsistency 
has not yet been given. In this study, the lack of behavioural effects could not 
be attributed to a lack of depletion. Furthermore, both behavioral and ERP 
measures of the working memory task showed the expected variations 
between the different task conditions (Pelosi, Hayward, & Blumhardt, 1995). 
It is important to note that the placebo condition in this study involves the 
administration of a balanced amino acid mixture, which led to a 40 % increase 
in the tyrosine and phenylalanine/ΣLNAA ratio. It is not clear how this may 
have affected the results, but for future studies inclusion of baseline testing 
may be considered.  
Furthermore, it is important to note that previous studies used other 
working memory tests than the one used in the present study. It is highly 
likely that dopamine has differential effects on different forms of working 
memory. However, even among studies using comparable tasks, there were 
some that found an effect of TPD, whereas others did not. It has therefore 
been proposed that although TPD does alter dopaminergic transmission, its 
effect may not be large enough to consistently alter neuropsychological 
function (Lythe, et al., 2005). With respect to the present data, this may be a 
valid suggestion, since we found no effects on behavioural measures, even 
though changes in the ERPs were observed.  
The effects of TPD on ERP measures indicate that TPD altered brain 
processes, which are possibly related to memory function. TPD delayed N200 
latency. N200 amplitude has been linked to response inhibition or –conflict 
(Bokura, Yamaguchi, & Kobayashi, 2001; Falkenstein, Koshlykova, Kiroj, 
Hoormann, & Hohnsbein, 1995; Forster & Pavone, 2008). Increased latency 
possibly reflects prolonged duration or delayed onset of response conflict. 
Alternatively, the current finding may indicate increased response selection 
time after depletion of tyrosine and phenylalanine, since N200 latency has 
also previously been related to the timing of response selection (Gajewski, 
Stoerig, & Falkenstein, 2008).   
TPD decreased P3a amplitude. P3a is considered a novelty related 
peak, where an increased amplitude most likely reflects an alerting effect of 
the novel stimulus (Coull, 1998). Decreased P3a amplitude, therefore, may 
indicate decreased alertness. This may be attributed either to a decrease in 
dopamine levels after TPD or an increase of dopamine levels after the placebo 
condition. Indeed, Grevet et al. (2002) reported increased subjective 
alertness ratings after consumption of the balanced amino acid mixture as 
compared to baseline. P3b latency was increased by TPD. Since P3b latency is 
known to increase when categorization of the stimulus is made more difficult 
by degrading the stimulus or when memory set size increases (Garcia-Larrea & 
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Cezanne-Bert, 1998; Smulders, Kok, Kenemans, & Bashore, 1995), it can be 
inferred that the stimulus categorization effect was increased by TPD.  
Together, the described effects suggest that TPD affected stimulus 
processing during working memory. However, since no effects were observed 
on behavioural measures it is suggested that effects of TPD are not large 
enough to affect performance. This idea is supported by findings from other 
studies (Ellis, et al., 2007; Mehta, Gumaste, et al., 2005).  
Episodic memory was not impaired by TPD. However, after TPD fewer 
false alarms and doubles were observed in the immediate recall phase. A 
decrease in false alarms has also been observed after 5-HT suppletion, 
whereas false alarms have been shown to increase after serotonin depletion 
(Meeter, Talamini, Schmitt, & Riedel, 2006). These contrasting effects are in 
line with the idea that dopamine and serotonin have opposing influences on 
working memory (Luciana, Collins, & Depue, 1998). Hit rate and false alarm 
rate (taking together false alarms and doubles) were combined post hoc in a 
sensitivity measure (A’) using the same formula as used in the recognition 
test. This measure indicated an increase in sensitivity after TPD (A’=.572 in 
the placebo condition and A’=.753 after TPD). This further supports the idea 
that dopamine and serotonin have opposing influences, since sensitivity has 
been observed to decrease after serotonin depletion (Schmitt et al., 2000). 
The finding that TPD did not negatively affect performance on the 
word learning test is at odds with the findings of Grevet et al. (2002), who 
found decreased performance on delayed recall as assessed in Rey’s Auditory 
Verbal Learning Test (RAVLT) after TPD. However, our findings are consistent 
with those of Harrison et al. (2004), who found no effect of TPD on a 15 word 
visual verbal learning test. Although this has not been tested explicitly it may 
be possible that TPD exerts larger effects on auditory word learning compared 
to visual word learning.  
On the recognition task there was no effect of TPD. The lack of 
memory impairing effects of TPD could not be explained by ineffectiveness of 
the task, since, as expected, hit rate in the immediate recall test increased 
over trials, and accuracy on the recognition task was lower for old, as 
compared to new items.  
 It was expected that TPD and placebo would differentially affect 
responses to positive and negative words (McLean, et al., 2004; Vrshek-
Schallhorn, et al., 2006). However, this was not the case. Perhaps differences 
between positive and negative words can only be observed when a response 
has to be made immediately after appearance of the stimulus (as is the case 
in the Go/No-Go task (McLean, et al., 2004) and not when there is a delay 
between stimulus presentation and testing. 
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 ERPs recorded during the encoding phase of this episodic memory task 
revealed that TPD delayed the latency of both P150 and P3b ERP components. 
P150 is, in addition to working memory, also thought to be related to stimulus 
categorization (Schendan, Ganis, & Kutas, 1998). Although in the VVLT no 
categorization is necessary, encoding may be regarded similarly to 
categorization. Delayed P150 latency may reflect a delay in this process. This 
is in line with the effect on P3b latency, since P3b is known to be dependent 
on stimulus categorization time (Luck, 2005), or in this case, encoding time. A 
delay in encoding therefore may lead to a delay in P3b latency. 
 During recognition testing, P3a latency was decreased by TPD. As 
explained above, P3a amplitude is thought to be related to alertness or 
novelty (Coull, 1998). An effect on latency is therefore more difficult to 
explain.  
 In summary, TPD did not affect episodic memory performance. 
Participants even produced fewer false alarms and reported fewer words two 
times in the immediate recall phase. On the ERPs, however, some effects 
were observed that were indicative of adverse effects of TPD on memory. 
Since an effect of TPD on word learning was found previously (Grevet, et al., 
2002) and electrophysiological correlates of memory were affected by TPD in 
the present study, it is suggested that effects of TPD did affect memory 
processing but effects on memory performance remained sub threshold.  
 In conclusion, the current findings suggest that TPD, which lowers 
dopamine levels, affects memory related processing. Dopamine is likely to be 
involved both in working memory as well as episodic memory. This has 
implications for the study of memory. Where previously the focus has been on 
other neurotransmitters such as acetylcholine and serotonin, it has now 
become clear that dopamine also deserves attention. Future studies may 
further improve the study design in order to produce more sizeable effects. 
 PART 2: THE ROLE OF DOPAMINE IN PSYCHOMOTOR FUNCTION 
 
 
  
 Chapter 5. Higher, faster stronger: The effect of dynamic stimuli on response 
preparation and CNV amplitude 
 
In revision 
 
Abstract 
 
The Contingent Negative Variation (CNV) is a slow negative shift in the 
electroencephalogram (EEG), observed during response preparation. To 
optimalize the CNV paradigm, this study developed a task using dynamic 
stimuli and next combined this task with a Go/No-go test. In the first 
experiment, 19 healthy volunteers were subjected to the classic Traffic light 
(TL) task and the new dynamic Lines task. In the Lines task, response time 
was faster and CNV amplitude was larger compared to the TL task. In the 
second experiment, 20 healthy participants were tested on a Go/No-go 
version of the Lines task. Response times increased as the probability of 
response requirement decreased. CNV amplitude was larger when probability 
of response requirement was higher. In conclusion, the dynamic task promotes 
response preparation. The new tasks may be especially valuable in groups 
with attention difficulties (i.e. elderly or ADHD patients). 
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Introduction 
 
The Contingent Negative Variation (CNV) is a slow negative shift in the 
electroencephalogram (EEG) which can be observed during response 
preparation to an anticipated stimulus (Bares, Rektor, Kanovsky, & Streitova, 
2003; Tecce, 1972; van Boxtel & Brunia, 1994). Since its’ discovery by Walter 
in 1964 it has been studied extensively (Walter, Cooper, Aldridge, McCallum, 
& Winter, 1964). The amplitude of the CNV has been shown to increase with 
increased motivation and attention (McCallum, Cooper, & Pocock, 1988; 
Tecce, 1972). The diversity of tasks that are employed to evoke the CNV 
reflects the variety of applications of the CNV, ranging from fundamental 
research to studies in different clinical groups. The CNV may be affected in 
patients with attention deficit/hyperactivity disorder (ADHD), Alzheimer’s 
Disease (AD) and Parkinson’s disease (PD) and can also be used to evaluate 
drug effects (Amabile, et al., 1986; Kratz, et al., 2009; Linssen, et al., 2011; 
Oishi, et al., 1995; van Deursen, Vuurman, Smits, Verhey, & Riedel, 2009). 
Hence, the CNV could potentially be used to screen for normalization of CNV 
amplitude in neuropsychiatric patients in response to treatment. The current 
paper describes the development of instruments that could eventually be 
applied as a screening tool, seeking to implement previously acquired 
knowledge about the CNV to optimize the CNV paradigm and reliably produce 
large CNVs. To this end, new response preparation tasks were designed to 
promote motivation and attention during task performance and induce larger 
CNVs and faster responses compared to conventional response preparation 
tasks.  
Two components can be distinguished in the CNV, an early and a late 
component or wave, or the ‘O-wave’ and ‘E-wave’, referring to orientation 
and expectancy (Klorman & Bentsen, 1975; Loveless & Sanford, 1974b). The 
early wave increases with stimulus intensity, is enhanced when auditory 
warning stimuli are used, and habituates over trials, all of which support that 
it reflects an orienting response (Gaillard, 1976; Loveless & Sanford, 1975; 
Weerts & Lang, 1973). It has been proposed that the late CNV is a composite 
of a readiness potential and stimulus preceding negativity (Brunia, 1988; van 
Boxtel & Brunia, 1994), reflecting motor preparation and stimulus anticipation 
(Brunia & van Boxtel, 2001).   
The early CNV has its cortical origin in prefrontal supplementary 
sensorimotor areas; the late wave in prefrontal, supplementary sensorimotor, 
primary somatosensory, primary motor, temporal and occipital areas 
(Babiloni, et al., 2005). Hence, early CNV has been found to be least 
prominent at the Pz electrode location whereas the late wave was hardly 
visible at the Fz electrode (Haagh & Brunia, 1985; Klorman & Bentsen, 1975).  
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 The classic CNV task constitutes a warning stimulus (S1) followed by 
an imperative stimulus (S2) after a fixed and known interval. Stimulus 
manipulations differentially affect the early and late CNV waves (Y. Nagai, et 
al., 2004). For example, the amplitude of the early CNV wave increases with 
increased warning signal duration (Klorman & Bentsen, 1975), whereas the 
amplitude of the late wave increases if the imperative stimulus contains 
information about the required response (van Boxtel & Brunia, 1994). In a 
Go/No-go paradigm, in which the warning stimulus gives information about 
the required response, the warning stimulus may affect both early and late 
CNV (Babiloni, et al., 2004; J. L. Smith, Johnstone, & Barry, 2006, 2007).  
In order for the response preparation task to be used as a screening 
tool, it needs to reliably evoke a CNV. Since CNV amplitude has been reported 
to be decreased in clinical groups such as PD and ADHD patients 
(Banaschewski & Brandeis, 2007; Oishi, et al., 1995), a successful task should 
induce large CNV waves. To acquire an optimal CNV, a substantial number of 
trials have to be recorded in which the subjects have to produce speeded 
responses. Furthermore, the interval between S1 and S2 needs to be rather 
long (3 to 4 seconds) in order to observe both an early and a late wave (Fan, 
et al., 2007). This is potentially problematic, as especially the elderly, 
children, AD and ADHD patients may suffer from loss of focused attention and 
possibly fail to show an anticipatory response (Loveless & Sanford, 1974a; van 
Deursen, et al., 2009).  In this study, an attempt was made to overcome these 
problems by developing new tasks using stimuli that promote response 
anticipation.  
In a conventional response preparation task, using static stimuli, there 
is a 4 second window in which nothing happens and attention is easily 
diverted away from the task. Therefore, it was decided a new task should 
employ moving stimuli. We designed a task in which participants view two 
lines moving towards each other that intersect after 4 seconds, to which the 
participant has to respond by a button press. In this ‘Lines task’ participants 
can continuously track the lines during the interval between S1 (the 
appearance of the lines) and S2 (the crossing of the lines). A major advantage 
of this task as opposed to static tasks or dynamic tasks in which the timing of 
S2 is varied (Jaskowski & Verleger, 1993) is that the movement of the lines 
allows very precise estimation of the occurrence of the imperative stimulus 
which was expected to enhance CNV amplitude and speed responses. An 
additional advantage of the Lines task could be that participants may feel 
more encouraged to provide a quick response and hence, maintain focused 
attention. In experiment 1, we tested the hypothesis that the ‘Lines task’ 
would lead to improved response preparation as indicated by an increase in 
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late CNV amplitude and faster response times when compared to a standard 
CNV task using static stimuli.  
Once efficacy of this task was established, the task was further 
adapted, creating a Go/No-go task. Within a Go/NoGo task, it is uncertain 
whether a response will be required. We were interested to see how this 
would affect the CNV. Moreover, in contrast with the S2 in the Lines task, the 
imperative stimulus in our Go/NoGo task carries information as to whether a 
response has to be given or not, an aspect that may affect not only the late, 
but also the early CNV wave. Both early and late CNV wave, as induced by the 
Go/No-go task were studied in experiment 2. 
 
Experiment 1 
 
Method 
Participants 
Nineteen healthy male volunteers (mean age=23.4, SD=5.4) were selected and 
paid to participate. They were all right handed. Participants were recruited 
by means of advertisement posters in university buildings and advertisements 
in the university newspaper. All subjects gave written informed consent. The 
study was part of a larger study which was approved by the ethical committee 
of Maastricht University and conducted in accordance with the Declaration of 
Helsinki 1975, revised Seoul, 2008.  
 
Procedure 
Participants were invited into the lab at either 8:00 or 8:30 AM. EEG was 
measured using eleven electrodes placed on the scalp, according to the 10-20 
system (Jasper, 1958)at the Fz, F3, F4, Cz, C3, C4, Pz, P3, P4, O1 and O2 
electrode positions. Electrodes placed on the left and right mastoid served as 
reference channels. The ground electrode was placed at the AFz location on 
the forehead. An electro-oculogram (EOG) was measured bipolarly above and 
below the right eye and horizontally next the left and right eye. Impedances 
were kept below 5kOhm. Data were sampled at 1000 Hz and filtered online 
between 0.05 and 100 Hz. Participants received task instructions both orally 
and on the computer screen. They performed two different tasks: first a 
standard response preparation task, the ‘TL task’ (static task) immediately 
followed by the ‘Lines task’ (dynamic task).  
 
CNV Traffic light task 
In the CNV Traffic light (TL) task, participants watched the computer screen 
and were presented with a filled red circle (S1) on a black background. After 
4 seconds, the red circle turned green (S2). Subjects were instructed to 
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respond to the green circle by pressing a button with the index finger of the 
dominant (right) hand on a table mounted response box as fast as they could. 
The test consisted of 32 trials.  
 
CNV Lines task 
In the CNV Lines task, S1 was the appearance of two red line drawings. The 
Lines were oriented at a 90 degree angle of each other and after appearing 
both moved diagonally upwards to the centre of the screen (forming and 
inverted V). The full movement of the lines spanned approximately 10cm2. 
Participants were instructed to fixate on the center of the screen between 
trials. This was indicated by a fixation cross, which disappeared at the start of 
the trial. After 4 seconds, the Lines crossed and turned green (S2). At this 
moment, participants pressed a response button with the index finger of the 
dominant (right) hand as fast as possible. The visual angle between the 
fixation cross and the location where the lines crossed was 0.026o.The test 
consisted of 25 trials.  
 
Data analysis 
EEG data were screened for artefacts offline, corrected for eye movements 
(Semlitsch, Anderer, Schuster, & Presslich, 1986) and a low pass filter of 10 
Hz was applied. Event-related potentials were extracted by stimulus locked 
averaging of epochs starting 100 milliseconds before S1 and ending 1000 
milliseconds after S2. A baseline correction was applied on the whole epoch, 
using the 100 ms interval preceding S1 as reference. Late CNV amplitude was 
calculated by averaging the amplitude over the last 100 milliseconds before 
S2. Since the CNV amplitude was expected to be maximal at the central 
electrodes analyses was restricted to Cz, C3 and C4 electrodes. 
Reaction time and EEG data were analyzed using repeated measures 
analysis of variance (ANOVA) with the within subjects factor task which had 
two levels, namely the TL task and the Lines task. For the amplitude data 
there was an additional within subjects factor electrode which had 3 levels 
(C3, Cz, C4). The behavioural dependent variable was response time (in ms) 
of correct responses (i.e. excluding responses before the lines changed color). 
The effects were evaluated using Greenhouse-Geisser correction and were 
considered significant at p<0.05. Where necessary, the Bonferroni correction 
was applied. In the case of a significant main effect, post hoc pairwise 
comparisons were conducted. Interaction effects were analyzed post hoc by 
conducting additional repeated measures ANOVAs, including only those factors 
that were involved in the interaction. Only significant effects are reported.  
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Results 
Average response time in the Lines task was faster than in the standard TL 
task (MTL=247 ms, MLines=59 ms; F1.0,0,18.00=932.752, p<.001).  
Averaged CNV waves recorded at the Cz electrode during performance 
of the TL task and the Lines task are shown in Figure 1. Mean CNV amplitudes 
at all electrodes are presented in Table 1. Amplitude of the CNV was 
significantly affected by both task (F1.00,18.00=8.653, p<.05) and electrode 
position (F1.77,31.84=8.648, p<.001). Amplitude was larger in the Lines task than 
in the TL task. Pairwise comparisons for electrode positions indicated that 
CNV amplitude was largest at Cz, smallest at C4, and intermediate at C3.  
 
Figure 1. Grand ERPs showing CNV waves measured at Cz during the TL and Lines tasks.  
 
Table 1 
Mean amplitudes (SEM) of the CNV for 3 electrode positions of Experiment  
Electrode  Stoplight   Lines   
C3 -5.12 (0.60) -9.29 (1.39)
Cz -5.79 (0.81) -11.07 (1.63)
C4 -4.62 (0.54) -8.60 (1.41)
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Experiment 2 
 
Method 
Participants 
Twenty healthy participants (10 male and 10 female, mean age=23.0, SD=1.2) 
were selected and paid to participate. All but one were right handed. They 
were recruited by means of advertisement posters at Maastricht University. 
This study was conducted as a pilot of a larger study which was approved by 
the ethical committee of Maastricht University and conducted in accordance 
with the Declaration of Helsinki 1975, revised Seoul, 2008.   
 
Procedure 
Participants were invited into the lab at either 9:00 or 11:00 AM. They signed 
informed consent and filled out a brief questionnaire assessing demographic 
variables. Next, they were prepared for EEG measurement. An electrode cap 
was placed which contained 32 electrodes at locations in accordance with the 
international 10-20 system (Jasper, 1958). Otherwise, EEG measurement 
procedures were identical to those in experiment 1.  
Participants received task instructions both orally and on the computer 
screen. The task was carried out in two identical parts each containing 144 
trials and lasting approximately 18 minutes, with a 5 minute break in 
between. The warning stimulus, S1, was the appearance of two red line 
drawings at the bottom left and right hand corner. The Lines were oriented at 
a 90 degree angle of each other and after appearing both moved diagonally 
upwards to the centre of the screen (forming and inverted V). The full 
movement of the lines spanned approximately 10cm2. Participants were 
instructed to focus on the fixation cross at the center of the screen. After 4 
seconds, the Lines crossed (S2). At this moment, participants pressed a 
response button with the index finger of the dominant (right) hand as fast as 
possible, but only if the Lines turned green (Go trial) at the moment they 
crossed. If the Lines remained red, participants should withhold the response 
(No-go trial). The chance that a trial was a Go trial was indicated at S1 by a 
percentage and could be either 20, 50 or 100% (randomized per block). For 
each of these percentages, there were 36 Go trials. Consequently, a total of 
36 100% trials was presented, whereas for the 50% trials, there were 72 trials 
(36 go and 36 No-go) and for the 20% trials, 180 trials were present (36 go and 
144 No-go).  
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Data analysis 
EEG data were screened for artefacts offline corrected for eye movements 
(Semlitsch, et al., 1986) and a low pass filter of 10 Hz was applied. Event-
related potentials were extracted by stimulus locked averaging of epochs 
starting 100 milliseconds before S1 and ending 4800 milliseconds after S2. A 
baseline correction was applied on the whole epoch, using the 100 ms interval 
preceding S1 as reference. Early CNV was determined as the average 
amplitude between 750 and 1200 ms after S1 relative to baseline. Late CNV 
was determined as the average amplitude between 3600 and 4000 ms after 
S1. For both waves, mean amplitudes were analysed for F3, Fz, F4, FC3, FCz, 
FC4, C3, Cz and C4. Only correct trials were taken into account.   
Behavioural and EEG data were analyzed using repeated measures 
analysis of variance (ANOVA) with the within subjects factor trial type which 
had three levels, namely the 20, 50 and 100% trials. For the amplitude data 
there was an additional within subjects factor electrode which had 9 levels 
(F3, Fz, F4, FC3, FCz, FC4, C3, Cz, C4). Behavioural dependent variables were 
response time (in ms) of correct responses (i.e. excluding prepotent responses 
and responses to No-go trials), hit rate, and false alarm rate. As in 
experiment 1, the effects were evaluated using Greenhouse-Geisser 
correction and were considered significant at p<0.05. Where necessary, the 
Bonferroni correction was applied. In the case of a significant main effect, 
post hoc pairwise comparisons were conducted. Interaction effects were 
analyzed post hoc by conducting additional repeated measures ANOVAs, 
including only those factors that were involved in the interaction. Only 
significant effects are reported. 
 
Results 
Task performance 
Means and standard errors of measurement for the main outcome variables 
including response time, hit rate and false alarm rate for each trial type are 
presented in Table 2. There was a significant main effect of trial type on 
response time (F1.11,21.24=357.243, p<.001). Pairwise comparisons revealed that 
response times increased as the probability of response requirement 
decreased. In other words, the more unsure participants were about whether 
they would have to respond, the slower they responded. Hit rate was smaller 
in the 100% Go trials compared to the 20 and 50% Go trials, due to premature 
responding in the 100% Go trials (F2,38=35.119, p<.001). False alarm rate was 
larger for the 50% No-go trials than for 20% No-go trials (F1,19=9.824, p<.01).  
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Table 2 
Mean (SEM) response times, hit rate and false alarm rate for Experiment 2 
 100% Go  50% Go  50% No-go  20% Go  20% No-go  
Response time 103* (10) 286* (4)   301* (5)   
Hit rate 0.93* (0.01) 1.00 (0.00)   1.00 (0.00)   
False alarm rate         0.024* (0.006)     0.007* (0.002) 
 
Amplitude data 
Averaged CNV waves recorded at the Cz electrode during performance of the 
Go/ No-go task are shown in Figure 2. Mean early and late CNV amplitudes at 
all electrodes are presented in Tables 3 and 4 respectively. 
Figure 2. Grand ERPs showing CNV waves measured at Cz during each of the three trial types with 
100%, 50% and 20% chance on a go trial. 
 
Early CNV wave 
A main effect of electrode position (F1.52,28.88=4.685, p<.05) indicated that the 
amplitude of the early CNV differed between electrode positions. Pairwise 
comparisons revealed that amplitude was larger at FCz compared to F4 and 
C4, and larger at Cz than at C4. When amplitudes were analyzed for each 
electrode separately, a main effect of trial type was found for the frontal 
electrodes (F3: F2,38=4.801, p<.05, Fz: F2,38=7.720, p<.01, F4: F1.33,25.19=4.617, 
p<.05) and FC3 (F1.53,29.13=3.801, p<.05) but not for the other 5 electrodes. 
Pairwise comparisons showed that the amplitude was larger when 
requirement of response probability was 100% compared to 50% at F3, Fz and 
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F4 and compared to 20% at Fz. For FC3 pairwise comparisons revealed no 
significant results. 
 
Table 3 
Mean amplitudes (SEM) of the early CNV for the different trial types in the 9 electrode positions 
Electrode  F df 100%   50%   20%   
F3 4.801* 1.78,33.75 -2.80 (1.03) -1.35 (1.01) -1.45 (0.75) 
Fz 7.720* 1.56,29.62 -3.94 (0.78) -2.28 (0.73) -1.89 (0.68) 
F4 4.617* 1.33,26.19 -1.64 (0.73) -0.07 (0.72) -0.01 (0.84) 
FC3 3.801* 1.53,29.13 -3.61 (1.01) -2.33 (0.88) -2.21 (0.66) 
FCz 2.206 1.35,25.67 -1.93 (0.82) -0.99 (0.75) -0.57 (0.80) 
FC4 3.375 1.55,29.40 -4.29 (0.95) -3.07 (0.86) -2.56 (0.71) 
C3 1.126 1.46,27.65 -2.77 (0.98) -1.96 (0.78) -1.93 (0.54) 
Cz 1.180 1.52,28.90 -3.54 (0.95) -2.83 (0.82) -2.42 (0.63) 
C4 0.512 1.42,26.89 -1.31 (0.81) -0.89 (0.68) -0.61 (0.67) 
* p<.05 
 
Late CNV wave 
Amplitude of the late CNV was significantly affected by both trial type (F-
1.49,28.25=4.638, p<.05) and electrode position (F2.64,50.15=21.012, p<.001). In 
addition, an interaction between these two factors was observed 
(F4.79,90.95=2.604, p<05). Pairwise comparisons revealed no significant 
differences for the trial types. For the electrode positions, pairwise 
comparisons indicated that the late CNV amplitude generally was smallest for 
the most frontal electrodes and increased as the position was more central. 
However, not all pairwise comparisons were significant.  
To further explore the interaction between electrode position and 
trial type, the effect of trial type was analyzed for each electrode position 
separately (see Table 4). It was shown that amplitude increased with 
increasing probability of response requirement at Cz, C3, C4, FCz, FC3 and 
FC4 and F4 (although this was only significant for the 100% vs. the 20% trials). 
This effect was most significant at the central electrode positions, less 
significant for the fronto-central positions and non-significant for two out of 
three frontal positions.  
In order to see if the late CNV was lateralized, a comparison was 
made between electrode positions that were contralateral vs. ipsilateral to 
the response finger. This revealed a trend suggesting that the late CNV was 
slightly larger at the central electrode contralateral to the response finger (C3 
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in most participants) compared to ipsilateral central electrode (C4 in most 
participants, F1,19=3.409, p<.10).  
 
Table 4 
Mean amplitudes (SEM) of the late CNV for the different trial types in the 9 electrode positions 
Electrode F df 100%   50%   20%   
F3 .992 1.39,26.35 -7.39 (1.05) -6.39 (1.03) -6.20 (0.91) 
Fz 2.576 1.60,30.39 -8.14 (0.97) -7.15 (1.07) -6.18 (1.08) 
F4 5.365* 1.53,29.09 -6.34 (1.17) -4.34 (0.97) -3.80 (0.99) 
FC3 3.844* 1.51,28.64 -9.73 (1.14) -7.88 (1.01) -7.58 (0.84) 
FCz 3.736* 1.44,27.27 -11.91 (1.26) -10.41 (1.31) -9.15 (1.17) 
FC4 5.188* 1.58,30.04 -8.37 (1.30) -6.75 (1.11) -5.63 (1.08) 
C3 4.486* 1.38,26.28 -11.16 (1.37) -8.72 (1.17) -8.57 (0.97) 
Cz 5.956* 1.35,25.63 -13.54 (1.51) -11.10 (1.21) -9.93 (1.16) 
C4 7.026* 1.62,30.77 -10.06 (1.32) -7.84 (1.17) -6.97 (1.06) 
* p<.05 
 
Discussion 
 
The current study aimed to develop response preparation tasks producing 
CNVs that could be potentially useful as a screening tool. We showed 
enhanced response preparation in a newly developed task applying dynamic 
stimuli in relation to a task with static stimuli, as was indicated by larger CNV 
amplitude and faster response times. In a second experiment we tested 
whether this effect persisted if the task was adjusted to a Go/No-go format. 
The probability that participants had to respond (Go trials) differed between 
the trials. As predicted this manipulation differentially affected amplitudes of 
the early and late CNV waves and response times. The smaller the probability 
of response requirement, the smaller the CNV amplitudes and the slower 
participants responded.  
The finding that participants responded faster in the new task, using 
dynamic stimuli, compared to the standard task with static stimuli, is in line 
with our hypothesis. Because the stimuli were steadily and continuously 
moving towards each other during the trial, timing of the response could be 
monitored very accurately. It is likely that this extra stimulus feature 
increased the participants’ motivation to respond as quickly as possible and 
maintain focused attention. This is supported by the increase in CNV 
amplitude, which has previously been associated with motivation and 
attention (McCallum, et al., 1988; Tecce, 1972).  
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Since the participants in experiment 2 were not the same as those in 
experiment 1, reaction times cannot be directly compared between the two 
experiments. However, it is still striking that although the same stimuli were 
used in the Go/No-go task, responses were much slower compared to the 
Lines task. Responses to the 50 and 20% trials were rather close to those in 
the TL task. In these ‘uncertain’ trials additional processing related to the 
decision to make a response can account for this result. Response times in the 
100% trials were faster compared to the TL task, but slower compared to the 
Lines task. This is surprising, since the 100% trials in the Go/No-go task are 
actually identical to the Lines task. Although participants can be sure that 
they will have to respond unconditionally, they are approximately twice as 
slow compared to the Lines task. This may partly be explained by the fact 
that this was a different group of participants. However, other explanations 
may be that inhibition in the uncertain trials spreads to the 100% Go trials or 
the participants did not trust the instructions. This latter explanation was 
given by Smith, Johnstone & Barry (2007) for the fact that participants 
seemed to prepare to give a response on specific No-go trials.  
 Within the Go/No-go task, the most prominent differences are 
observed between ‘certain’ versus ‘uncertain’ trials. Nevertheless, results of 
the 50% and 20% No-go trials do indicate that they were processed differently. 
Responses were slower to 20% trials compared to the 50% trials, perhaps 
indicative of stronger inhibition. In support of this idea, relatively more false 
alarms were produced in the 50% trials than in the 20% trials.  
The size of the early CNV was positively related to the probability 
participants had to produce a response. As expected the task manipulation 
exerted the largest effect on the early CNV at frontal electrodes (Haagh & 
Brunia, 1985; Klorman & Bentsen, 1975). The late CNV on the other hand was 
maximal over central electrode positions, which is also in line with previous 
findings (Haagh & Brunia, 1985; Klorman & Bentsen, 1975). The effect of the 
manipulation was largest at these electrodes. The late CNV seemed to be 
lateralized to the side contralateral to the response hand, which was 
expected based on previous findings (Butler & Glass, 1974; Verleger, Paehge, 
Kolev, Yordanova, & Jaskowski, 2006).  
In sum, in this study, two new tasks were developed to induce a more 
optimal CNV wave that could possibly be used as a screening tool in future 
clinical-/pharmacological studies. The adaptations to the regular task proved 
to be successful in enhancing response preparation as indicated by higher 
amplitude and faster response times. The tasks’ properties are thought to 
promote motivation and effort of subjects to optimally prepare for each trial 
and this makes the task especially valuable in participants who have problems 
sustaining attention such as elderly participants or ADHD patients. 
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Furthermore, varying the probability that a response has to be given affects 
stimulus processing, response preparation and execution as reflected by the 
effect on the early CNV wave, the late CNV wave and response times 
respectively. The Go/No-go CNV task presented here may lead to new insights 
regarding response preparation and inhibition in both clinical and non-clinical 
groups on or off medication. 
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Abstract 
 
Rationale: The basal ganglia play an important role in motor control, which is 
dependent on dopaminergic input. Preparation of a motor response has been 
associated with dopamine release in the basal ganglia, and response readiness 
may therefore serve as a pharmacodynamic marker of dopamine activity. 
Methods: We measured response readiness using the amplitude of the 
contingent negative variation (CNV), a slow negative shift in the 
electroencephalogram. The CNV is evoked in a paradigm in which a warning 
stimulus (S1) signals the occurrence of the imperative stimulus (S2) 4 s later, 
to which the participant has to respond. CNV was assessed in healthy 
volunteers after administration of placebo or 10, 20 or 40 mg of 
methylphenidate, a catecholamine re-uptake blocker which primarily 
enhances the synaptic concentration of dopamine and to a lesser extent also 
noradrenaline. In addition, participants filled out two visual analogue scales 
measuring subjective ratings of mood and alertness: Profile of Mood States 
and Bond and Lader. 
Results: Methylphenidate dose dependently increased CNV amplitude and 
decreased reaction times. Furthermore, participants reported improved 
mood, feeling more alert, vigorous and content and less angry and tired after 
methylphenidate. 
Conclusions: These results indicate that dopamine availability increases 
response readiness as measured by the CNV paradigm. The CNV appears to be 
a good candidate biomarker for assessing changes in dopaminergic function by 
treatments that either directly or indirectly target the dopaminergic system.
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Introduction 
 
Dopamine abnormalities are implicated in neuropsychiatric diseases such as 
Parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder 
(ADHD; (Iversen & Iversen, 2007; Nieoullon, 2002), but the precise nature of 
these disturbances and their treatments remains to be understood. This drives 
the relevance of dopamine-related research and the value of new tools aiding 
this research. In the present study, a candidate biomarker of dopamine 
activity is proposed and validated. 
 The contingent negative variation (CNV) is a slow negative shift in the 
EEG that can be observed between a warning signal and an imperative 
stimulus during a reaction time task. The occurrence of this wave has been 
associated with expectation, anticipation, orientation, attention, intention to 
act, motivation and response readiness (Bares, et al., 2003; Tecce, 1972; van 
Boxtel & Brunia, 1994; Walter, et al., 1964). 
 Evidence from studies with Parkinson’s disease patients using 
intracranial electrodes and studies combining EEG/fMRI techniques suggests 
that the CNV is generated in the basal ganglia (Bares & Rektor, 2001; Fan, et 
al., 2007; T. Nagai, et al., 2007; Oishi, et al., 1995; Rektor, et al., 2004; 
Rektor, et al., 2003). An important neuromodulator within the basal ganglia is 
dopamine which, consequently, has been considered a possible biochemical 
mechanism underlying the CNV (Amabile, et al., 1986). Converging evidence 
suggests that CNV may indeed be modulated by dopamine availability 
(Amabile, et al., 1986; Kopell, Wittner, Lunde, Wolcott, & Tinklenberg, 1974; 
Oishi, et al., 1995; Tecce, 1991; Tecce & Cole, 1974; Tecce, Cole, & 
Savignano-Bowman, 1975). Consequently, changes in CNV may signal 
alterations of dopamine levels in the brain, and the CNV may thus be a basal 
ganglia originated marker of dopamine activity. 
Research with agents affecting other neurotransmitters such as 
serotonin, noradrenaline and acetylcholine showed that the influence on the 
CNV is indirect (through interactions with the dopamine system), absent or 
dose dependent (Ashton, et al., 1980; Ashton, Millman, Telford, & Thompson, 
1976; Ashton & Rawlins, 1978; Hansenne, Pitchot, Pinto, Papart, & Ansseau, 
2000; Mulder, Linssen, & de Geus, 2002). Benzodiazepines decrease CNV 
amplitude (Ashton, et al., 1976; Papart, Ansseau, & Timsit-Berthier, 1997; 
Rockstroh, Elbert, Lutzenberger, & Altenmuller, 1991). 
An early and a late CNV component or ‘wave’ can be distinguished 
(Klorman & Bentsen, 1975). The early wave is thought of as an orientation 
response (Klorman & Bentsen, 1975) whereas the late CNV consists of a 
readiness potential and stimulus preceding negativity (Brunia, 1988; van 
Boxtel & Brunia, 1994). The late CNV reflects motor preparation and stimulus 
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anticipation (Brunia & van Boxtel, 2001) and is the wave targeted here. To 
observe both waves, an interval of 4 s is used in the current study. 
Before the CNV can be successfully applied as a dopaminergic 
biomarker, its sensitivity needs to be established. It is essential to know both 
the minimal change in dopamine levels that can be detected by means of the 
CNV and the dose–response curve of the paradigm. Therefore, this study 
measured CNV amplitude across a range of doses of a dopamine-enhancing 
drug. The drug chosen was methylphenidate. Methylphenidate inhibits 
dopamine re-uptake by blocking the dopamine transporter (DAT) and thus 
enhances dopamine availability (Volkow, Wang, Fowler, Gatley, et al., 1998), 
has a wide safe dose range, is generally well tolerated and has been used for 
similar purposes in previous studies (Volkow, et al., 2008; Volkow, Wang, 
Fowler, Hitzemann, et al., 1998). Methylphenidate is used to treat ADHD and 
narcolepsy. The maximum dose in children with ADHD is 60 mg/day. PET 
research has shown that methylphenidate leads to dose-dependent DAT 
blockade with a dose of 5 mg producing a 12% blockade, 10 mg 40%, 20 mg 
54%, 40 mg 72% and 60 mg 74% (Volkow, Wang, Fowler, Gatley, et al., 1998). 
Hence, therapeutic doses of methylphenidate are likely to block more than 
50% of DAT. Tmax is observed 1–3 h after intake, with a half life of 
approximately 3 h (Leonard, et al., 2004; Spencer, et al., 2006). 
Participants were treated with 10, 20 and 40 mg of methylphenidate, 
and in addition to CNV amplitude, task performance and subjective drug 
effects were also measured. It was expected that CNV amplitude would show 
a dose-related increase and that reaction time would dose dependently 
decrease. Based on the PET research cited above and other previous studies 
with methylphenidate (Cooper, et al., 2005; Hermens, et al., 2007), it was 
expected that a dose of 10 mg would lead to minimal effects. The largest 
effects were expected with 40 mg of methylphenidate, whereas 20 mg was 
expected to induce intermediate effects. 
 
Materials and methods 
 
Participants 
Nineteen healthy male volunteers (mean age = 23.4, SD = 5.4, range = 19–37) 
were selected and paid to participate. Participants were recruited by means 
of advertisement posters in university buildings and advertisements in the 
university newspaper. Prescreening occurred using a medical history 
questionnaire and was followed by medical examination. 
 The main inclusion criteria were between 18 and 40 years of age, 
body mass index between 18 and 30 kg/m2 and right-handed. The main 
exclusion criteria were history or presence of mental or physical disorders as 
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assessed by medical history and anamnesis at inclusion, reported presence of 
psychiatric diseases in first degree relatives, previous drug dependence, self-
reported regular drug use, smoking more than five cigarettes per day and 
consumption of more than 21 alcohol units per week or more than five 
caffeine containing drinks per day (average reported daily use <2). In 
addition, volunteers with polymorphisms of the CES1 gene indicative of being 
a poor metaboliser of methylphenidate were excluded. One participant was 
excluded based on this criterion. 
All subjects gave written informed consent. The study was carried out 
in accordance with the declaration of Helsinki and approved by the medical 
ethical committee of Maastricht University. 
 
Design 
The study was conducted according to a double-blind, placebo-controlled, 
four-way crossover design. Between the testing days, a period of at least 48 h 
elapsed, but generally testing days were scheduled approximately 1 week 
apart. Each participant received one of four single treatments including 
placebo (PLA) and 10, 20 and 40 mg methylphenidate (M10, M20 and M40) on 
each testing day. The order of the treatments was randomized following a 
Williams Latin square design resulting in four different sequences constructed 
using SAS programme. 
 
Dependent measures 
EEG measurement  
During two response preparation tasks, EEG was measured using 11 electrodes 
placed on the scalp, according to the 10–20 system at the Fz, F3, F4, Cz, C3, 
C4, Pz, P3, P4, O1 and O2 electrode positions. The remaining electrodes 
consisted of four to register vertical and horizontal eye movements, two on 
the mastoids for reference and one on the forehead as ground. Data were 
recorded with a 1,000-Hz sample rate and filtered online between 0.05 and 
100 Hz. Offline, data were first screened for artefacts and a low pass filter of 
10 Hz was applied on all data. Next, epochs were extracted from the 
continuous EEG. Each epoch lasted 5,100 ms, starting 100 ms before S1 and 
ending 1,000 ms after S2. A baseline correction was applied to the whole 
epoch, using the 100 ms interval preceding S1 as reference. Averaging the 
sequential epochs yielded a S1 stimulus locked event-related potential (ERP). 
CNV amplitude was calculated by averaging the amplitude over the last 
100 ms before S2. Since the CNV amplitude was expected to be maximal at 
the central electrodes (Brunia, 1988; Klorman & Bentsen, 1975; van Boxtel & 
Brunia, 1994), Cz, C3 and C4 were of main interest and are reported in the 
Results section. 
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Response preparation tasks  
CNV stoplight task 
In the CNV stoplight task, participants watched the computer screen and were 
presented with a filled red circle (S1) on a black background. After 4 s, the 
red circle turned green (S2). Subjects were instructed to respond to the green 
circle by pressing a button on a table mounted response box as fast as they 
could. Each test consisted of 32 trials. Reaction time to the onset of S2 was 
measured in each trial and averaged over the test. 
 
CNV lines task  
A CNV task with a long preparation time can be boring, and participants may 
become less motivated to produce speeded responses to the imperative 
stimulus. This may have a detrimental effect on CNV amplitude. Therefore, a 
new task involving dynamic stimuli was designed. In the CNV lines task, S1 was 
the appearance of two red line drawings at the bottom left- and right-hand 
corner. The lines were oriented at a 90° angle to each other and after 
appearing both moved towards the centre of the screen. After 4 s, the lines 
crossed and turned green (S2). At this moment, participants pressed a 
response button as fast as possible. In two thirds of the trials, a horizontal 
yellow bar partially blocked the view of the lines as they moved towards the 
centre of the screen, but the lines were always visible at the moment of 
crossing. The yellow bar could be small or large, blocking less or more of the 
trajectory of the lines as they moved towards the centre. The trials with the 
small bar are collectively called ‘lines 1’, those with the large bar ‘lines 2’ 
and those without a bar ‘lines 3’. Of each type, 25 trials were presented. 
Reaction time was measured and averaged per trial type. These three 
variations of the new paradigm and the standard paradigm were compared in 
order to find out which task led to optimal CNV amplitude. 
 
Subjective measures  
Participants completed two rating scales of subjective effects, the Profile of 
Mood States (POMS; (McNair, et al., 1992)) and the Bond and Lader (B&L) 
visual analogue scales (Bond & Lader, 1974). These rating scales involved the 
presentation of 16 (B&L) or 32 (POMS) bipolar items presented at the ends of 
a horizontal line on a computer touch screen. Each item consisted of two 
words describing mood states. Participants had to score their preference for 
either of the items in accordance with their mood by marking the line closer 
to one of the two words. Dependent measures were factor scores on the 
dimensions Alertness, Contentedness and Calmness (B&L) and Depression, 
Anger, Fatigue, Vigour and Tension (POMS). 
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Blood plasma values and physiological measures  
Blood samples were drawn in order to measure blood levels of the drug and 
neuroendocrine responses. Dependent variables were changes in levels of 
methylphenidate, prolactin and cortisol in blood during the testing days. 
Physiological measures including systolic and diastolic blood pressure and 
heart rate were also taken. 
 
Procedure 
A training session in which all behavioural tasks were practiced took place 
within 2 weeks before the first testing day. Participants abstained from 
alcohol during the last 24 h prior to each testing day and from caffeine 
containing drinks during the testing days. On testing days, they were collected 
at their home and arrived at the lab in fasted condition at either 8.00 am or 
8:30 am. Inclusion exclusion criteria were checked, including a drug screen 
(which tested presence of the following substances in urine: cannabis, 
opiates, cocaine, methamphetamine, benzodiazepines, amphetamines) and 
blood alcohol concentration measurement. Next, EEG electrodes and a 
catheter were placed, and participants were given a standardized meal for 
breakfast at 80 min per dose (t = −80). At t = 0, participants ingested four 
identically appearing capsules with water that all contained either PLA, M10, 
M20 or M40. Participants went through seven cycles of testing at t = −60, 30, 
60, 120, 180, 240 and 300 min relative to dosing. At t = 220, a standard light 
lunch was served. Each cycle included a fixed order of the CNV stoplight task, 
the CNV lines task, POMS, B&L, registration of heart rate and blood pressure 
and the drawing of blood samples. After collection of the blood samples, the 
catheter was cleaned with heparin dissolved in isotonic saline, and blood 
samples were centrifuged for 10 min at 4,000 rpm. Plasma was stored at 
−20°C and frozen PK samples were moved to a −80°C freezer. After the last 
measurement, the EEG electrodes and catheter were removed and 
participants were transported home by taxi. 
 
Data analysis 
Data were analysed using repeated measures analysis of covariance analysis. 
In this mixed model, the repeated measures of drug (independent variable) on 
the dependent variables (mean CNV amplitude, reaction time, scores on POMS 
and Bond & Lader, heart rate, blood pressure, cortisol and prolactin levels in 
blood, Tmax and Cmax) were tested using baseline (measurement of the 
dependent variable at t − 60) as a covariate and period (first, second, third or 
fourth testing day) as between subjects variable. Since treatment consisted of 
different doses of the same drug and the lower doses may have no or little 
effect on amplitude, response time and subjective measures, the likelihood of 
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finding a main effect on these measures may be rather small, even though 
higher doses may have a significant effect. Therefore, main effects of drug 
were not evaluated for the amplitude and reaction time data and the 
subjective measures. Instead, a priori planned comparisons between each 
dose relative to placebo were tested for significance, at p < 0.05, using LSD 
correction. This is not the case for blood plasma values and physiological 
measures, where even small doses of the drug were expected to exert 
significant effects on heart rate, blood pressure, cortisol and prolactin levels 
and Tmax and Cmax. Therefore, main effects are reported for these measures at 
a significance level of p < 0.05. Post hoc testing using LSD correction was done 
to find out which doses had an effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Grand average ERPs showing a clear CNV wave during the Stoplight (a) and Lines 2 (b) 
response preparation tasks. The ERPs depicted were recorded at Cz, at t240 relative to dosing. 
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Results 
 
CNV amplitude 
Averaged CNV waves recorded during performance of response preparation 
tasks are shown in Figure 1. Mean differences on CNV amplitude relative to 
morning baseline are depicted in Figure 2 for stoplight and lines 2 at Cz. Mean 
differences on CNV amplitude relative to morning baseline and results of 
significant difference testing are presented in Table 1.  
Figure 2. Mean difference CNV amplitudes and reaction times relative to morning baseline at t30, 
60, 120, 180, 240 and 300 minutes relative to dosing in the Stoplight (amplitudes at Cz, a; 
reaction times, c) and Lines 2 (amplitudes at Cz, b; reaction times, d) response preparation 
tasks. Error bars are only shown for PLA (placebo) and M40 (methylphenidate, 40 mg). 
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Increases in CNV amplitude after methylphenidate measured at t60 and t240 
account for, respectively, 27% and 46% of the total amount of significant 
differences observed in all paradigms and at all electrodes. More specifically, 
the effects at 1 and 4 h post-dosing were as follows (for a complete overview, 
see Table 1): Significant increases in CNV amplitude after methylphenidate 
during performance of the stoplight task were observed at t60 after intake of 
40 mg of the drug at Cz, C3 and C4 (Cz: p < 0.013, C3: p < 0.035, C4: p <
0.049). At t60, the amplitude was also larger after M10 at Cz (p < 0.045). At 
t240, M40 lead to a significantly increased amplitude at all three electrodes 
(Cz: p < 0.032, C3: p < 0.028, C4: p < 0.017). 
During performance of the lines task version 1, amplitude was 
significantly larger after 40 mg of methylphenidate compared to placebo at 
t240 at the Cz electrode (p < 0.025). Analysis of the lines task version 2 
showed significantly higher amplitudes after M40 at t60 at the C3 electrode 
position (p < 0.035) and at t240 at C4 (p < 0.014). At Cz, all doses led to higher 
CNV amplitude at t240 (M10: p < 0.025, M20: p < 0.014, M40: p < 0.006). 
 
Reaction time data 
Mean differences on reaction times relative to morning baseline are depicted 
in Figure 2 for stoplight and lines 2. Mean differences on reaction time 
relative to morning baseline and results of significant difference testing are 
presented in Table 2.  
Reaction times to the imperative stimulus in the stoplight task were 
shorter after 40 mg of methylphenidate compared to placebo at all time 
points. At t240, reaction times were also shorter after 10 and 20 mg of 
methylphenidate. 
On the lines task, version 1, reaction times were also shorter after 
40 mg of methylphenidate at t60, t120, t240 and t300. On version 2 of the 
lines task, reaction times were shorter after 40 mg from t60 to t300 and after 
all doses at t120. Reaction times were also shorter after the two lower doses 
at t120 and t240. Finally, M40 decreased reaction times on the lines 3 task on 
all time points. In addition, reaction times were shorter after 10 mg of 
methylphenidate at t120 and t240. 
 
Subjective measures 
The Bond & Lader factor scores indicated that participants felt more alert 
between 1 and 2 h after 20 and 40 mg drug intake and more content from 1 to 
3 h after 20 mg of methylphenidate. Furthermore, analysis showed increased 
scores for calmness after 40 mg of methylphenidate at t120 but decreased 
scores after 10 mg at t180 and t300. 
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 Table 1 
Mean differences (SEM) on CNV amplitude relative to morning baseline for Stoplight and Lines  
  C3               Cz       
 Stoplight  Lines 1 Lines 2 Lines 3 Stoplight Lines 1 
 Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) 
T30             
PLA 2.21 (-0.89) -0.50 (1.09) 1.78 (1.03) 2.79 (1.09) 2.59 (1.10) -0.73 (1.12) 
M10 1.43 (0.87) 0.66 (0.87) -0.18 (0.67) -0.33 (0.98) 1.17 (0.79) 0.62 (0.87) 
M20 3.50 (1.46) 0.53 (0.84) 0.79 (1.27) 1.60 (0.91) 1.79 (1.41) 0.41 (0.90) 
M40 2.71 (1.71) -2.21 (1.11) -1.91** (1.03) 1.76 (0.96) 1.85 (1.38) -1.79 (0.94) 
T60             
PLA 3.22 (1.03) 0.65 (0.92) 1.49 (0.97) 3.03 (1.19) 4.32 (1.04) -0.22 (1.21) 
M10 2.00 (1.02) 1.29 (1.05) 1.11 (1.00) 0.27 (0.84) 1.55* (0.96) 1.24 (1.11) 
M20 1.81 (0.77) -0.02 (1.08) 0.22 (0.95) 0.35^ (0.79) 1.55^ (1.17) 0.28 (1.06) 
M40 0.27* (1.06) -0.50 (0.94) -1.80* (1.45) 0.52 (0.62) 0.27* (1.22) 0.15 (0.93) 
T120             
PLA 0.42 (1.07) -0.01 (1.21) 0.00 (1.03) 2.89 (1.54) 1.35 (1.20) -0.22 (1.16) 
M10 0.05 (0.82) 0.27 (1.17) -1.87^ (0.84) -1.48^ (0.92) 0.05 (0.68) -0.27 (1.11) 
M20 1.62 (1.15) -1.62 (1.03) -1.57 (0.98) 0.11 (1.20) -0.01 (1.21) -2.33 (1.34) 
M40 -0.02 (0.78) -2.42 (0.88) -1.72 (1.18) -0.55^ (0.86) -0.42 (0.78) -1.42 (1.01) 
T180             
PLA 2.37 (0.92) -0.32 (1.14) -0.07 (1.02) 0.20 (0.87) 2.03 (1.09) -0.60 (1.05) 
M10 1.28 (0.79) -0.20 (1.35) -1.08 (0.91) -2.73 (0.96) 1.10 (0.71) 0.06 (1.02) 
M20 0.74^ (0.89) -1.52 (1.08) -1.61^ (1.14) 0.04 (1.09) 0.24 (0.98) -2.27 (1.48) 
M40 0.12 (1.15) -2.14 (1.44) -2.89* (1.09) -1.84 (0.77) -0.84 (1.19) -2.96^ (1.52) 
T240             
PLA 1.35 (1.06) 0.45 (0.82) 0.84 (1.72) 1.89 (1.24) 1.42 (1.22) -0.13 (0.94) 
M10 0.89 (1.01) -1.03 (0.99) -1.34^ (0.94) -2.12^ (1.15) 0.28 (0.97) -1.06 (1.12) 
M20 1.61 (1.05) -1.17 (0.87) -1.09^ (1.07) -1.17^ (0.91) 0.61 (1.01) -1.42 (1.19) 
M40 -2.35* (1.22) -2.05^ (1.27) -1.84^ (1.03) -0.31 (0.78) -2.65* (1.46) -3.14* (1.45) 
T300             
PLA 1.21 (1.15) 0.50 (0.97) 0.12 (1.45) 1.60 (1.18) 2.20 (1.41) -1.26 (0.89) 
M10 0.75 (1.01) -0.34 (1.15) -0.22 (1.07) -1.12 (1.01) 1.37 (0.99) -0.42 (1.34) 
M20 1.82 (1.04) -0.71 (0.96) -0.60 (0.79) -0.62 (1.07) 0.67 (1.16) -1.24 (1.14) 
M40 -0.63 (0.99) -0.44 (0.98) -0.03 (0.77) -0.93 (1.10) -0.70 (1.05) -2.66 (1.04) 
 ^p<.1; *p<0.05 **; p<.01; ***p<.001 (signigicant effects and trends). 
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tasks at C3, Cz, and C4 at all time points 
        C4               
Lines 2 Lines 3 Stoplight Lines 1 Lines 2 Lines 3 
Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) 
            
0.44 (1.07) 2.74 (1.13) 2.61 (0.86) -0.32 (0.94) 0.99 (1.12) 2.69 (1.10) 
-0.67 (0.83) -0.90^ (1.03) 1.01 (0.59) 0.29 (0.76) -0.14 (0.82) -0.65 (0.82) 
1.78 (1.57) 0.97 (1.08) 2.32 (0.96) -0.12 (0.78) 2.01 (1.26) 1.96 (0.87) 
-1.65^ (0.89) 1.16 (1.34) 2.10 (1.20) -1.61 (0.87) -1.46* (0.98) 0.79 (1.29) 
            
-0.08 (1.01) 1.85 (1.40) 3.63 (0.78) -0.11 (0.98) 0.65 (1.01) 1.42 (1.17) 
1.35 (1.25) 0.66 (1.14) 1.49 (0.91) 1.67 (0.96) 1.52 (0.97) 0.77 (1.22) 
1.77 (1.34) 0.68 (1.14) 1.01^ (0.97) 0.93 (1.04) 1.39 (0.98) 0.59 (0.90) 
-1.08 (1.37) 1.00 (0.88) 0.52* (1.14) 0.18 (0.93) -1.40^ (1.21) 0.23 (0.75) 
            
-0.23 (1.17) 2.21 (1.51) 1.28 (0.98) -0.33 (1.22) 0.62 (0.98) 1.77 (1.32) 
-1.34 (0.860 -1.40 (0.99) 0.26 (0.64) 0.41 (0.94) -1.30^ (0.79) -1.01 (0.75) 
-0.97 (0.82) -0.16 (1.28) 0.67 (1.06) -1.38 (1.29) -0.01 (0.98) 0.68 (1.10) 
-2.02^ (1.33) -0.95^ (1.13) -0.50 (0.65) -1.15 (0.83) -1.64^ (1.16) 0.09 (0.90) 
            
-0.85 (1.40) -0.27 (0.99) 2.57 (0.89) -0.19 (0.90) 0.05 (1.15) 0.32 (0.88) 
-1.46 (1.11) -2.30 (1.03) 1.19 (0.62) 0.36 (1.14) -1.46 (1.13) -1.59 (0.76) 
-2.44^ (1.34) -1.01 (1.49) 0.67 (0.81) -1.00 (1.14) -1.61 (1.22) 0.21 (1.25) 
-2.91^ (1.17) -1.97 (0.83) 0.64 (1.25) -1.94* (1.29) -1.53 (1.20) -1.55 (0.60) 
            
0.81 (2.17) 0.66 (1.41) 1.96 (0.85) 0.22 (0.75) 0.65 (1.61) 1.00 (1.35) 
-1.64* (1.13) -2.43 (1.17) 0.29 (0.73) 0.03 (1.02) -0.55 (1.04) -1.28 (0.99) 
-1.43* (1.38) -2.14^ (1.18) 0.47 (1.04) -0.66 (1.10) -0.40^ (1.17) -0.08 (1.07) 
-3.55** (1.19) -1.62 (0.89) -2.15* (1.72) -1.82^ (1.39) -2.58* (1.00) -0.83 (0.99) 
            
-0.45 (1.67) -0.01 (1.11) 2.34 (0.98) 0.01 (0.97) 1.00 (1.64) 0.58 (0.87) 
0.37 (1.21) -1.47 (1.14) 2.22 (0.99) -0.04 (1.01) 0.64 (0.80) -0.78 (0.96) 
-0.85 (0.96) -1.91 (1.35) 1.27 (0.99) -0.07 (0.95) 0.02 (1.02) -0.47 (1.13) 
-1.85 (1.04) -2.65^ (0.82) -0.84* (0.89) -1.24^ (0.73) -0.73 (0.90) -0.82 (0.70) 
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Analysis of POMS factor scores indicated that after methylphenidate, 
participants experienced improved mood (all doses) and less anger (20 mg) 
compared to placebo between 1 and 3 h after drug intake. Factor scores 
indicated less fatigue at t60, t120 and t240 after 20 and 40 mg of 
methylphenidate, more vigour from 1 to 4 h after methylphenidate intake (all 
doses) and less tension after 40 mg of methylphenidate at t30 and t300. 
 
Table 2 
Mean differences (SEM) on reaction times relative to morning baseline for Stoplight and Lines 
task 
    Stoplight   Lines 1   Lines 2   Lines 3   
  Mean (SEM) Mean (SEM) Mean (SEM) Mean  (SEM) 
T30 PLA 11.4 (4.4) 5.4 (4.4) 1.5 (3.5) -0.1 (4.3) 
 M10 7.0 (6.3) 4.0 (3.3) 0.4 (4.6) -5.5 (2.6) 
 M20 7.3 (4.9) 6.2 (4.0) -1.0 (3.1) 1.2 (4.1) 
 M40 -3.1* (3.8) -3.6 (5.6) -10.3 (6.3) -12.6* (5.4) 
T60 PLA 20.7 (5.4) 5.9 (4.6) 1.4 (3.8) 2.4 (4.2) 
 M10 9.4 (7.1) 5.7 (3.7) 6.6 (6.0) 0.7 (5.4) 
 M20 8.5 (6.0) 1.7 (3.7) -3.5 (4.8) -6.3 (4.4) 
 M40 -8.7** (5.4) -9.4* (5.9) -16.5* (6.9) -14.8* (6.5) 
T120 PLA 11.4 (4.5) 6.0 (4.6) 1.3 (3.0) -3.7 (4.5) 
 M10 -3.1 (6.4) -2.0 (2.7) -7.2* (3.5) -11.7** (2.7) 
 M20 2.5 (4.4) -4.4 (3.1) -14.5* (3.4) -11.9 (3.9) 
 M40 -11.6** (6.8) -9.5* (5.5) -15.0* (6.8) -20.2** (6.0) 
T180 PLA 12.6 (5.7) 0.6 (4.6) -4.7 (3.9) -6.3 (5.2) 
 M10 -0.4 (9.3) 1.2 (2.9) -5.1 (4.2) -8.7 (3.0) 
 M20 1.5 (5.9) -1.5 (2.7) -8.0 (3.2) -10.2 (5.2) 
 M40 -11.9* (6.1) -11.2^ (5.8) -20.5* (6.7) -22.0** (6.2) 
T240 PLA 20.7 (4.3) 3.5 (3.8) 5.4 (5.4) -4.3 (5.2) 
 M10 -2.3* (9.1) -3.0 (2.7) -6.7** (4.1) -11.6* (2.2) 
 M20 2.0* (3.9) -1.6 (4.9) -14.6** (3.8) -10.8 (5.1) 
 M40 -15.9*** (8.6) -10.2* (5.7) -18.9*** (5.7) -19.1** (5.8) 
T300 PLA 16.7 (7.8) 4.4 (4.5) -0.4 (5.6) -5.8 (5.4) 
 M10 12.4 (8.1) 2.2 (3.4) -5.6 (4.7) -8.5 (2.6) 
 M20 1.2^ (5.0) -2.9 (3.1) -11.3 (3.5) -14.2 (4.9) 
  M40 -5.3* (8.0) -7.0** (4.7) -14.6* (5.2) -16.8* (5.8) 
^p<.1; *p<0.05; **p<.01; ***p<.001 (significant effects and trends).   
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Table 3 
Means (SEM) of cortisol and prolactin levels in blood, absolute baseline values and mean 
differences (SEM) relative to morning baseline for heart rate, systolic and diastolic blood 
pressure (BP) at all time points 
    Cortisol Prolactin Heart Rate BP systolic BP diastolic 
  Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) 
BL PLA 491 (27) 11.4 (0.9) 66.3 (2.2) 133.9 (3.3) 73.8 (3.8) 
 M10 504 (28) 11.6 (1.2) 66.7 (2.7) 130.6 (2.5) 71.8 (2.8) 
 M20 576 (27) 13.6 (1.3) 67.7 (2.3) 133.1 (3.0) 70.7 (1.7) 
 M40 512 (43) 11.8 (1.2) 66.3 (2.5) 133.2 (2.7) 72.7 (1.7) 
T30 PLA     -2.1 (1.4) -0.2 (1.8) -0.5 (1.6) 
 M10     -3.1 (1.4) -1.0 (2.1) -0.8 (3.0) 
 M20     -2.5 (1.1) -1.8 (2.0) 0.8 (1.3) 
 M40     -2.9 (0.9) -1.8 (2.0) 1.1 (1.7) 
T60 PLA 325 (21) 9.0 (0.6) -6.8 (1.2) -6.8 (2.7) -2.7 (3.2) 
 M10 405* (35) 7.6** (1.0) -3.6 (2.0) -1.5 (1.6) 2.2 (3.9) 
 M20 454** (31) 7.0*** (0.6) -0.5** (1.4) 0.9** (2.3) 6.4** (1.5) 
 M40 510*** (32) 6.4*** (0.9) 2.9*** (2.1) 2.9*** (2.4) 5.7** (2.3) 
T120 PLA 300 (18) 8.5 (0.7) -9.6 (1.1) -5.5 (1.8) -0.6 (2.9) 
 M10 332 (30) 6.4*** (0.9) -5.8* (1.4) 2.3* (2.4) 2.2 (3.3) 
 M20 409** (31) 5.8*** (0.7) -2.4*** (1.4) 0.8* (2.6) 6.6* (1.7) 
 M40 481*** (35) 4.4*** (0.4) 0.9*** (2.2) 3.7*** (2.3) 5.6** (2.2) 
T180 PLA 313 (21) 7.9 (0.7) -9.8 (1.1) -4.6 (2.3) -1.7 (3.8) 
 M10 347 (25) 6.4*** (0.8) -5.5* (1.6) 2.0* (1.5) 0.4 (3.3) 
 M20 411** (28) 5.8*** (0.7) -2.6*** (1.6) 0.7* (2.1) 6.1** (1.9) 
 M40 411*** (30) 4.9*** (0.7) 1.3*** (1.8) -0.2 (2.5) 3.3* (1.6) 
T240 PLA 400 (31) 10.1 (1.1) 0.2 (1.6) -0.4 (2.5) -5.0 (3.0) 
 M10 419 (24) 9.1 (0.8) 1.3 (1.6) 5.0* (2.1) -0.1 (3.9) 
 M20 423 (28) 8.0** (0.8) 4.9** (2.0) 5.3* (2.0) 2.9* (1.5) 
 M40 457 (24) 6.8** (0.8) 7.9*** (1.8) 2.9 (1.9) 2.5** (1.6) 
T300 PLA 281 (16) 9.8 (0.8) 1.0 (1.6) -3.0 (2.4) -3.1 (3.0) 
 M10 312 (21) 9.3 (1.0) 0.5 (1.6) 3.7* (1.8) 0.3 (3.2) 
 M20 354** (18) 9.6 (1.0) 4.4* (1.3) 1.2 (2.3) 2.2 (1.3) 
  M40 369*** (19) 8.0 (0.7) 6.6** (1.6) -1.9 (2.2) 0.4 (1.9) 
^p<.1; *p<0.05; **p<.01; ***p<.001 (significant effects and trends).  
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Blood plasma values 
Mean levels of cortisol and prolactin in blood and results of significant 
difference testing are presented in Table 3. Methylphenidate significantly 
increased cortisol levels. At t60, cortisol levels were significantly higher after 
all doses of methylphenidate when compared to placebo (F3, 41.43 = 9.207, p <
0.001). At t120 (F3, 40.71 = 11.964, p < 0.001), t180 (F3, 41.86 = 8.238, p < 0.001) 
and t300 (F3, 39.02 = 8.663, p < 0.001) cortisol levels were significantly higher 
after M20 and M40 but not M10. At t240, there was no effect of drug on 
cortisol levels (F3, 39.24 = 0.647, p > 0.05).  
Prolactin levels were lower after all doses of methylphenidate in 
comparison to placebo from t60 to t180 (t60: F3, 36.32 = 13.247, p < 0.001; t120: 
F3, 38.18 = 32.293, p < 0.001, t180: F3, 39.97 = 29.558, p < 0.001) and after M20 and 
M40 at t240 (F3, 37.11 = 4.702, p < 0.01) At t300, the effect was no longer 
significant (F3, 37.52 = 0.945, p > 0.05). 
 Maximum methylphenidate concentration in blood differed 
significantly between treatment conditions (Cmax: M10 mean (SEM) = 4.9 (0.4); 
M20 mean (SEM) = 9.3 (0.7); M40 mean (SEM) = 17.2 (1.2), F2, 30 = 140.130, p <
0.001). Tmax was equal for all treatments (mean (SEM) = 2.9 (0.2), F2, 30 =
0.134, p > 0.05). 
 
Physiological measures 
Absolute baseline values of physiological measures and mean differences 
relative to morning baseline and results of significant difference testing are 
presented in Table 3. Methylphenidate (20 and 40 mg) significantly increased 
heart rate compared to placebo from 1 up to 5 h after drug administration 
(t60: F3, 43.88 = 10.194, p < 0.001; t120: F3, 44.04 = 14.395, p < 0.001; t180: F3, 42.78
= 13.325, p < 0.001; t240: F3, 38.97 = 9.195, p < 0.001; t300: F3, 41.84 = 7.271, p <
0.001). At t120 and t180, all doses significantly increased heart rate. Systolic 
blood pressure was significantly higher after M20 and M40 compared to 
placebo at t60 (F3, 40.13 = 5.433, p < 0.01) and after all doses at t120 (F3, 40.46 =
5.178, p < 0.01). At t180, t240 and t300, there was no main effect of drug on 
systolic blood pressure, but systolic blood pressure was higher compared to 
placebo after M10 (t180: p < 0.05; t240: p < 0.05; t300: p < 0.05) and M20 
(t180: p < 0.05; t240: p < 0.05) as was revealed by the planned contrasts. 
Diastolic blood pressure significantly increased 1 h after intake of 20 and 
40 mg of methylphenidate compared to placebo (t60: F3, 42.39 = 5.279, p <
0.01). This effect remained significant until 4 h after drug intake (t120: F3,
43.39 = 4.808, p < 0.01; t180: F3, 43.73 = 4.468, p < 0.01; t240: F3, 42.04 = 3.796, p <
0.05). 
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Discussion 
 
In the current study, the effects of different doses of methylphenidate on the 
late CNV wave were assessed in order to explore the utility of the CNV 
amplitude as a marker of dopamine activity. In line with the expectations, 
methylphenidate dose dependently increased CNV amplitude and decreased 
reaction time in both response preparation paradigms. Furthermore, 
subjective measures indicated that participants experienced improved mood, 
felt more alert and vigorous and less angry and tired after methylphenidate. 
Physiological measures including blood pressure and heart rate increased, 
confirming previous findings (Volkow, et al., 1996). These results indicate that 
dopamine activity increases response readiness as measured by the CNV 
paradigm. 
CNV has been previously reported to be sensitive to dopaminergic 
modulation (Amabile, et al., 1986; Kopell, et al., 1974; Oishi, et al., 1995; 
Tecce, 1991; Tecce & Cole, 1974; Tecce, et al., 1975). However, little was 
known about dose-related effects. In the present study, the effects on 
reaction time and CNV amplitude could be detected after a dose of 
methylphenidate as low as 10 mg, demonstrating the sensitivity of the CNV 
paradigm to changes in dopamine availability. In support of a dose–response 
relationship, the effects were most prominently and consistently observed 
after the highest dose of methylphenidate. Importantly, the current effects 
are measured on the late CNV wave. Previous studies, using shorter intervals 
between S1 and S2 (Luthringer, et al., 1999), may possibly have measured a 
composite of the early and late wave. An internal validation of the paradigms 
used in this study is provided by correlation analysis, which revealed 
consistent correlations between the difference scores for response time and 
CNV amplitude at Cz in the 40 mg of methylphenidate condition in all 
paradigms at all time points, ranging between 0.46 and 0.96 with average of 
0.78. This correlation also emerged for the lower doses but a little less 
consistent, which is again indicative of a dose–response relationship. The 
lower doses may generate more variance which may less often lead to 
significant correlations. 
Because methylphenidate inhibits re-uptake of dopamine, but also of 
noradrenaline (Arnsten & Dudley, 2005), it cannot be stated with absolute 
certainty whether the current findings should be ascribed solely to increased 
dopamine levels. Dopamine levels in the brain cannot be measured directly, 
but changes in prolactin level in blood are a good surrogate marker since the 
prolactin level is known to rise as the dopamine level decreases and vice versa 
(Ben-Jonathan, 1985). The decrease in prolactin levels observed here suggests 
that methylphenidate did successfully increase central dopamine levels. 
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Methylphenidate not only enhanced CNV amplitude but also increased 
response speed. As Fan et al., (2007) suggested, it seems that anticipation of 
the response, as reflected by CNV amplitude, improves response preparation 
and execution. Between S1 and S2, two waves can be observed, the early and 
the late CNV wave (Klorman & Bentsen, 1975). In this study, the late CNV 
wave was investigated. The late wave is thought to be a mixture of a 
readiness potential and stimulus preceding negativity (Brunia & van Boxtel, 
2001). Improved performance may be the result of better motor preparation, 
increased anticipatory attention or a combination of both. 
Based on the literature, it was expected that methylphenidate levels 
in the blood would peak 2 h after drug intake (Volkow, Fowler, Wang, Ding, & 
Gatley, 2002). In the current study, Tmax was observed somewhat later, almost 
3 h after intake. Although methylphenidate reaches a plateau between 2 and 
3 h, a delay in reaching Tmax may possibly be related to the composition of the 
breakfast (Patrick, et al., 2007). Behavioural effects already appeared at 
30 min after drug intake and were still present after 5 h. The effects on the 
EEG measures were more dispersed in time. Moreover, the effects clustered 
mainly around two time points, at approximately 1 and 4 h after drug intake. 
In other words, the effects are observed relatively shortly after drug intake 
and 1 h after Tmax. 
The current method does not allow source localization. However, 
previous research suggests that the CNV is generated in the basal ganglia 
(Fan, et al., 2007; Y. Nagai, et al., 2004). Taking into account the 
neuroanatomic projections of the dopaminergic pathways, the effect observed 
1 h after drug intake may be mediated by a fast response of the nigrostriatal 
pathway, being responsible for an early attention enhancing effect. This idea 
is supported by our observation that participants felt more alert this time 
point. The late effect, on the other hand, is more likely to be mediated by 
the mesocortical pathway, which may be responsible for the top-down control 
of anticipatory processes affecting response readiness (Brunia & van Boxtel, 
2001; Fan, et al., 2007). Alternatively, the schedule at testing days may have 
played a role in the timing of the effects. Whereas participants were probably 
rather energetic at t60 and t240, before which they just had a lunch break, 
they may have been less focused at t120 and t180. However, this only partly 
fits with the subjective effects reported by the participants. 
The pattern of effects was quite similar for behavioural and EEG data. 
Both measures were modulated the most in the stoplight and lines 2 version of 
the task. There were only subtle differences between these tasks with respect 
to the methylphenidate effect on both response time and amplitude. 
However, since the lines 2 version is a little more attractive to participants, 
this task may be preferred for future use. 
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Generalization of the results may be limited by the fact that only 
male participants were included. Furthermore, taking into account the 
number of tasks administered, the testing days may have been rather 
demanding for the participants. This may have caused detrimental effects on 
performance or decrease of motivation. A limitation of the Bond and Lader 
visual analogue scale is that the calmness scale is based on very few (two) 
items. Therefore, interpretation of this scale warrants caution. 
In conclusion, the current findings indicate that methylphenidate dose 
dependently increases response readiness. In sum, the CNV appears to be a 
good candidate biomarker for assessing changes in the dopaminergic function 
by treatments that either directly or indirectly target the dopamine system. 
Future research should aim to dissect the pharmacological selectivity of the 
CNV. 
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Abstract 
 
The Contingent Negative Variation (CNV) is a slow negative shift in the EEG 
and is thought to be correlate of attention and psychomotor function. 
Previous CNV research suggests that there is potential for the CNV to be used 
as a biomarker for dopamine activity. However, selectivity of the CNV for 
dopamine activity remains to be determined. To investigate the specific 
dopaminergic influence on the CNV amplitude the effects of 40 mg 
methylphenidate (MPH) on CNV were compared to those of 100 mg of the 
dopamine precursor levodopa (LEV) in a placebo-controlled crossover study 
testing 30 healthy volunteers. In addition, participants completed two visual 
analogue scales and heart rate and blood pressure were monitored. MPH and 
LEV had opposite effects on CNV amplitude and reaction time. MPH increased 
CNV amplitude and decreased reaction time in comparison with LEV. It is 
suggested that combined dopamine- and noradrenaline reuptake inhibition 
may be essential to enhance response readiness and that MPH effects may be 
more pronounced if conditions are more demanding. 
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Introduction 
 
As an electrophysiological correlate of attention and psychomotor function, 
the Contingent Negative Variation (CNV) is studied extensively in clinical as 
well as psychopharmacological experiments. The CNV is a slow negative shift 
in the electroencephalogram (EEG) that appears between a warning and 
imperative stimulus in a reaction time task. CNV amplitude is reduced in 
Parkinson Disease patients (Ikeda, et al., 1997; Pulvermuller, et al., 1996; 
Verleger, et al., 1999; Wascher, et al., 1997) and may also be affected in 
patients with schizophrenia, ADHD, depression and Alzheimer’s Disease (Golob 
& Starr, 2000; Kratz, et al., 2009; Timsit-Berthier, 1991; van Deursen, et al., 
2009; Verleger, et al., 1999). Therapeutic response to drug treatment in these 
patient groups may be reflected by normalization of CNV amplitude. 
The underlying mechanism for the observed alterations in the CNV in 
neuropsychiatric patients is likely to be controlled by influences from 
GABAergic, cholinergic, serotonergic, dopaminergic, and noradrenergic 
neurotransmitter systems (Timsit-Berthier, 1991). The exact nature of some 
of these influences remains to be fully understood but previous research has 
shown that benzodiazepines, including diazepam, nitrazepam and clonazepam 
reduce CNV amplitude (Ashton, Millman, Telford, & Thompson, 1974; Ashton, 
et al., 1976; Papart, et al., 1997; Rockstroh, et al., 1991). Increases in 
acetylcholine levels induced by nicotine intake show inconsistent, possibly 
biphasic effects on the CNV (Ashton, et al., 1980; Ashton, et al., 1974; Knott 
& Venables, 1980; Rockstroh, et al., 1991). Conflicting results are reported 
for serotonin (Hansenne, et al., 2000; Zank, Strehl, Larbig, & Kotchoubey, 
2008). It has been proposed that serotonin may affect CNV through its effects 
on the catecholaminergic system (Mulder, et al., 2002). 
The catecholamines noradrenaline and dopamine are thought to play 
an important role in the generation of the CNV (Timsit-Berthier, et al., 1986) 
and underlie alterations in the CNV amplitude in migraine patients (Mulder, et 
al., 2002). Furthermore, methylphenidate, a catecholamine reuptake 
inhibitor, showed dose-related effects on response readiness, reflected by 
increased CNV amplitude and faster responses to the imperative stimulus 
(Linssen, et al., 2011). Noradrenaline involvement in CNV is also suggested by 
the effect of clonidine, a noradrenergic drug that acts through the alpha-
adrenergic receptors and has a biphasic effect on CNV amplitude, showing an 
initial increase and later decrease of CNV amplitude (Ashton & Rawlins, 1978). 
However, propranolol, a noradrenergic drug that acts through the beta-
adrenergic receptors did not affect CNV amplitude (Ashton, et al., 1976).  
Evidence of dopaminergic effects on CNV includes the observation 
that reduced CNV amplitude can be restored by levodopa treatment in 
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Parkinson’s patients (Amabile, et al., 1986; Oishi, et al., 1995). In healthy 
individuals, manipulation of dopamine levels may also induce changes in CNV 
amplitude (Tecce, 1991). CNV amplitude has been shown to reduce with 
dopamine antagonists, such as chlorpromazine (Tecce 1975). In sum, previous 
research on pharmacological influences on the CNV shows that several 
neurotransmitters can mediate changes in CNV amplitude, but a major role is 
played by the catecholamines.  
Previous CNV research suggests that there is potential for the CNV to 
be used as a biomarker (Linssen, et al., 2011; Tecce & Cole, 1974). Besides 
normalization of CNV amplitude in neuropsychiatric patients in response to 
treatment, CNV may also predict therapeutic response to pharmacological 
treatment of migraine (Schoenen, Maertens de Noordhout, Timsit-Berthier, & 
Timsit, 1986). Specifically, CNV is proposed as a marker for dopaminergic 
neurotransmission (Luthringer, et al., 1999). Support for the CNV as a suitable 
biomarker is provided by a recent study demonstrating the sensitivity of the 
CNV amplitude; it was affected even by a low drug dose and its response was 
dose dependent (Linssen, et al., 2011). These results were obtained with 
methylphenidate, which inhibits the reuptake of both dopamine and 
noradrenaline transporters. Therefore, it is not clear to what extent 
dopamine and noradrenaline individually contribute to methylphenidate’s 
effect on response readiness. It is suggested that methylphenidate’s potency 
may be higher for the noradrenaline- than the dopamine transporter 
(Kuczenski & Segal, 1997), but as dopamine is also transported by the 
noradrenaline transporter, it is not clear if noradrenaline or dopamine is more 
affected by methylphenidate (Hannestad, et al., 2010; Pacholczyk, et al., 
1991). Hence, this study does not give conclusive support for the CNV as a 
biomarker that is selective for dopamine activity. 
Considering the number of neuropsychiatric diseases that involve 
dopamine abnormalities including Parkinson’s Disease, Schizophrenia and 
ADHD and the amount of literature that supports a role for dopamine in 
modulation of the CNV amplitude, the validation of CNV as a marker for 
dopamine activity is both valuable and promising. Therefore, the current 
study investigates the specific dopaminergic influence on the CNV amplitude 
by comparing the effects of methylphenidate on CNV to those of the DA 
precursor levodopa. This enables us to compare the effects of a selectively 
dopaminergically acting drug to that of a mixed dopamine-noradrenaline 
acting drug.  
On separate occasions, participants were treated with 40 mg of 
methylphenidate, 125 mg of levodopa/carbidopa and placebo. The latter drug 
consists of 100 mg of levodopa and 25 mg of carbidopa. Levodopa is 
transformed into dopamine both in the brain as well as in the body. Carbidopa 
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does not cross the blood brain barrier and peripherally inhibits the enzyme 
dopa decarboxylase which converts levodopa to dopamine (Julien, 2005). 
Consequently, more levodopa can be transported to the brain and less side 
effects will develop. 
In addition to CNV amplitude, task performance and subjective drug 
effects were also measured. Based on research cited above, noradrenergic 
and dopaminergic influences might both be expected to affect CNV amplitude 
and this may be reflected by differential effects of methylphenidate versus 
levodopa. However, as the evidence for dopamine involvement in the CNV is 
more substantial, it was hypothesised that CNV amplitude would be similarly 
positively affected by levodopa and methylphenidate.  
 
Method 
 
Participants  
Twenty healthy male volunteers and 10 healthy female volunteers (mean age 
= 20.7, SD = 2.3, range=18-28) were selected and paid to participate. 
Participants were recruited by means of local advertisements. Prescreening 
occurred using a medical history questionnaire and was followed by medical 
examination.  
The main inclusion criteria were: between 18 and 45 years of age, 
body mass index between 18 and 30 kg/m2 and right-handedness. The main 
exclusion criteria were history or presence of mental or physical disorders, 
consumption of more than 21 alcohol units per week or more than five 
caffeine-containing drinks per day, pregnancy or lactation, use of medication 
other than oral contraceptives, use of recreational drugs from 2 weeks before 
until the end of the experiment. All subjects gave written informed consent. 
The study was carried out in accordance with the Declaration of Helsinki and 
approved by the medical ethical committee of Maastricht University.  
 
Design 
The study was conducted according to a double-blind, placebo-controlled, 
three-way crossover design. Between the testing days, a period of at least 48 
h elapsed, but generally, testing days were scheduled approximately 1 week 
apart. Each participant received one of three single treatments including 
placebo (PLA), 40 mg of methylphenidate (MPH) and 125 mg of 
levodopa/carbidopa (LEV) on each testing day. Tmax is approximately 2 hours 
for MPH and 1 hour for LEV(Chana, Fierro, Reyes-Parada, & Saez-Briones, 
2003; Leonard, et al., 2004). LEV was given in combination with 10 mg of 
domperidone (a peripherally acting dopamine antagonist) to prevent nausea. 
Six different treatment sequences were used, with each sequence occurring 
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4, 5 or 6 times. MPH was administered upon arrival at 8.30 or 9.00 (T0). Due 
to the different half life, LEV was administered an hour later (T60). 
 
Dependent measures 
EEG measurement  
During two response preparation tasks, EEG was measured using 11 electrodes 
placed on the scalp, according to the 10–20 system at the Fz, F3, F4, Cz, C3, 
C4, C3’, C4’, Pz, P3 and P4 electrode positions. The ground electrode was 
placed on the AFz location, on the forehead. Two electrodes placed on the 
mastoids served as reference channels. An electro-oculogram (EOG) was 
measured bipolarly vertically above and below the right eye and horizontally 
next to the right and the left eye. Data were sampled at 250 Hz and filtered 
online between 0.05 and 100 Hz. Offline, data were first screened for 
artefacts and a low pass filter of 10 Hz was applied on all data. Next, epochs 
were extracted from the continuous EEG. Each epoch lasted 5100 ms, starting 
100 ms before the warning stimulus (S1) and ending 1000 ms after the 
imperative stimulus (S2) of the reaction time tasks. A baseline correction was 
applied to the whole epoch, using the 100 ms interval preceding S1 as 
reference. Averaging the sequential epochs yielded a S1 stimulus locked 
event-related potential (ERP). CNV amplitude was calculated by averaging the 
amplitude over the last 100 ms before S2. Since the CNV amplitude was 
expected to be maximal at the central electrodes (Brunia, 1988; Klorman & 
Bentsen, 1975; van Boxtel & Brunia, 1994), C3, C3’, Cz, C4, C4, P3, Pz and P4 
were of main interest and are reported in the Results section. In the results 
section, the lateral electrodes will be referred to as Csame, Copposite, C’same, 
C’opposite, Psame and Popposite, depending on their position relative to the response 
finger (e.g. Csame includes results of C3 for right finger responses and C4 for 
left finger responses).  
 
Response preparation tasks 
CNV traffic light task 
In the CNV traffic light task, participants watched the computer screen and 
were presented with a filled red circle (S1) on a black background. After 4 s, 
the red circle turned green (S2). Subjects were instructed to respond to the 
green circle by pressing a button on a table mounted response box as fast as 
they could. The test consisted of 32 trials. Reaction time to the onset of S2 
was measured in each trial and averaged over the test. 
CNV Lines task 
In the CNV lines task, S1 was the appearance of two red line drawings at the 
bottom left- and right-hand corner. The lines were oriented at a 90° angle to 
each other and after appearing both moved towards the centre of the screen. 
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After 4 s, the lines crossed and turned green (S2). At this moment, 
participants pressed a response button as fast as possible. As movement of 
the lines allows better estimation of the occurrence of the imperative 
stimulus, participants’ responses are faster compared to the traffic light task. 
To introduce different levels of difficulty, in half of the trials, a horizontal 
yellow bar partially blocked the view of the lines as they moved towards the 
centre of the screen, but the lines were always visible at the moment of 
crossing. Participants were cued to either respond with the left or right index 
finger by the presentation of an arrow pointing in either direction throughout 
the trial in order to balance lateralization effects. Participants responded 
with the left and right index finger equally often; numbers were balanced 
across bar and no bar trials and the order was randomized. The test consisted 
of 100 trials. Reaction time was measured and averaged per trial type (bar vs 
no bar).  
 
Subjective measures 
Participants completed two rating scales of subjective effects, the Profile of 
Mood States (POMS; (McNair, et al., 1992)) and the Bond and Lader (B&L) 
visual analogue scales (Bond & Lader, 1974). These rating scales consisted of 
16 (B&L) or 32 (POMS) bipolar items. Each item consisted of two words 
describing mood states. Participants had to score their preference for either 
of the items in accordance with their mood by marking the line closer to one 
of the two words. Dependent measures were factor scores on the dimensions 
Alertness (B&L), Depression, Anger, Fatigue, Vigour and Tension (POMS). Both 
rating scales were administered at four time points (T0, T50, T130 and T180) 
on each testing day. 
 
Physiological measures 
Physiological measures included systolic and diastolic blood pressure and 
heart rate and were taken at four time points (T0, T50, T130 and T180) on 
each testing day. 
 
Procedure 
The current study was integrated in a larger study on the effects of 
methylphenidate and levodopa on cognition and psychomotor function. A 
training session in which the tasks were practiced took place within 2 weeks 
before the first testing day. Participants abstained from alcohol during the 
last 24 h prior to each testing day. On testing days, participants were either 
collected at their home or came by public transport. They arrived at the lab 
in fasted condition at either 8.30 am or 9:00 am. Due to the different half 
lives of the medication, drug administration occurred at different time points, 
128 
Chapter 7  
MPH at T=0 and LEV at T=60. To ensure double blinding, participants received 
identically appearing capsules at all time points on each testing day. 
Participants were given a standardized meal for breakfast. Then, the 
electrode cap was placed and participants could relax until actual testing 
started at T=120. First, a baseline EEG measurement was taken, followed by 
cognitive testing in the following order: Visual verbal learning test, Sternberg 
memory scanning task, delayed recall and recognition test of the visual verbal 
learning test, paired associates learning and spatial working memory task. In 
addition, two blood samples were taken at T=120 and T=180. Subjective and 
physiological measures were taken at four time points (T0, T50, T130 and 
T180). At the end of the testing day, participants were returned to their home 
by car.  
 
Data analysis 
Data were analyzed using a repeated measures analysis of variance with the 
within-subjects factor treatment, which had three levels: PLA, MPH and LEV. 
Since the effects of MPH and LEV were anticipated to go into the same 
direction, main effects of the drugs were not evaluated. Instead, a priori 
planned comparisons between each dose relative to placebo were tested for 
significance at p<0.05, using LSD correction.  
 
Results 
 
CNV amplitude 
Averaged CNV waves recorded during performance of response preparation 
tasks are shown in Figure 1. Mean values of the CNV amplitude and p-values 
for the planned comparisons are presented in Table 1. Neither MPH nor LEV 
affected the CNV amplitude during performance of the traffic light task 
(Table 1). During performance of the CNV Lines task, CNV amplitude increased 
significantly after MPH at the lateral P-electrode opposite (Popp) to the 
response finger (P3 in case of right finger response and P4 in case of left 
finger response) on trials with a yellow bar partially blocking the view on the 
lines. In trials where there was no bar, MPH significantly increased CNV 
amplitude at Cz and Pz electrodes. Pairwise comparisons for LEV vs. PLA were 
not significant, but CNV amplitude was significantly smaller after LEV 
compared to MPH for bar-trials at Cz, Copposite, C’same, C’opposite, Psame, Pz and 
Popposite electrodes and for trials without a bar at Cz, Copposite, C’same, C’opposite 
and Popposite electrodes.  
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Figure 1. Grand average ERPs showing a CNV wave during the CNV traffic light task (a) and CNV 
Lines (No bar) task (b). The ERPs depicted were recorded at Cz. 
 
Reaction time data 
Mean reaction times for CNV traffic light and Lines tasks are presented in 
Table 2. Response time was faster after MPH compared to PLA on the trials 
with a bar in the CNV Lines tasks. Furthermore, contrasts show (Table 2) that 
for the CNV traffic light task and both CNV Lines tasks, response times were 
significantly faster after MPH compared to LEV 
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Table 1 
Mean values (SEM) of CNV amplitudes after PLA, MPH and LEV and p-values of contrasts PLA vs. 
MPH, PLA vs. LEV and MPH vs. LEV for the three CNV tasks (TL=CNV Traffic Light). 
  Mean amplitude (SEM) per treatment    Contrasts (p)   
 PLA  MPH  LEV  PLA vs. PLA vs.  MPH vs. 
TL        MPH  LEV  LEV 
Copposite -7.50 (0.85) -8.12 (0.90) -7.22 (0.94) 0.526 0.784 0.267 
C'opposite -9.09 (0.99) -10.18 (1.21) -8.74 (1.30) 0.392 0.774 0.193 
Cz -9.85 (1.05) -11.07 (1.30) -10.33 (1.17) 0.368 0.678 0.493 
C'same -8.50 (0.99) -8.85 (1.23) -9.12 (1.26) 0.770 0.512 0.815 
Csame -6.40 (0.71) -7.52 (1.11) -6.86 (0.79) 0.261 0.516 0.484 
Popposite -5.64 (0.97) -6.65 (1.07) -6.24 (1.28) 0.354 0.645 0.716 
Pz -7.05 (1.05) -7.79 (1.11) -7.57 (1.10) 0.572 0.666 0.820 
Psame -5.58 (0.91) -6.66 (0.97) -5.60 (0.89) 0.292 0.985 0.157 
Lines bar          
Copposite -8.09 (0.88) -8.87 (0.82) -7.59 (0.65) 0.220 0.466 0.033* 
C'opposite -9.55 (1.00) -10.66 (0.99) -8.94 (0.79) 0.163 0.568 0.023* 
Cz -7.41 (0.91) -8.03 (0.68) -6.31 (0.66) 0.489 0.243 0.014* 
C'same -8.89 (0.94) -9.60 (0.91) -7.98 (0.82) 0.430 0.284 0.012* 
Csame -6.97 (0.78) -7.35 (0.78) -6.35 (0.66) 0.587 0.368 0.101 
Popposite -6.75 (1.06) -8.21 (0.94) -5.98 (0.64) 0.026* 0.309 0.001* 
Pz -8.26 (1.03) -8.96 (0.94) -7.16 (0.86) 0.381 0.232 0.016* 
Psame -6.41 (0.94) -7.07 (0.90) -5.53 (0.63) 0.256 0.199 0.016* 
Lines no bar          
Copposite -8.38 (1.01) -9.69 (0.90) -8.06 (1.02) 0.105 0.697 0.010* 
C'opposite -10.19 (1.10) -11.12 (1.03) -8.94 (1.13) 0.321 0.163 0.012* 
Cz -10.38 (1.16) -12.40 (1.07) -9.98 (1.27) 0.027 0.703 0.009* 
C'same -8.57 (1.02) -10.19 (0.90) -8.37 (1.13) 0.071 0.812 0.045* 
Csame -6.94 (0.90) -7.48 (0.75) -6.40 (1.12) 0.487 0.518 0.178 
Popposite -5.85 (1.04) -7.04 (0.92) -5.51 (1.17) 0.070 0.680 0.049* 
Pz -5.25 (1.17) -6.92 (0.97) -5.14 (1.22) 0.040 0.913 0.060 
Psame -5.22 (0.92) -6.12 (0.84) -4.55 (1.11) 0.199 0.447 0.059 
*p<.05 
 
Subjective measures  
Analysis of POMS factor scores indicated that after methylphenidate, 
participants experienced less fatigue at 1 and 3 hours after drug intake 
(p=.014 and p=.019 respectively). Methylphenidate also caused an increase in 
reported tension at 1 hour and 2 hours after administration (p=.040 and 
p=.015 respectively). Factor scores indicated less vigour at 1 and 3 hours after 
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methylphenidate intake (p=.003 and p=.005 respectively). The Bond & Lader 
factor scores indicated that participants felt more alert 3 hours after MPH 
intake (p=.037). 
 
Table 2  
Mean values (SEM) of response times after PLA, MPH and LEV and p-values of contrasts PLA vs. 
MPH, PLA vs. LEV and MPH vs. LEV 
  Mean response times (SEM)    Contrasts (p)   
 PLA  MPH  LEV  PLA vs. PLA vs. MPH vs. 
        MPH  LEV  LEV 
TL 223.2 (6.4) 215.9 (5.4) 226.4 (5.4) 0.095 0.525 0.008* 
Lines bar 61.9 (3.5) 53.3 (3.8) 63.4 (3.9) 0.010* 0.603 0.006* 
Lines no bar 47.5 (3.4) 44.4 (3.3) 49.5 (3.4) 0.205 0.346 0.043* 
*p<.05. 
 
Physiological measures 
MPH significantly increased heart rate compared to PLA at all time points 
(T50: p<.001; T130: p<.001; T180: p<.001). Furthermore, compared to PLA, 
MPH also significantly increased systolic at all time points (T50: p<.001; T130: 
p<.001; T180: p<.001) and diastolic blood pressure (T50: p<.001; T130: 
p=.002; T180: p=.002). LEV did not affect heart rate and systolic blood 
pressure at T130, but significantly decreased diastolic blood pressure relative 
to PLA (p=.047). In both PLA and LEV, heart rate decreased from T0 to T180, 
but this decrease was significantly smaller after LEV (p=.035). At T180, there 
were no effects of LEV on blood pressure. 
 
Discussion 
 
In the current study, the effects of MPH-induced dopamine and noradrenaline 
reuptake inhibition on the CNV were compared to those of a selectively 
dopaminergic drug, LEV. Contrary to our expectations, the effects of MPH on 
CNV amplitude and reaction time were opposite to those of LEV. MPH 
increased CNV amplitude in the Lines task relative to LEV and, to a lesser 
extent also relative to PLA. Similarly, MPH speeded responses compared to 
LEV in all tasks, and in the CNV Lines-bar task participants were also faster 
after MPH compared to PLA. Subjective measures indicated that participants 
experienced less fatigue, more tension, and less vigour after MPH and felt 
more alert after MPH. These results do not support the hypothesis that the 
effect of MPH on CNV amplitude and response time is  specifically related to 
its dopamine enhancing effect.  
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 Previous research has shown that catecholamines modulate CNV 
amplitude (Timsit-Berthier, et al., 1986). Most studies have focused on 
dopaminergic influences on the CNV and it has been suggested that the CNV 
may be a good candidate biomarker of dopamine activity (Linssen, et al., 
2011; Luthringer, et al., 1999; Tecce, 1991), also since a recent study showed 
dose-dependent effects of MPH on CNV amplitude and response time . The 
current study aimed to determine the extent to which dopamine, rather than 
noradrenaline, enhancement accounts for the MPH effects on the CNV by 
comparing MPH to a selective dopaminergic drug. The present findings do not 
support the hypothesis that MPH induced CNV enhancement is primarily 
mediated by dopamine. However, it is important to consider the differences 
between the mechanisms of the drugs used. MPH tonically increases 
extracellular dopamine in the striatum and prefrontal cortex (Leonard, et al., 
2004), while LEV increases presynaptic dopamine availability, affecting both 
tonic as well as phasic dopaminergic neurotransmission (Breitenstein, 
Korsukewitz, et al., 2006).  
Intuitively, one might expect that the impact of dopamine 
enhancement by LEV may thus be relatively larger than that of MPH. 
Dopaminergic effects on performance are often described by an inverted U 
curve in which intermediate dopamine levels are associated with an optimal 
state and a higher dose may cause adverse effects, i.e. in this study, 
decreased readiness to respond, reflected by smaller CNV amplitude and 
slower responses (Levy, 2009; Mehta, et al., 2004). However, to achieve such 
high levels of dopamine activity, a relatively high dose of a dopaminergic 
agent is needed. Increased tonic dopamine activity reduces the phasic release 
of dopamine by binding to postsynaptic- and autoreceptors (Breitenstein, 
Floel, et al., 2006; Seeman & Madras, 2002). Low doses of a dopamine agonist 
or LEV thus result in less dopamine activity at the post-synapse (Seeman & 
Madras, 2002). Higher doses overcome this effect and cause widespread 
stimulation (Seeman & Madras, 2002). Although LEV has the potential to 
enhance tonic as well as phasic dopamine activity, it is possible that the 
combined actions resulted in a state with no net change in dopamine levels, 
as the LEV dose used in the current study was relatively low (100 mg). This 
dose was used to prevent sedation. Sedation is seen with doses of 200 mg 
(Andreu, et al., 1999; Micallef-Roll, Rihet, Hasbroucq, Possamai, & Blin, 2001) 
while behavioural effects have been observed with 100 mg (Breitenstein, 
Floel, et al., 2006; Knecht, et al., 2004). 
Hence, it is possible that the LEV dose was too low to enhance CNV 
amplitude or speed responses. However, that does not explain why the LEV 
effects go in the opposite direction compared to MPH. Although the LEV 
effects did not significantly differ from PLA, the averages show a consistent 
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pattern in which MPH leads to the highest CNV amplitude and the fastest 
responses; LEV induces the lowest CNV amplitude and slowest responses; and 
intermediate values are observed with PLA.  
It is more likely that the MPH effect on CNV amplitude and response 
time is not primarily dopamine mediated. This does not necessarily mean that 
the MPH effect is purely noradrenergic. The combined dopamine and 
noradrenaline reuptake inhibition may be essential to enhance response 
readiness. The MPH effect might be explained by the additive effects of 
enhanced motor function mediated by dopamine enhancement (Nieoullon, 
2002) and noradrenergically mediated effects on attention, alertness 
(Breitenstein, Floel, et al., 2006; Coull, Frith, Dolan, Frackowiak, & Grasby, 
1997). Indeed, subjects reported to experience less fatigue after MPH and felt 
more alert after MPH. Although these subjective effects cannot completely 
account for the current results, they may affect participants’ motivation to 
perform the task (Gevins, Smith, & McEvoy, 2002). In studies testing high 
performing healthy volunteers, subjective feelings and motivational effects 
may be a source of variability in an otherwise homogeneous group. 
Ideally this study would have disentangled dopaminergic and 
noradrenergic effects by including a purely noradrenergic substance. Based on 
previous studies, commonly used noradrenergic drugs were regarded 
unsuitable for this aim because of non-specificity, lack of safety or adverse 
side effects that would interfere with task performance. For example, as 
dopamine is also transported by the noradrenaline transporter, a 
noradrenaline reuptake inhibitor would not reveal purely noradrenergic 
effects (Hannestad, et al., 2010; Pacholczyk, et al., 1991).  
Regardless of the dopaminergic contribution to the MPH effect on 
CNV, LEV was expected to enhance CNV amplitude, based on previous findings 
in Parkinson’s Disease patients. These patients show reduced CNV amplitude, 
which can be restored by LEV treatment (Amabile, et al., 1986; Oishi, et al., 
1995). The absence of a CNV increasing effect in healthy volunteers suggests 
that pure dopamine enhancement only enhances CNV amplitude in individuals 
with suboptimal dopamine levels in the brain. Performance of CNV tasks by 
healthy volunteers may not benefit from additional dopaminergic activity 
alone because their dopamine levels are already close to optimal.  
In our previous study, MPH enhanced CNV amplitude and decreased 
reaction time compared to PLA (Linssen, et al., 2011). In the current study, 
only few significant differences were observed between MPH and PLA. There 
may be several reasons for the apparent dissimilarity between these results. 
First of all, the timing of CNV task performance relative to dosing was 
different from the previous study. In the previous study CNV tasks were 
administered at T30, T60, T120, T180, T240 and T300 while in the current 
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study CNV measurement occurred at T150. As an example, the previous study 
observed CNV enhancing effects in the CNV traffic light task of MPH at T60 
and T240 (i.e. not at T120 or T180). The current study only administered this 
task at T150, a time point at which no effect was observed in the previous 
study. The current result is thus in line with the previous study. The MPH 
effect on CNV is time dependent and does not occur at all time points after 
dosing.  
Secondly, the study procedure of the current study was much less 
demanding than that of the previous study. In the previous study, participants 
were subjected to seven test cycles spanning approximately 8 hours with few 
short breaks in between. It is possible that the stimulating effects of MPH 
were more pronounced in the previous study due to fatigue induced by 
continuous computer task performance, leading to a relative reduction in 
performance in the PLA condition. This reasoning is in line with a previous 
study that showed performance enhancing effects of MPH after sleep 
deprivation but not after normal sleep (Bishop, et al., 1997). 
In conclusion, the current findings indicate that MPH and LEV, in the 
doses given in this study, have opposite effects on CNV amplitude and 
reaction time. MPH increased CNV amplitude and decreased reaction time in 
comparison with LEV. It is suggested that combined dopamine- and 
noradrenaline reuptake inhibition may be essential to enhance response 
readiness and that MPH effects may be more pronounced if task conditions are 
more demanding.  
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 GENERAL DISCUSSION 
 
 
 The present dissertation aimed to investigate the role of dopamine in 
cognitive function (part 1) and study the CNV as a potential dopaminergic 
biomarker (part 2). In the first part, dopaminergic involvement in cognitive 
function in healthy volunteers was studied by means of a literature review 
and three experimental studies. The second part started with the evaluation 
of a new CNV paradigm under normal conditions which was subsequently 
studied under the influence of dopamine enhancing drug treatment. In this 
general discussion, the results are linked to provide a coherent view of the 
role of dopamine in cognition and to evaluate the CNV as a dopaminergic 
biomarker.  
 
The role of dopamine in cognition in the healthy population 
To gain more knowledge about the role of dopamine in cognitive function, this 
dissertation describes the effects of pharmacological manipulations that alter 
dopamine activity in the healthy brain. Modulation of dopamine activity may 
involve either an increase or a decrease in dopamine activity. Dopamine 
activity can be enhanced by drugs such as methylphenidate and levodopa. 
According to a current belief among the general population, methylphenidate 
may enhance cognitive performance in healthy individuals. In order to test 
this idea, a literature review was performed on the effects of 
methylphenidate on cognitive function in healthy volunteers. In two 
experimental studies the methylphenidate effect on several cognitive tasks 
was further tested and compared to the effect of levodopa. A third 
experiment tested the cognitive effects of reduced dopamine activity induced 
by tyrosine/phenylalanine depletion. 
 
Verbal learning and memory 
Results from the literature review in chapter 1 showed that methylphenidate 
improved verbal learning and memory in healthy volunteers in more than one 
third of all previous studies. Enhanced performance was mainly observed on 
word list learning tasks. Strikingly, low and intermediate doses of 
methylphenidate were more effective than higher doses. In a minority of 
cases high doses even led to decreased memory performance on short-term 
verbal memory tasks. 
 The experimental studies described in part 1, studied the effects of 
dopaminergic manipulations on word list learning. As previous studies that 
failed to detect performance modulating effects of methylphenidate used 
relatively short lists of 15 words, a ceiling effect may have occurred. 
Therefore, the studies in this dissertation presented participants with lists of 
30 words, decreasing the likelihood that participants reached ceiling 
performance under placebo conditions. This left room for methylphenidate to 
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improve memory performance, which was expected based on previous studies 
reviewed in chapter 1.  
The studies in chapter 2 and 3 demonstrated that this expectation was 
only confirmed under specific circumstances. Chapter 2 showed that when 
participants were subjected to demanding study procedures, methylphenidate 
enhanced memory consolidation within 30 minutes after word learning in a 
dose-related fashion. If participants, on the other hand, relaxed before task 
performance, performance was not affected by methylphenidate at the 30 
minute delay (chapter 3). However, the latter study showed that 
methylphenidate did improve memory consolidation over a 24 hour delay. 
Together, the results of the first two studies may thus suggest that memory 
enhancing effects of methylphenidate are potentially more pronounced when 
the circumstances are more challenging. While the first study was very 
demanding for participants because they continuously performed computer 
tasks over a period of 8 hours, the study procedures of the second study were 
much shorter, but required to remember words over a 24 hour delay (chapter 
3). It is possible that under these circumstances, healthy volunteers may 
benefit more from the stimulant effects of methylphenidate than under 
normal circumstances. 
The study in chapter 3 aimed to determine the dopaminergic 
contribution to the effects of methylphenidate, which inhibits the reuptake of 
both noradrenaline and dopamine. Since levodopa, a pure dopaminergic drug, 
failed to affect memory performance, this study did not appear to provide 
evidence in favor of the idea that the methylphenidate effect on cognitive 
function was primarily mediated by dopamine. Based on these behavioral 
results, one might be tempted to conclude that the memory enhancing effect 
of methylphenidate was mediated by noradrenaline or that the combination 
of noradrenaline and dopamine reuptake inhibition led to better memory. 
However, the ERP results suggested that levodopa slowed down memory 
processing and led to increased effort. As the levodopa dose was relatively 
low it is not unlikely that levodopa failed to enhance dopamine activity. In 
fact, levodopa may even have reduced phasic dopamine activity relative to 
the placebo condition (Breitenstein, Korsukewitz, et al., 2006; Paulus & 
Trenkwalder, 2006; Seeman & Madras, 2002), an idea supported by the ERP 
results. Hence, the results in this dissertation do not dismiss the idea of a 
dopaminergic contribution to methylphenidate’s effects on memory. In this 
context it is important to note that although levodopa and methylphenidate 
both affect dopamine activity, they differ in mechanisms by which they do so. 
This issue is discussed in more depth in the ‘Methodological considerations’.  
The effect of a reduction of dopamine activity on word learning and 
recall as achieved by depletion of the dopamine precursors tyrosine and 
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 phenylalanine was discussed in chapter 4. It was hypothesized that dopamine 
depletion would disturb verbal learning. However performance on the word 
learning test was not affected by this treatment. Results from the 
simultaneous EEG measurement, though, suggested that 
tyrosine/phenylalanine depletion did have adverse effects on memory 
processing. EEG may be more sensitive than behavioral measures, and hence, 
small effects may be detected in the EEG, without being expressed in 
behavior. 
While there is some support for the idea that dopamine may be 
involved in essential memory processing and contributes to optimal memory 
performance, the limited robustness of memory enhancing effects of 
methylphenidate, combined with a lack of behavioral effects of levodopa and 
dopamine depletion suggest that dopamine plays only a restricted role in 
verbal learning and memory. Furthermore, it is important to note that 
conclusions from the studies in this dissertation regarding the dopaminergic 
contribution to cognitive function are limited by the fact that 
methylphenidate is not a pure dopaminergic drug and that the levodopa 
manipulation likely did not lead to enhanced dopamine activity.  
 
Working memory 
Previous research has shown that dopamine is necessary for working memory 
and that both too little as well as too much dopamine can have deleterious 
effects on working memory performance (Cools & Robbins, 2004). The effects 
of several dopamine modulating manipulations were described in part 1 of this 
dissertation. From the literature review in chapter 1, it was concluded that of 
all cognitive domains, working memory was most affected by 
methylphenidate. Nearly 70% of published results revealed performance 
enhancing effects of methylphenidate on working memory tasks. Based on the 
positive association between dopamine and working memory described in the 
literature, methylphenidate effects on working memory were thought to be 
primarily mediated by dopamine. 
 Therefore, when comparing the effects of methylphenidate to those 
of the pure dopaminergic drug levodopa in the study described in chapter 3, 
we expected to observe working memory enhancing effects of both drugs. In 
contrast with this expectation, methylphenidate led to minor improvement of 
working memory and levodopa to a minor decrease in working memory 
performance. These results were unexpected in two respects. First, the drug 
effects were smaller than expected, as working memory performance only 
differed between the two drug conditions and not relative to placebo. 
Second, the drug effects went in opposite directions. As suggested above, 
levodopa may have failed to enhance dopamine activity, but this does not 
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explain how levodopa could lead to a reduction in performance. Neither can it 
be explained by a noradrenergic component in the methylphenidate effect. 
The minor decrease in performance once again supported the idea that 
levodopa decreased the impact of phasic dopamine activity relative to 
placebo. When we view these results in the light of previous literature on the 
positive association between dopamine and working memory it is most likely 
that the levodopa manipulation did not have the intended enhancing effect on 
dopamine activity.  
While working memory enhancement was expected after dopamine 
enhancing drugs, dopamine depletion was hypothesized to have a negative 
impact on working memory. This hypothesis was tested in chapter 4. Although 
tyrosine/phenylalanine depletion failed to alter working memory task 
performance, results from the simultaneous EEG measurement suggested that 
tyrosine/phenylalanine depletion had adverse effects on brain processing 
related to working memory, which remained sub threshold on the behavioral 
level.  
 Overall, the results from the research in this thesis suggest that 
methylphenidate may have a small but positive effect on working memory. 
We could not prove that the methylphenidate effect on working memory was 
dopamine dependent, but the suggestion that levodopa reduced phasic 
dopamine signals, would support a positive association between working 
memory performance and dopamine activity.  
 
Other cognitive processes 
Dopamine neurotransmitter activity has been associated with various 
cognitive functions, but most evidence is available for its involvement in 
motor control and motivated behavior (reward and punishment). In the 
literature review on methylphenidate effects (chapter 1) the full spectrum of 
cognitive functions was considered. The results showed that, after working 
memory, speed of processing was the cognitive domain that was most 
enhanced by methylphenidate. Low doses of methylphenidate were most 
successful, revealing a pattern consistent with an inverted U curve describing 
the relationship between dopamine activity and performance.  
Contrary to our expectations, the reviewed literature revealed only a 
minor influence of methylphenidate on attention and vigilance. Reasoning and 
problem solving were also hardly affected by methylphenidate, while visual 
learning and memory showed a complete lack of performance enhancing 
effects of methylphenidate. The experimental study described in chapter 2 
included two attention tasks that were both positively affected by 
methylphenidate. However, we found no effect on problem solving.  
141 
 In sum, the results from the review and the experimental studies 
demonstrate performance enhancing effects of methylphenidate of varying 
degrees in several cognitive subdomains. It is important to note that 
methylphenidate effects on speed of processing may obscure performance 
enhancing effects on cognitive tasks. In our studies, performance was not 
impaired by methylphenidate due to a speed-accuracy trade-off. However, in 
cognitive tasks requiring a motor response, improved performance may partly 
reflect increased speed of processing.  
 
CNV as a dopaminergic biomarker 
The CNV is a slow negative shift in the EEG that can be observed during 
response preparation to an anticipated stimulus. A first step in the validation 
of the CNV as a dopaminergic biomarker was the optimization of the paradigm 
to induce a CNV wave. While a CNV can be induced by a simple reaction time 
task called the Traffic light task in which participants press a button when a 
red dot turns green, the task could be improved to make it more attractive 
and thereby improve response preparation. The experiments described in 
chapter 5 evaluated two new tasks that were designed to induce optimal 
levels of motivation and attention during task performance and induce a 
larger CNV wave. Results showed that the new tasks induced larger CNV waves 
and faster responses compared to the Traffic light task.  
 Next, sensitivity of the CNV to dopamine activity was studied. The 
study described in chapter 6 showed that methylphenidate dose dependently 
increased CNV amplitude and decreased response times. From these results it 
was concluded that CNV was a good candidate biomarker for dopamine 
activity. However, because methylphenidate affects not only dopamine but 
also noradrenaline neurotransmitter activity, pharmacological selectivity of 
the CNV still needed to be determined. To do this, the study in chapter 7 was 
conducted. CNV was measured in healthy volunteers under the influence of 
levodopa, a drug that selectively affects dopamine activity, and compared to 
a methylphenidate condition. This study showed that methylphenidate and 
levodopa had opposite effects on CNV amplitude and response time.  
The results of the latter study seemed to challenge the conclusion of 
the study in chapter 6. CNV possesses characteristics that are important for a 
biomarker, including for example sensitivity, which was demonstrated by the 
fact that a low dose of methylphenidate evoked a measureable change in CNV 
amplitude and CNV results differentiated between doses. However, the 
studies described in this dissertation do not support the idea that the CNV is a 
biomarker which is selective for dopamine activity. On the other hand, taking 
into account that the levodopa dose in the final experiment was rather low, 
the results do not allow the conclusion that dopamine is not involved in CNV. 
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Considering the literature on dopamine and CNV (e.g. (Amabile, et al., 1986; 
Oishi, et al., 1995; Tecce, 1991; Tecce, et al., 1975)), it is likely that 
dopamine does play a role in CNV. However, the findings described in the 
present dissertation provide insufficient support to claim a role of the CNV as 
a dopaminergic biomarker because the evidence was limited by the fact that 
methylphenidate is not a pure dopaminergic drug and that the attempt to 
show that the effects were specifically dopamine dependent failed. This issue 
may be addressed in future research. 
 
Methodological considerations 
A crucial aspect of our studies on dopaminergic influences on cognitive 
function and the CNV wave was the choice of the dopaminergic 
manipulations. In order to study a dose–response relationship we needed to 
find a drug that had a wide safe dose range. Methylphenidate fulfilled this 
requirement and is generally well tolerated. A drawback of employing 
methylphenidate in our studies was that it blocks the reuptake of both 
dopamine and noradrenaline (Hannestad, et al., 2010; Kuczenski & Segal, 
1997; Volkow, Wang, Fowler, Gatley, et al., 1998). Methylphenidate’s potency 
may be higher for the noradrenaline- than the dopamine transporter 
(Kuczenski & Segal, 1997), but  dopamine is also transported by the 
noradrenaline transporter (Hannestad, et al., 2010; Pacholczyk, et al., 1991). 
Therefore it could not be deduced whether effects of methylphenidate on 
cognition and the CNV wave were mediated by dopamine, noradrenaline or a 
combination of the two. 
 In order to disentangle dopaminergic and noradrenergic effects, 
methylphenidate should have been contrasted with a pure dopaminergic- and 
a pure noradrenergic manipulation, ideally with the same mechanism. Due to 
the lack of respective specificity of dopamine and noradrenaline to the 
dopamine- and noradrenaline transporters (Hannestad, et al., 2010; 
Pacholczyk, et al., 1991), reuptake inhibiting drugs were not an option and 
other drugs had to be considered. Available noradrenergic drugs, including for 
example clonidine, guanfacine, idazoxan and propranolol were disregarded 
for various reasons such as lack of specificity or safety, or adverse side effects 
that would interfere with task performance (Currie, Lewis, McDevitt, 
Nicholson, & Wright, 1988; Jakala, et al., 1999; Middleton, Sharma, Agouzoul, 
Sahakian, & Robbins, 1999). Due to lack of availability of an appropriate 
purely noradrenergic drug, methylphenidate effects were thus only compared 
to a dopaminergic manipulation. As the precursor of dopamine, levodopa was 
the most purely dopaminergic drug available. However, even levodopa might 
not only affect dopamine but also noradrenaline, as noradrenaline is 
synthesized from dopamine (Breitenstein, Floel, et al., 2006; Julien, 2011). In 
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 fact, it might not be feasible to completely disentangle dopamine- from 
noradrenaline mediated effects. Given that these two neurotransmitters 
originate from common precursors and the close interactions between 
dopamine and noradrenaline, the practical relevance of disentangling their 
effects might actually be limited. In future research, investigators may 
consider if their research should focus on ‘catecholamines’ rather than 
dopamine or noradrenaline alone. 
Another issue related to the choice of levodopa as a dopaminergic 
drug is that the mechanism by which it affects dopamine activity differs from 
that of methylphenidate. While levodopa has the potential to enhance 
presynaptic dopamine availability and thus may affect both tonic and phasic 
dopaminergic processes, methylphenidate does not have a direct releasing 
action (Breitenstein, Korsukewitz, et al., 2006; Seeman & Madras, 2002). Low 
doses of dopamine agonists may even reduce phasic dopamine signals since 
phasic dopamine activity is inhibited by tonic dopamine activity on 
postsynaptic receptors and autoreceptors (Breitenstein, Korsukewitz, et al., 
2006; Seeman & Madras, 2002). A higher dose overcomes such an effect and 
causes generalized stimulation of the nervous system (Seeman & Madras, 
2002).  
As the levodopa dose used in the studies in this dissertation was 
relatively low in order to avoid sedation, dopamine activity at the 
autoreceptors may have reduced the impact of phasic dopamine signals in our 
experiments. Combined influences of levodopa on tonic and phasic dopamine 
activity may have thus resulted in a net null effect of levodopa on dopamine 
availability. Such a supposition could be tested by assessment of prolactin in 
blood as prolactin levels decrease under the influence of increased dopamine 
availability. However, in our studies we administered domperidon, a 
peripheral dopamine antagonist, along with the levodopa treatment to 
prevent nausea. An increase in prolactin level induced by levodopa would thus 
be counteracted by domperidon (Brouwers, Assies, Wiersinga, Huizing, & 
Tytgat, 1980). 
 Besides choice of drug, there was another methodological issue that 
was raised in this dissertation. The study procedures described in chapters 2 
and 6 involved 8 hours of almost continuous performance of cognitive tasks on 
a computer. In contrast, participants in the studies described in chapters 3 
and 7 were only involved in 1.5 hours of cognitive testing and could relax for 
approximately two hours before testing started. These circumstances may 
have contributed to performance on the cognitive tests. Participants 
subjected to 8 hours of testing may have been more tired than participants 
involved in 1.5 hours of testing. In the former situation, it is not unlikely that 
fatigue was induced in the participants and we may have unintentionally 
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tested the influence of methylphenidate on cognitive performance under 
fatigue. This may be especially true for tests scheduled later on the day, 
including the word learning test. The differences between the designs of 
these studies limit the comparability of the results. On the other hand, these 
differences may have provided us with the key factor determining the 
cognitive enhancing potential of methylphenidate. 
 
Conclusions and implications 
The cognition enhancing effects of methylphenidate suggest that dopamine 
plays a role in cognitive functions such as verbal learning and memory, 
working memory, attention and speed of processing. However, the evidence is 
limited by the fact that methylphenidate is not a pure dopaminergic drug and 
that the attempt to show that the effects were specifically dopamine 
dependent failed. This issue also played a role in the validation of the CNV as 
a dopaminergic biomarker. CNV possesses characteristics that are important 
for a biomarker, but the findings described in the present dissertation provide 
insufficient support to claim a role of the CNV as a biomarker that is specific 
for dopaminergic activity. 
The research described in this thesis highlights the impact of the 
experimental design and study procedures on the outcome of a study. 
Together, the results of the different studies employing different designs and 
procedures, but testing the same substance, suggest that healthy individuals 
may particularly benefit from methylphenidate’s enhancing effects under 
challenging circumstances. Based on these results and considering that the 
use of methylphenidate to enhance study performance is currently common 
practice among university students (Greely, et al., 2008), future research may 
target practical applications of methylphenidate. For example, future studies 
may investigate if methylphenidate affects studying under pressure of an 
important exam, if it affects exam score and the time frame of such effects. 
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 SUMMARY 
 
 
 Dopamine is a neurotransmitter that is involved in several neuropsychiatric 
conditions with cognitive impairment including Parkinson’s Disease, 
schizophrenia and ADHD. As recent advances in pharmacological treatment of 
these conditions have been disappointing, psychopharmacological research in 
this area continues to be highly relevant. A first step in the improvement of 
treatment of dopamine-associated diseases is to increase our knowledge 
about the dopamine system. Therefore, the first part of this dissertation 
aimed to determine the role of dopamine in cognitive function in the healthy 
population, primarily focusing on (working) memory.  
Furthermore, research aimed at advancing pharmacological treatment 
of diseases in which dopamine is involved would be aided by a biomarker for 
dopamine activity. This dissertation proposed the use of contingent negative 
variation (CNV) amplitude as a marker of dopamine activity in the basal 
ganglia. Such a marker could be used to quickly verify whether interventions 
that are thought to elevate dopamine in that region actually do so. Therefore, 
the second part of this dissertation aimed to validate the CNV as a 
dopaminergic biomarker reflecting changed activity in the midbrain. To this 
end experiments were designed in which dopamine was deliberately 
manipulated 
In the experimental studies described in this dissertation, dopamine 
activity and availability were experimentally elevated by administration of 
methylphenidate and levodopa respectively. Methylphenidate blocks the 
reuptake of dopamine and noradrenaline. Levodopa is the precursor of 
dopamine. A reduction of dopamine activity was achieved by depleting the 
brain of the dopamine precursors tyrosine and phenylalanine. 
Part 1 discussed the role of dopamine in cognition. In chapter 1 the 
available literature on cognitive effects of methylphenidate in healthy 
volunteers was reviewed. In this review the extent to which methylphenidate 
enhanced cognitive performance in a certain domain was quantified by a 
percentage that reflected the number of studies showing positive effects of 
methylphenidate. To evaluate whether the dose-response relationship 
followed an inverted-U-shaped curve, methylphenidate effects on cognition 
were also quantified for low, medium and high doses respectively. The studies 
reviewed showed that methylphenidate improved cognitive performance in 
the healthy population in the domains of working memory (68%) and speed of 
processing (57%), and to a lesser extent also improved verbal learning and 
memory (34%), reasoning and problem solving (18%) and attention and 
vigilance (15%), but did not have an effect on visual learning and memory. 
Methylphenidate effects were shown to be dose dependent and the dose 
response relationship differed between cognitive domains.  
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 Chapter 2 described a study in which dose related effects of 
methylphenidate on declarative memory, working memory, attention and 
executive function were investigated in healthy young volunteers. In a 
placebo-controlled crossover design 19 male participants (mean age: 23.4) 
were tested after a single dose of 10, 20 or 40 mg of methylphenidate. 
Performance on the 30 minute delayed recall test of a word learning task 
improved by 20 and 40 mg of methylphenidate. Methylphenidate also 
improved set shifting and stop signal task performance but did not affect 
spatial working memory or planning task performance. As this was the first 
study to report dose-related effects of methylphenidate on declarative 
memory consolidation in healthy volunteers, we aimed to replicate these 
findings in the study described in the next chapter. 
 Besides replicating the previous results from chapter 2, chapter 3 
aimed to study the dopaminergic contribution to the methylphenidate effects, 
as methylphenidate inhibits the reuptake of both dopamine and 
noradrenaline. To this end, effects of 40 mg of methylphenidate on memory 
performance were compared to 100 mg of levodopa in a placebo-controlled 
crossover study with 30 healthy volunteers (20 males, 10 females, mean age: 
20.7). Methylphenidate did not improve 30 minute delayed recall. However, 
performance on the 24 hour delayed recall was better when words were 
learned under influence of methylphenidate compared to placebo and 
levodopa. Methylphenidate and levodopa had opposite effects on (working) 
memory task performance and electrophysiological correlates. Together the 
results of chapter 2 and 3 suggested that memory enhancing effects of 
methylphenidate were more pronounced when the circumstances were more 
challenging. Furthermore, it is likely that the levodopa manipulation in 
chapter 3 did not lead to enhanced dopaminergic activity. 
 The last chapter of part 1 of this dissertation, Chapter 4, described a 
study on the effects of a reduction of dopamine activity achieved by 
tyrosine/phenylalanine depletion (TPD). In a double blind placebo-controlled 
crossover design, the effect of TPD on memory performance and its 
electrophysiological correlates was studied in 17 healthy volunteers (6 males, 
11 females, mean age: 21.1). Working memory performance was not affected 
by TPD. However, event-related potential (ERP) measures were affected by 
the treatment, indicating that TPD impaired stimulus processing during 
working memory performance. Performance on the word learning test was not 
impaired after TPD but alterations in ERP measures suggested adverse effects 
of TPD on memory-related processing.  
 Part 2 focused on psychomotor control and how it is mediated by 
dopamine. As a first step in the validation of the CNV paradigm, differences 
between several paradigms that elicit a CNV were studied in chapter 5. The 
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 CNV is a slow negative shift in the electroencephalogram and is observed 
during response preparation. In an effort to optimize the CNV paradigm, a 
task using dynamic stimuli was developed. In the first experiment, 19 healthy 
male volunteers (mean age: 23.4) were subjected to the classic Traffic light 
(TL) task and the new dynamic Lines task. In the Lines task, response time 
was faster and CNV amplitude was larger compared to the TL task. In the 
second experiment, 20 healthy participants (10 males, 10 females, mean age: 
23.0) were tested on a Go/No-go version of the Lines task. Response times 
increased as the probability of response requirement decreased. CNV 
amplitude was larger when probability of response requirement was higher. 
Thus the Lines task promoted response preparation and was employed in 
subsequent pharmacological studies alongside the Traffic Light task.  
 To determine sensitivity of CNV amplitude to dopamine activity the 
study described in chapter 6 assessed CNV amplitude in 19 healthy male 
volunteers (mean age: 23.4) after administration of placebo or 10, 20 or 
40 mg of methylphenidate. Methylphenidate dose-dependently increased CNV 
amplitude and decreased reaction times. These results indicated that 
dopamine availability increased response readiness as measured by the CNV 
paradigm. The CNV appeared to be a good candidate biomarker for assessing 
changes in dopaminergic function. However, because methylphenidate 
inhibits reuptake of dopamine but also of noradrenaline, it could not be 
stated with certainty whether these findings could be ascribed solely to 
increased dopamine levels. 
 Therefore, Chapter 7 aimed to determine selectivity of the CNV for 
dopamine activity. To investigate the specific dopaminergic influence on the 
CNV amplitude the effects of 40 mg methylphenidate on CNV were compared 
to those of 100 mg of the dopamine precursor levodopa in a placebo-
controlled crossover study testing 30 healthy volunteers (20 males, 10 
females, mean age: 20.7). Methylphenidate and levodopa had opposite effects 
on CNV amplitude and reaction time: methylphenidate increased CNV 
amplitude and decreased reaction time in comparison with levodopa. It was 
suggested that levodopa might not have led to enhanced dopamine activity or 
that combined dopamine- and noradrenaline reuptake inhibition may be 
essential to enhance response readiness and that methylphenidate effects 
may be more pronounced if conditions are more demanding. 
 In the general discussion the findings from the studies in this 
dissertation were reviewed to form a comprehensive view with respect to the 
two central aims of this thesis. The cognition enhancing effects of 
methylphenidate suggested that dopamine plays a role in cognitive functions 
such as verbal learning and memory, working memory, attention and speed of 
processing. Healthy individuals may particularly benefit from 
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methylphenidate’s enhancing effects under challenging circumstances. 
However, the evidence is limited by the fact that methylphenidate is not a 
pure dopaminergic drug and that the attempt to show that the effects were 
specifically dopamine dependent failed. This issue also played a role in the 
validation of the CNV as a dopaminergic biomarker. CNV possesses 
characteristics that are important for a biomarker, but the findings described 
in the present dissertation provide insufficient support to claim a role of the 
CNV as a biomarker that is specific for dopaminergic activity. 
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 Dopamine is een neurotransmitter die betrokken is bij verschillende 
neuropsychiatrische aandoeningen waarbij sprake is van cognitieve 
beperkingen zoals de ziekte van Parkinson, schizofrenie en ADHD. Aangezien 
de mate van vooruitgang in farmacologische behandeling van deze 
aandoeningen de laatste tijd teleurstellend is geweest, blijft 
psychofarmacologisch onderzoek van groot belang. Een eerste stap in de 
verbetering van behandeling van dopamine gerelateerde ziekten is het 
vergroten van onze kennis van het dopamine systeem. Daarom heeft het 
eerste deel van dit proefschrift als doel te bepalen wat de rol van dopamine is 
in het cognitief functioneren van gezonde mensen, waarbij de focus ligt op 
het (werk)geheugen. 
 Daarnaast zou onderzoek met als doel farmacologische behandeling 
van ziekten waarbij dopamine betrokken is te verbeteren ook gebaat zijn bij 
het vinden van een biomarker van dopamine activiteit. In dit proefschrift 
wordt de amplitude van de Contingent Negative Variation (CNV) voorgesteld 
als marker van dopamine activiteit in de basale ganglia. Een marker zou 
gebruikt kunnen worden om sneller vast stellen of interventies die geacht 
worden het dopamine niveau te verhogen dit ook daadwerkelijk doen. Daarom 
is het doel van het tweede deel van dit proefschrift om de CNV te valideren 
als biomarker die veranderde dopamine activiteit in de midden-hersenen 
aangeeft. Met dit doel werden experimenten ontworpen waarin het dopamine 
niveau gemanipuleerd werd. 
 In de experimentele studies die in dit proefschrift beschreven worden, 
werd dopamine activiteit experimenteel verhoogd door toediening van 
metylfenidaat en levodopa. Metylfenidaat blokkeert de heropname van 
dopamine en noradrenaline. Levodopa is de precursor van dopamine. Een 
verlaging van dopamine activiteit werd bereikt door de beschikbaarheid van 
de dopamine grondstoffen tyrosine en fenylalanine te verminderen. 
 Deel 1 beschrijft de rol van dopamine in cognitie. In hoofdstuk 1 
wordt de beschikbare literatuur over de cognitieve effecten van 
metylfenidaat in gezonde vrijwilligers beschreven. In dit hoofdstuk wordt de 
mate waarin metylfenidaat cognitieve prestaties binnen specifieke domeinen 
verbetert, uitgedrukt in een percentage dat weergeeft hoeveel studies 
positieve effecten van metylfenidaat lieten zien. Om na te gaan of de dosis-
response curve een omgekeerde U vorm had, werden metylfenidaat effecten 
op cognitie ook gekwantificeerd voor respectievelijk lage, middelhoge en 
hoge doseringen. De studies lieten zien dat metylfenidaat cognitieve 
prestaties van de gezonde populatie verbeterde binnen de domeinen 
werkgeheugen (68%), en verwerkingssnelheid (57%), en in mindere mate ook 
verbaal leren en geheugen (34%), redeneren en probleem oplossen (18%) en 
aandacht en vigilantie (15%), maar geen effect had op visueel leren en 
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geheugen. Metylfenidaat effecten waren afhankelijk van de dosering en de 
vorm van de dosis-respons curve verschilde per cognitief domein. 
 Hoofdstuk 2 beschreef een experiment waarin dosis gerelateerde 
effecten van metylfenidaat op declaratief geheugen, werkheugen, aandacht 
en executief functioneren werden onderzocht in gezonde jonge vrijwilligers. 
In een placebo gecontroleerd experiment werden 19 mannelijke 
proefpersonen (gemiddelde leeftijd: 23.4) getest na een enkele dosering van 
10, 20 of 40 mg metylfenidaat. Prestatie op een geheugentest 30 minuten na 
een woordenleertaak verbeterde na inname van 20 en 40 mg metylfenidaat. 
Metylfenidaat verbeterde ook de prestatie op de zogenaamde set-shifting en 
stop signal taken maar had geen effect op spatieel werkgeheugen of planning. 
Omdat dit de eerste studie was die dosis-gerelateerde effecten van 
metylfenidaat op consolidatie in het declaratief geheugen van gezonde 
vrijwilligers gerapporteerd heeft, stelden we ons als doel deze bevindingen te 
repliceren in een studie die in het volgende hoofdstuk werd besproken. 
 Behalve het repliceren van eerdere resultaten uit hoofdstuk 2, had 
hoofdstuk 3 als doel om te bestuderen in welke mate dopamine bijdraagt aan 
de metylfenidaat effecten, aangezien metylfenidaat heropname van zowel 
dopamine als noradrenaline remt. Daarom werden de effecten van 40 mg 
metylfenidaat op geheugenprestaties vergeleken met 100 mg levodopa in een 
placebo gecontroleerde gebalanceerde studie met 30 gezonde vrijwilligers (20 
mannen, 10 vrouwen, gemiddelde leeftijd: 20.7). Metylfenidaat leidde niet 
tot verbetering van prestatie op de geheugentest die 30 minuten na het leren 
werd afgenomen. Echter, na 24 uur was het geheugen voor woorden die onder 
invloed van metylfenidaat werden geleerd wel beter dan bij placebo en 
levodopa. Metylfenidaat en levodopa hadden tegengestelde effecten op 
(werk)geheugen en hun electrofysiologische correlaten. Samen wijzen de 
resultaten uit de hoofdstukken 2 en 3 erop dat geheugen verbeterende 
effecten van metylfenidaat duidelijker aanwezig zijn wanneer de 
omstandigheden uitdagender zijn. Het is bovendien waarschijnlijk dat de 
levodopa manipulatie uit hoofdstuk 3 niet heeft geleid tot verhoogde 
dopamine activiteit.  
 Het laatste hoofdstuk van deel 1 van dit proefschrift, hoofdstuk 4,  
beschreef een studie naar de effecten van een reductie van dopamine 
activiteit die bereikt werd door tyrosine/fenylalanine depletie (TFD). In een 
dubbelblind placebo gecontroleerd gebalanceerd design, werd het effect van 
TFD op geheugen en de electrofysiologische correlaten bestudeerd in 17 
gezonde vrijwilligers (6 mannen, 11 vrouwen, gemiddelde leeftijd: 21.1). 
Werkgeheugen prestatie werd niet beïnvloed door TFD. Echter, Event-related 
Potentials (ERPs) werden wel beïnvloed door de behandeling, wat er op wees 
dat TFD stimulus verwerking tijdens werkgeheugen taken verslechterde. 
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 Prestatie op de woordenleertaak was niet aangetast na TFD maar 
veranderingen in de ERP maten suggereerden wel nadelige effecten van TFD 
op geheugen gerelateerde verwerkingsprocessen.  
 Deel 2 focuste op psychomotore controle en hoe deze gemedieerd 
wordt door dopamine. Als een eerste stap in de validatie van de CNV werden 
verschillen tussen paradigma’s die een CNV oproepen bestudeerd in 
hoofdstuk 5. De CNV is een langzame negatieve golf in het 
electroencefalogram die geobserveerd wordt tijdens respons voorbereiding. In 
een poging om het CNV paradigma te optimaliseren werd er een taak met 
dynamische stimuli ontwikkeld. In het eerste experiment werden 19 gezonde 
mannelijke vrijwilligers (gemiddelde leeftijd 23.4) onderworpen aan de 
klassieke Verkeerslichttaak en de nieuwe dynamische Lijnentaak. In de 
Lijnentaak waren de responstijd en de CNV amplitude groter in vergelijking 
met de Verkeerslichttaak. In het tweede experiment werden 20 gezonde 
proefpersonen (10 mannen, 10 vrouwen, gemiddelde leeftijd: 23.0) getest op 
een Go/No-go versie van de lijnentaak. Responstijden werden langer 
naarmate de kans dat men moest reageren afnam. De lijnentaak bevorderde 
dus respons voorbereiding en zal in vervolg studies naast de Verkeerslichttaak 
gebruikt worden. 
 Om de gevoeligheid van de CNV amplitude voor dopamine activiteit te 
bepalen werden in de studie beschreven in hoofdstuk 6, 19 gezonde 
mannelijke vrijwilligers (gemiddelde leeftijd: 23.4) getest na toediening van 
placebo of 10, 20 of 40 mg metylfenidaat. Metylfenidaat vergrootte de CNV 
amplitude en verkortte reactie tijden op een dosisafhankelijke wijze. Deze 
resultaten wijzen erop dat dopamine beschikbaarheid de bereidheid te 
reageren, zoals gemeten met de CNV taak, verbetert. De CNV leek een goede 
kandidaat biomarker te zijn voor het meten van veranderingen in dopminerge 
functies. Echter, omdat metylfenidaat heropname van zowel dopamine als 
noradrenaline remt kan niet met zekerheid worden gezegd of deze 
bevindingen enkel en alleen aan verhoogde dopamine niveaus kunnen worden 
toegeschreven.  
 Daarom had hoofdstuk 7 als doel om de gevoeligheid van de CNV voor 
dopamine activiteit te bepalen. Om de specifieke dopaminerge invloed op de 
CNV amplitude te bepalen werden de effecten van 40 mg metylfenidaat op de 
CNV vergeleken met die van 100 mg van de dopamine precursor levodopa in 
een placebo gecontroleerde gekruiste studie waarin 30 gezonde vrijwilligers 
(20 mannen, 10 vrouwen, gemiddelde leeftijd: 20.7) werden getest. 
Metylfenidaat en levodopa hadden tegengestelde effecten op de CNV 
amplitude en reactietijd: metylfenidaat verhoogde de CNV amplitude en 
verkortte de reactietijd in vergelijking met levodopa. Er werd gesuggereerd 
dat levodopa ofwel niet tot een verhoging in dopamine activiteit had geleid 
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ofwel dat gecombineerde dopamine- en noradrenaline heropname remming 
essentieel zou kunnen zijn voor het verbeteren van bereidheid te reageren. 
Daarnaast werd gesuggereerd dat metylfenidaat effecten duidelijker aanwezig 
zijn als de condities uitdagender zijn. 
 In de algemene discussie werden de bevindingen van dit proefschrift 
nader bekeken om zo een samenhangend beeld te krijgen van twee centrale 
doelstellingen van dit proefschrift. De cognitie verbeterende effecten van 
metylfenidaat suggereren dat dopamine een rol speelt in cognitieve functies 
als verbaal leren en geheugen, werkgeheugen, aandacht en 
verwerkingssnelheid. Gezonde individuen zouden in het bijzonder van 
metylfenidaat kunnen profiteren wanneer de omstandigheden uitdagend zijn. 
Echter, het bewijs is beperkt doordat metylfenidaat geen puur dopaminerge 
stof is en dat de poging om aan te tonen dat de effecten specifiek dopamine 
afhankelijk zijn gefaald heeft. Dit probleem speelde ook een rol bij de 
validatie van de CNV als dopaminerge biomarker. De CNV bezit eigenschappen 
die belangrijk zijn voor een biomarker, maar de bevindingen zoals beschreven 
in dit proefschrift vormen onvoldoende bewijs om te beweren dat de CNV een 
biomarker kan zijn die specifiek is voor dopaminerge activiteit.  
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